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CHAP1ER I 
INTRODUCTION 
1.1 GENERAL INTRODUCTION 
Blood consists of plasma containing cells and cell fragments. Three groups 
of blood cells can be identified, namely (a) red blood cells or erythrocytes, (b) 
white blood cells or leucocytes and (c) platelets or thrombocytes. The white blood 
cells can be separated into neutrophilic-, eosinophilic- and basophilic granulocytes, 
lymphocytes and monocytes. The life time of these cells is limited. For example, 
in man life time for normal erythrocytes is about 120 days and for granulocytes a 
few days. The daily production of these cells required to maintain normal numbers 
in blood can be calculated from their life span, their concentration in the blood 
and the total blood volume. Thus, an adult human male produces approximately 2 
x 1011 erythrocytes and 1 x 1010 granulocytes every day. These amounts are 
necessary for normal maintenance but the production of blood cells can be increased 
after stress, for example, infection or' blood loss. 
During embryogenesis blood cell production starts in the yolk sac and sub-
sequently during fetal life it can be found in the liver, spleen and bone marrow 
(Moore and Metcalf, 1970; Niewisch, 1970). In adult mammals production of hemo-
poietic cells occurs mainly in the cavities of skeletal bones. The proportion of the 
bone marrow cavity that is filled with hemopoietic cells depends on species, age 
and the demand for functional cells. When there is an extra demand for blood 
cells, hemopoiesis extends to normally inactive bone marrow and sometimes hemo-
poietic activity can even be found in organs with active hemopoiesis during embryo-
genesis, e.g. spleen and liver. In mice (the animal used for the investigations 
described in this thesis) the skeleton is completely filled with active marrow and 
normally some hemopoiesis is also found in the spleen. 
In principle, a single progenitor cell, the pluripotent hemopoietic stem cell 
(PHSC), has the capacity to produce all mature blood cells. The PHSC can produce 
daughter cells which have virtually the same capacities as the original cell (self 
renewal) and cells with a limited proliferative capacity and a commitment to one 
or more differentiation pathways. Blood cell production (self renewal, proliferation, 
differentiation and maturation) is regulated by humoral and stromal components 
that will be discussed in the following chapters. Investigation of the PHSC and 
early progenitors has been stimulated greatly by the discovery of in vivo and in 
vitro clonal assays for these cells. The development of a culture technique to 
maintain in vitro hemopoiesis for several months has greatly facilitated the 
characterization of the stromal cells of the hemopoietic microenvironment (HM) 
and their role in supporting hemopoiesis. 
The hemopoietic system has a large reserve capacity for increasing the output 
of mature cells in response to increased demands. There is no evidence of exhaus-
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tion with age (Boggs et al., 1984; Botnick et al., 1982; Schofield et al., 1986; 
Tyan, 1982), although the bone marrow reserve capacity can be diminished (Williams 
et al., 1986). Exposure to high dose radiation and/or chemotherapeutic agents 
(e.g. used for cancer treatment, during warfare, or as a consequence of an industrial 
accident) may result in acute and or long-term damage to the hemopoietic system. 
Acute damage to the hemopoietic system is often the dose limiting factor for 
these cancer treatments and higher doses can only be given when they are followed 
by a bone marrow transplantation (BMT). Usually the hemopoietic system re-
generates very quickly, resulting in (almost) normal numbers of mature and pro-
genitor cells in blood and bone marrow. Sometimes, however, persistent defects 
may be observed in the stem cell compartment and also in the stromal HM. Late 
complications that may result from chemotherapy or irradiation are obviously of 
particular relevance in patients with cancer in whom prolonged remission or a 
cure is achieved. The experiments described in this thesis were performed to 
study the effects of radiation and chemotherapy upon the hemopoietic tissue, with 
an emphasis on the stromal cells of the HM. 
12 HEMOPOIESIS 
12.1 THE PLURIPOTENT HEMOPOIETIC STEM CELL AND THE 
EARLY PROGENITORS 
The mature, functionally active cells (leucocytes, erythrocytes, etc.) are 
produced by proliferation and differentiation of pluripotent hemopoietic stem cells 
(PHS C) and progenitors. Essentially, one PHSC is capable to produce all hemopoietic 
cells of an individual. Certain tissue cells also originate from the PHSC, like 
osteoclasts (Ash et al., 1980; Scheven et al., 1986), tissue mast cells (Kitamura et 
al., 1981), non-lymphoid (dendritic) cells of peripheral lymph nodes (Pugh et al., 
1983), epidermal Langerhans cells (Volc-Platzer et al., 1984), antigen-presenting 
cells in the thymus (Longo and Schwartz, 1980) and Kupffer cells (van Furth, 
1980). The capacity of PHSC to produce both lymphoid and myeloid progeny has 
been demonstrated by Wu et al. (1968) and Abramson et al. (1977) using radiation-
induced chromosomal aberrations and recently by Lemischka et al. (1986) using 
retrovirus-mediated gene transfer to mark hemopoietic stem cells in vitro. Using 
the last method, it has been demonstrated that only a few (1-2) stem cell clones 
account for the majority of all hemopoietic cells found at any time in the mouse. 
Furthermore, it is suggested that normal hemopoiesis results from the sequential 
activation of different stem cell clones rather than from an averaged contribution 
of the entire stem cell pool (Burton et al., 1982; Lemischka et al., 1986; Mintz et 
al., 1984). The latter concept introduced by Kay (1965) is supported by studies 
using long term bone marrow cultures (Chertkov et al., 1985; Reincke et al., 1985). 
It is suggested from studies by Botnick et al. (1982) and Mauch et al. (1982) that 
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a selective utilization of hemopoietic stem cells with a lower mean self-renewal 
capacity occurs in vivo to maintain hemopoiesis. 
The PHSC and early progenitors committed to one or several hemopoietic 
lineages occur in very low frequencies in hemopoietic tissue and are very difficult 
to identify (if at all) in these tissues on pure morphological features. The proli-
ferative and differential capacities of these cells can be examined using in vivo or 
in vitro assays. Till and McCulloch (1961) have been the first to describe an in 
vivo method to estimate the number of hemopoietic stem cells (the spleen colony-
forming unit or CFU-s). Murine CFU-s are assayed by intravenous injection of a 
small number of hemopoietic cells from bone marrow, spleen, fetal liver or any 
other organ containing CFU-s into lethally irradiated recipient mice. The hemo-
poietic stem cells that home in the spleen proliferate extensively in the irradiated 
hosts and seven to 15 days after injection macroscopically visible nodules appear 
on the splenic surface. The number of spleen nodules is during the first 12 days 
after injection linearly related to the amount of injected normal bone marrow 
cells (BMC)(Till and McCulloch, 1961). The absolute number of PHSC can be cal-
culated by determination of the fraction of injected cells that seed into the spleen. 
Recently it has been shown that the cells determined with the CPU -s assay 
consist of a heterogeneous population (Magli et al., 1982; Wolf and Priestley, 
1986). About half of the day-7 spleen colonies are transient and about half of 
the day 11/12 colonies are not yet visible on day 8, although colony numbers 
derived from normal hemopoietic tissue remain constant between 7-15 days. These 
observations suggest that the early, transient, spleen colonies are derived from 
stem cells with restricted proliferative potential, though with pluripotent properties, 
or are derived from the progeny of precursor cells with restricted differential 
potentials and therefore do not arise from PHSC. Further evidence for the idea of 
heterogeneity of the CFU-s population is the observation that with fluorescence-
activated cell sorting different cell fractions can be obtained which almost ex-
clusively give rise to either day-7 or day-12 spleen colonies (Ploemacher and 
Brons, 1988a; 1988b; Ploemacher et al., 1987). The occurrence of late appearing 
colonies may be explained by the assumption that these colonies are derived from 
the same cell type as the early appearing colonies but originate from a 'younger' 
stem cell that proliferates in the bone marrow and subsequently migrates to the 
spleen to give rise to several day 12 colonies (Hodgson and Bradley, 1979; Mulder 
et al., 1984; Wolf and Priestley, 1986; van Zant, 1984). This hypothesis may also 
explain the observation that a single cell may give rise to more than one spleen 
colony (Barnes et al., 1968). There is also some evidence that the spleen colony 
assay does not detect a type of stem cell with sufficient self-renewal capacity in 
vivo to repopulate an entire individual (Boggs et al., 1982, 1984; Magli et al., 
1982; Sharkis et al., 1978). Furthermore, evidence has been presented that day 12 
or day 8 CFU-s are not the cells responsible for long-term in vitro hemopoiesis 
but that the latter is supported by a population of younger, resting stem cells 
(not in cell cycle) (Chertkov et al., 1986; Spooncer et al., 1985). The above men-
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tioned observations stress the idea of heterogeneity of the stem cells and the exis-
tence of a gradual scale or a continuum of cells with a decreasing self-renewal 
capacity, increasing commitment (Chertkov et al., 1986; Grossman, 1986; Hellman 
et al., 1978; Hodgson and Bradley, 1979; Van Zant, 1984) and a different capacity 
to lodge in the spleen or bone marrow (Ploemacher et al., 1987; Wolf and Priestley, 
1986). The youngest progenitor or 'pre CFU-s' is a resting cell, not in cycle and 
consequently not very sensitive to certain cytostatic agents, e.g. the antimetabolites 
and other cell cycle dependent cytostatic agents (Chertkov et al., 1986; Rosendaal 
et al., 1979). The proportion of cells in cycle increases with increasing commit-
ment e.g., day 12 CFU-s are less in cell cycle than day 8 CFU-s and these again 
less than CFU-C (Chertkov et al., 1986; Hodgson and Bradley, 1979; Pietrzyk et 
al., 1985). 
Pluripotent cells with high self renewal capacity can also be assayed by in 
vitro methods (Keller and Philips, 1982; Nakahata and Ogawa, 1982). The frequency 
of progenitors, which still have the capacity to differentiate in more than one 
direction, and cells which are committed to a single line of differentiation (e.g. 
CFU -GEMM, CFU -GM, BFU-E or CFU-E) can commonly be determined in semi-solid 
cultures (Bradley and Metcalf, 1966; Johnson and Metcalf, 1977, 1980; Metcalf and 
MacDonald, 1975). Survival, self-renewal, proliferation and differentiation of PHSC 
and progenitors in vivo and in vitro is dependent on specific factors and will be 
discussed in the next chapters. 
122 THE HEMOPOIETIC MICROENVIRONMENT 
The occurrence of effective hemopoietic activity in restricted parts of the 
body is strong evidence for the existence of a specific HM. In the adult, hemo-
poiesis is restricted to red bone marrow, whereas in the mouse, the spleen is also 
an organ with active hemopoiesis. 
12.2.1 MORPHOLOGY OF THE HEMOPOIETIC MICROENVIRON-
MENT AND SPATIAL DISTRIBUTION OF HEMOPqiESIS 
The hemopoietic cells in bone marrow are surrounded by cells and cell 
products which form the HM. The HM can be divided in several compartments: (a) 
a vascular compartment of arteries, veins and sinuses, (b) a neural compartment 
of myelinated and unmyelinated nerve fibers and Schwann cells, (c) a connective 
tissue compartment of adventitial reticular cells, (pre)adipocytes, fibroblasts, 
macrophages and an extracellular matrix of fibers and amorphous ground substance 
(reviewed by Lichtman, 1981, 1984; Weiss and Sakai, 1984). 
In mammals hemopoietic cell proliferation occurs under normal steady state 
conditions extravascularly. Hemopoiesis is not randomly distributed in the HM but 
there is a complete or regional segregation of the various lines of differentiation 
in human spleen and bone marrow. Young granulopoietic cells are preferentially 
4 
found close to bone and a gradient of more mature granuloid cells is found towards 
the axial center of the bone marrow (Lennert, 1952). Megakaryocytes are localized 
alongside of the sinuses, and large cytoplasmic protrusions from which platelets 
are derived can be found in the sinus lumen (Becker and De Bruyn, 1976). Clusters 
of erythroblasts with a central macrophage surrounding them are also found close 
to the sinus wall (Bessis, 1958). No clear morphologic evidence exists for a regional 
distribution of hemopoiesis in the mouse bone marrow. However, in some mouse 
strains the hemopoietic progenitor cells CFU-s, CFU-G/M and BFU-E, are preferen-
tially localized in specific regions of the bone marrow (Lord et al., 1975; Xu and 
Hendry, 1981). The CFU-s with a high self- renewal capacity and a low cycling rate 
are found axially and CFU-G/M, BFU-E and cycling CFU-s are found close to the 
bone. Furthermore, a stromal cell population producing a factor inhibiting CFU-s 
proliferation is found in axial bone marrow and a cell population of mononuclear 
phagocytes that produce a stimulator for CFU-s proliferation is found close to the 
bone (Wright and Lord, 1986; Wright et al., 1982). Further evidence for the spatial 
distribution of hemopoiesis has been demonstrated by the development of endogenous 
hemopoietic colonies after irradiation in both spleen and femur. During the first 
7-8 days after irradiation, most endogenous colonies are of single lineage with a 
typical distribution in the marrow. Undifferentiated granulopoietic and megakaryo-
poietic colonies have been found near bone whereas erythrocytic colonies tend to 
proliferate in intermediate and central marrow zones (Lambertsen and Weiss, 1983). 
The spatial distribution of erythropoiesis in central areas and of granulopoiesis 
and thrombopoiesis concentrated along bone remains for several weeks after 
irradiation. Hemopoietic colonies developing in spleen after irradiation and BMT 
also show a spatial distribution, i.e. the large erythroid colonies are subcapsular 
and do not grow into the stroma, in contrast with the granulocytic colonies growing 
alongside splenic capsule and trabeculae (Curry et al., 1967; Wolf and Trentin, 
1968; Wolf and Rosse, 1982). The distribution of CFU-s in spleen is also not at 
random, the highest concentration of CFU-s is found subcapsular (Ploemacher and 
Brons, 1985). Upon infusion of normal BMC into lethally irradiated mice, the ratio 
of erythroid versus granuloid colonies (E:G ratio) is about 0.7 in the marrow, 
while it averages 3.5 in the spleen (Wolf and Trentin, 1968). The E:G ratio estimated 
after injection of normal BMC in both spleen and femur is determined by the 
microenvironment and does not change after e.g. erythropoietin (EPO) stimulation 
or repression, cYtotoxic treatment or transplantation of the organs to other sides 
of the body (Curry et al., 1967; Ploemacher et al., 1982). The E:G ratio of marrow 
stroma even remains unchanged after transplantation into the spleen (Wolf and 
Trentin, 1968). 
12.22 FUNCTIONAL ASPECI'S OF THE HEMOPOIETIC MICRO-
ENVIRONMENT 
The HM possesses a variety of functions for an optimal production of normally 
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active hemopoietic cells. The functions of the HM can be divided in (a) nourishment 
of the hemopoietic cells and removal of waste products, (b) regulation of self-
renewal, proliferation and differentiation of the hemopoietic progenitors, (c) storage 
of functional cells, (d) regulation of the release of functional cells into the blood 
stream, (e) lodgement of PHSC and other progenitors from the blood into the HM. 
Nourishment, removal of waste products, release of hemopoietic cells from 
the bone marrow, and lodgement of hemopoietic cells are regulated by the blood 
vessels and/or the vascular wall that consists of endothelial cells, basement mem-
brane and adventitial reticular cells. The main arterial blood supply of the HM 
comes from the nutrient artery. It penetrates the cortex through the nutrient 
canal and bifurcates in ascending and descending medullary arteries from which 
radial small branches form the cortical capillaries which drain into the marrow 
sinuses, while the blood leaves the marrow via an emissary vein (Brookes, 1971). 
The diameter of the blood vessels in the microcirculation of the bone marrow is 
variable, which permits regulation of the blood flow through the sinuses. The 
bone marrow microvasculature can be rebuilt to a considerable extent in response 
to increased demands for hemopoietic activity as has been demonstrated by McClu-
gage et al. (1971) using a device in the tibia of rabbits for in vivo microscopy. 
Hemopoietic cells enter and leave the HM through the sinuses. The endo-
thelial cells are thought to be responsible for the selective lodgment of hemopoietic 
progenitors in both spleen aild bone marrow during their migration between diffe-
rent parts of the body and after a BMT. The mechanism of the interactions of 
progenitors and mature blood cells with the endothelial cells is still not understood. 
However, one of the factors determining homing of progenitors might be the 
existence of specific surface glycoproteins on the progenitors (Hardy et al., 1986; 
Ploemacher and Brons, 1981; Ploemacher et al., 1981a, 1981b ). 
The regulation of the · release of functional hemopoietic cells into the blood 
stream is complex and several cell types, e.g. endothelial cells, adventitial reticular 
cells and the hemopoietic cells themselves may take part in this regulation (Camp-
bell, 1982). The adventitial reticular cells cover the vascular sinus and are lifted 
away as maturing hematopoietic cells approach the sinus (Weiss, 1976). The lining 
of the sinuses with adventitial reticular cells is incomplete and can be changed 
according to the demand of functional cells. The adventitial cover is decreased 
after endotoxin-induced leukopenia (Weiss, 1970) or after an EPO injection (Cham-
berlain et al., 1975a) and is increased after hypertransfusion (Chamberlain et al., 
1975b ). A reduction of the sinusoidal lining by adventitial reticular cells is not a 
prerequisite for an increased release of functional cells, other factors (e.g., the 
complement system) and/or cells are also contributing to the regulation of cell 
egress (Ploemacher et al., 1980). Furthermore, the egress of hemopoietic cells into 
the blood stream may be an active process of the contractile adventitial reticular 
cells by squeezing the cells through the pores in the endothelial cells (Campbell, 
1972; Tavassoli, 1977; Weiss, 1970). Changing the blood flow through the marrow 
sinuses may be another possibility to change cell egress. The blood cells migrate 
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through pores in the endothelial cells of the sinus wall and not between endothelial 
cells. The migration is efficiently regulated under normal conditions, i.e. mature 
blood cells enter the blood stream while immature forms remain in the marrow 
cords (De Bruyn et al., 1971; Chamberlain and Lichtman, 1978). 
The proliferative status of stem cells and the self-renewal capacity is probably 
under influence of stromal cells. The nature of these cells is not yet fully eluci-
dated, but macrophages are thought to be the cell type producing the stimulator 
for stem cell proliferation (Lord and Wright, 1982). It is believed that PHSC are 
quiescent cells with respect to cell cycle activity and that induction of proliferation 
subsequently decreases the self-renewal capacity and increases differentiation 
(Grossman, 1986). Schofield (1978) has proposed the existence of special stem cell 
niches, which are assumed to prevent the stem cell from going into cycle and to 
mature i.e. to become sensitive to specific hemopoietins and subsequently loose its 
self-renewal capacity. Using a long-term culture technique, it has been demonstrated 
that primitive hemopoietic progenitors are adherent to the stromal layer (Cou-
lombe! et al., 1983a; Reincke et al., 1985). Furthermore, implantation of the stromal 
layer of a long-term bone marrow organ culture in conjunction with the adherent 
primitive hemopoietic progenitors under the. kidney capsule of lethally irradiated 
hosts gave rise to more day 12 and less day 8 spleen colonies than intravenous 
injection of a single cell suspension derived from similar cultures. Apparently, trans-
plantation of stem cells in close association with stromal cells appears to maintain 
more primitive stem cells than transplantation without these stromal cells (Sharp 
et al., 1985). Accordingly, the observation of decreasing self-renewal ability after 
serial transplantation may be due to the method used (Harrison et al., 1978; Hellman 
et al., 1978), because the stem cells are transplanted as a single cell suspension and 
the contact of PHSC with stromal cells is necessary for remaining "primitiveness" 
of the stem cells. 
There are strong indications that the process of commitment is stochastic 
(Ogawa et al., 1983; Till et al., 1964), but the regulation of proliferation and 
differentiation of the committed progenitors is thought to be under influence of 
stromal cells. Evidence for a role of stromal cells regulating hemopoiesis is obtained 
from in vitro culture techniques. The role of each cell group that participates in 
the HM will be discussed briefly below. 
I223 THE CELLULAR COMPOSffiON OF THE HEMOPOIETIC 
MICROENVIRONMENT WITH AN EMPHASIS ON REGUlA-
TION OF HEMOPOIESIS 
A normal function of PHSC and progenitor cells appears to be dependent 
upon close range interactions with cells or cell products within the hemopoietic 
organs. The development of an in vitro culture system, the long-term bone marrow 
culture (LTBMC), for maintaining long-term hemopoiesis has facilitated the study 
of the interactions between the hemopoietic stroma and the hemopoietic progenitors. 
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The development of a stromal layer composed of endothelial cells, macrophages, 
fibroblasts, adventitial reticular cells, and adipocytes on the surface of the culture 
vessel is essential for long-term maintenance of hemopoiesis (Allen and Dexter, 
1976; Dexter et al., 1973, 1977a, 1984). Almost all of the following data with respect 
to the role of stromal cells and their cell products regulating hemopoiesis are 
derived using this culture technique. 
Some of the cell products stimulate hemopoiesis and are called hemopoietic 
growth factors (HGFs) and some factors inhibit hemopoiesis (reviewed by Brox-
meyer, 1984; Moore et al., 1984; Resnitzky et al., 1986). The HGFs are glycoproteins 
with a molecular weight of 20 to 70 kDalton and can be divided in: (a) factors 
stimulating a variety of hemopoietic progenitor cells to proliferate and differentiate 
into more than one fully differentiated blood cell type, like interleukin-3 (Il-3) 
(Ihle et al., 1981, 1983; Iscove et al., 1985; Nicola and Metcalf, 1986; Walker et 
al., 1985) and granulocyte/macrophage-CSF (GM-CSF) (Burgess and Metcalf, 1977; 
Metcalf et al., 1980, 1986a); (b) lineage-specific growth factors, like EPO (Metcalf 
and Moore, 1971; Wagemaker et al., 1977), thrombopoietin (Evatt et al., 1976; 
McDonald, 1976), granulocyte-CSF (G-CSF) and macrophage-CSF (M-CSF) (Metcalf 
and Burgess, 1982; Metcalf and Nicola, 1983; Metcalf et al., 1986a; Stanley and 
Heard, 1977) and (c) factors which have no intrinsic colony stimulating activity 
but are synergistic to other HGFs like Hemopoietin-1 (is IL-l) (Stanley et al., 
1986) or those changing the cycling rate of CFU -s ( Guigon and Frindel, 1978; 
Guigon et al., 1982; Lord and Wright, 1982). Besides stimulating primitive progenitors 
to proliferate, some of the HGFs are also essential for survival of these progenitors 
by increasing glucose transport and ATP generation (Suda et al., 1985; Whett9n et 
al., 1984) and, moreover, have an effect on mature cells. They can increase func-
tional activity, e.g. phagocytosis, oxidative metabolism, inhibition of migration, 
antibody-dependent cytotoxic killing of tumor cells, expression of function-as-
sociated cell surface antigens and stimulation of the synthesis of membrane and 
nuclear proteins (Fleischmann et al., 1986; Gasson et al., 1984; Lopez et al., 1986; 
Nicola et al., 1986; Stanley and Burgess, 1983; Weisbart et al., 1985). 
Many of the above mentioned HGFs have been purified, biochemically char-
acterized, and produced using recombinant DNA techniques. In vivo injection of 
these purified and recombinant HGFs generates strong evidence for a physiological 
role of these substances in stimulating and regulating hemopoiesis. Continuous 
subcutaneous infusion or multiple intraperitoneal injections of IL-3 in normal 
mice results primarily in an increased hemopoietic activity of all hemopoietic 
lineages in the spleen (Kindler et al.,1986; Metcalf et al., 1986b ). Continuous IL-3 
infusion of lethally irradiated mice increases the recovery of injected hemopoietic 
progenitors (Kindler et al., 1986). Furthermore, 24 hours after a single injection 
of IL-3 the cycling state of femoral CFU-GEMM, BFU-E and CFU"GM is increased 
(Broxmeyer et al., 1986). The combined in vivo and in vitro results suggest that 
IL-3 production is increased during stress situations when there is a demand for 
more than one hemopoietic cell lineage. Increased IL-3 production will result in 
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the production of more early multipotential precursors which in turn produce more 
functionally active mature cells. 
Continuous in vivo infusion of recombinant human GM-CSF into primates 
stimulates femoral hemopoiesis and evokes leucocytosis and reticulocytosis (Donahue 
et al., 1986). A single injection of murine recombinant GM-CSF into mice increases 
the cycling rate of CFU-GEMM and CFU-GM but not of progenitors committed to 
the erythroid lineage (Brox:meyer et al., 1986). Multiple intraperitoneal injections 
of murine recombinant GM-CSF in mice increases overall numbers of granulocytes 
and macrophages and their functional activity. Furthermore, an increased splenic 
and a relatively decreased femoral non-erythroid progenitor content has been 
found (Metcalf et al.,1987). These observations strongly support the idea that 
GM-CSF is a regulator of granulocyte-macrophage populations. 
Lineage specificity of G-CSF is demonstrated in vivo by continuous intra-
venous infusion of (recombinant human) G-CSF in hamsters (Zsebo et al., 1986) 
and by multiple subcutaneous injections in monkeys (Welte et al., 1987). G-CSF 
increases the levels of peripheral neutrophilic granulocytes but has no effect on 
lymphocytes, monocytes or eosinophils in both hamsters and monkeys. Furthermore, 
G-CSF is capable to shorten the time period of granulocyte recovery after cyclo-
phosphamide(CTX)'-induced myelosuppression (Welte et al., 1987). Injection of EPO 
(the oldest purified HGF) into mice with suppressed erythropoiesis results in an 
increased erythroid proliferation and differentiation (Alexanian and Alfrey, 1970; 
Fried et al., 1970; Miller et al., 1983; Movssaghi et al., 1967) implicating an in 
vivo role for EPO in regulating erythropoiesis. 
GM-CSF and other HGFs are detectable in serum of mice and are increased 
in response to bacterial products, infections and other stress situations (Karp et al., 
1983; Metcalf et al., 1967; Ploemacher et al., 1986; Shadduck et al., 1971; Staber 
et al., 1978). Although no definitive proof is obtained it is very likely that the 
HGFs play a role in in vivo maintenance of hemopoiesis. The relative contribu-
tions of the different sources of HGFs (i.e. produced within the hemopoietic organs 
or outside bone marrow or spleen) are not known, however, it has been demon-
strated that granulopoietic proliferation is associated predominantly with intra-
medullary HGF production (Chan and Metcalf, 1972, 1973). Extramedullary CSF 
production occurs as a response to infection and tissue damage and attracts and 
activates granulopoietic and monocytic cells (Metcalf, 1985). 
The role of each different stromal cell type participating in the complex 
hemopoietic regulatory system and its capacity to produce HGFs will be discussed 
briefly below. 
1223.1 ENDOTHELIAL CELLS 
A definitive role for marrow endothelial cells in the regulation of hemo-
poiesis has not yet been found. They have been detected in LTBMC from human 
(Castro-Malaspina et al., 1981a; Keating and Singer, 1983) and murine bone marrow 
(Zuckerman and Wicha, 1983). Endothelial cell layers (not from bone marrow origin) 
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can be stimulated in vitro to produce specific hemopoietic regulators or colony 
stimulating factors (GM-CSA and burst- promoting activity) by monocyte/macrophage 
conditioned media (Bagby et al., 1983a, 1986; Zuckerman et al.,l985), probably 
interleukin 1 (IL-l) (Segal et al., 1987) and/or tumor necrosis factor (TNF) (Broudy 
et al., 1986a; Munker et al., 1986). Both, IL-l and TNF are monokines produced in 
response to an infection or tissue damage (Beutler et al., 1985; Pettipher et al., 
1986) and both agents can stimulate endothelial cells to produce hemopoietic 
regulator molecules. Furthermore, both factors induce the production of colony 
stimulating factors after in vivo injection (Vogel et al., 1987). Gamma interferon 
and lipopolysaccharide (LPS) also induce endothelial cells to produce colony-stimula-
ting activity (Adamson, 1986). Combining the above mentioned data, it is very 
likely that endothelial cells play a role in the local and/or systemic production of 
hemopoietic factors after an infection or other tissue damage. Whether endothelial 
cells play a role in regulating hemopoiesis in the bone marrow microenvironment 
is not known. 
122.32 RETICULAR FIBROBLASTS 
Long-term in vitro hemopoiesis is dependent on the development of a stromal 
layer. A quantitative and perhaps also qualitative important cell type in this stromal 
layer is the reticular fibroblast (reviewed by Bentley, 1984). In vivo the fibroblasts 
form a large three dimensional supportive network of cytoplasmic extrusions in 
association with reticular fibers throughout the marrow parenchyme (Weiss, 1976; 
Westen and Bainton, 1979). The fibroblastoid cells are not of hemopoietic origin as 
has been demonstrated using chromosomal markers (Golde et al., 1980; Hentel and 
Hirschorn, 1971; Lim et al., 1986) and the cultured fibroblastoid cells are different 
from macrophages and endothelial cells by surface markers (Piersma et al., 1985a), 
functional activity (phagocYtosis and synthesis of certain factors like fibronectin, 
collagen, laminin, and factor VIII), and morphology (Bentley and Foidart, 1980; 
Bentley et al., 1981; Castro-Malaspina et al., 1980; Jaffe and Mosher, 1978; Piersma 
et al., 1985a; Yamada and Olden, 1978). 
There is a lot of indirect (morphological) evidence that fibroblasts play a 
role in hemopoiesis both in mice and man (Chen and Weiss, 1975; Ploemacher et 
al., 1984a; Westen and Bainton, 1979). A supportive and determinative role for 
hemopoietic organ derived fibroblasts has been demonstrated after in vitro culture 
and autologous retransplantation of the cultured fibroblasts under the kidney 
capsule. These fibroblasts can produce an active hemopoietic tissue fragment similar 
to the place of origin, i.e. spleen or red or yellow bone marrow (Bainton et al., 
1986; Friedenstein et al., 1974a; Patt et al.,l982). The fibroblasts derived from red 
or yellow marrow do not differ morphologically by electron microscopy and both 
produce the same types of collagen (I and III). However, these fibroblasts differ 
strikingly in enzymatic content of alpha-naphtylbutyrate esterase, which is abundant 
only in the yellow marrow derived cells (Bainton et al.,l986). Whether yellow and 
red marrow fibroblasts display different phenotypes of the same cell type or are 
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in fact different cell groups is unknown. The first option is more likely since 
fibroblastoid cells can be induced to produce fat (Greenberger, 1978; Tavassoli, 
1984a). A decreasing hemopoietic activity is correlated with an increasing content 
of adipocytes in vivo and perhaps also in vitro (Touw and Lowenberg, 1983). 
Indirect evidence for an in vivo regulating role in hemopoiesis of fibroblastoid 
cells is demonstrated by the capability of these cells to produce several regulator 
molecules in vitro (Blackburn and Patt, 1977; Brockbank and van Peer, 1983; 
Harigaya et al., 1981; Wilson et al., 1974; Zipori et al., 1982). However, some 
groups have failed in detecting CSA in both murine and human fibroblast-condi-
tioned media (Bentley and Foidart, 1980; Castro-Malaspina et al., 1980; Greenberg 
et al., 1981). This may be due to consumption or degradation of the produced 
growth factor(s) by contaminating cells e.g. macrophages (Ploemacher et al., 1984; 
Tushinski et al., 1982). With the help of other cells or cell products, e.g. macro-
phages, T lymphocytes, endothelial cells, or ll-1, fibroblasts can also produce 
multilineage growth factors (Broudy et al.,1986b; Zucali et al., 1986) or other 
regulating factors (Nagao et al., 1986; Piersma et al., 1985a; Zipori et al., 1985). 
Furthermore, some bone marrow derived fibwblastoid cell lines have been reported 
to support the continuous growth of early hemopoietic and lymphoid progenitors 
(Hunt et al., 1987; Quesenberry et al., 1987). 
There exists ample evidence for a regulatory role of fibroblastoid cells in in 
vitro culture systems, but their role in regulating hemopoiesis in the marrow HM 
is not (yet) proved. The relation of fibroblastoid progenitors with disease and the 
quantitative and qualitative differences during disease and after cytotoxic treatment 
will be discussed in chapter !.3.3. 
L2.233 MACROPHAGES 
The resident bone marrow macrophages are stromal cells derived from the 
PHSC and can be distinguished from fibroblasts and endothelial cells by their 
capacity to phagocytise, by surface membrane antigens (Springer et al., 1979), and 
by acid phosphatase activity. Many studies have shown intimate associations between 
macrophages ~d developing hemopoietic cells and some of the macrophages possess 
long cytoplasmic protrusions which surround developing hemopoietic cells from 
both erythroid and myeloid lineages, e.g. the central macrophage in erythroblastic 
islets in bone marrow and in the adult murine liver after phenylhydrazine-induced 
hemolytic anemia and the resident bone marrow macrophage (Bessis et al., 1978; 
Crocker and Gordon, 1985; Hume et al., 1983; de J ong et al., 1987; Ploemacher, 
1978). Macrophages are a very heterogeneous cell population with respect to the 
presence of specific surface antigens and perhaps also with respect to functional 
activity (Crocker and Gordon, 1985; de Jong et al., 1987). 
Macrophages can produce multilineage and lineage specific growth factors, 
including EPO (Nicola and Vadas, 1984; Rich et al., 1982), and products that 
stimulate fibroblasts (Zuckerman et al., 1985) and T lymphocytes (Bagby et al., 
1981) to produce multilineage and lineage-specific growth factors. The in vitro 
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production of EPO (and other growth factors) by macrophages can be regulated by 
varying the oxygen tension during culture (Pennathur-Das and Levitt, 1987; Rich, 
1986a, 1986b ). On the other hand, macrophages can inhibit cell growth by degrading 
growth factors (Ploemacher et al.,1984a; Tushinski et al., 1982) or by producing 
inhibiting factors (reviewed by Broxmeyer, 1984; Moore et al., 1984; Resnitzky et 
al., 1986). Recently it has been demonstrated by Gewirtz et al. (1986) that removal 
of macrophages from a bone marrow culture from a patient with acquired amega-
karyocytic thrombocytopenic purpura (AATP) significantly augments megakaryocyte 
formation. This megakaryocyte inhibitory activity has been found also in the medium 
conditioned by the patients macrophages. It has been suggested that in some cases, 
AA TP may be due to a stromal defect, in particular a dysfunction of macrophages 
regulating megakaryocytopoiesis (Gewirtz et al., 1986). Furthermore, other factors 
(e.g. lactoferrin, produced by neutrophilic granulocytes) may modulate macrophages 
to produce regulator molecules (Bagby et al.,1983a). These observations taken 
together seem to indicate that macrophages in the HM play a role in the regulation 
of hemopoiesis. 
1223.4 T LYMPHOCYTES 
T lymphocytes are derived from the PHSC and usually are not considered to 
be a part of the hemopoietic stroma. Activated T lymphocytes are thought to be 
the only cell type capable of producing the multilineage growth factor IL-3 (Ihle 
et al., 1983; Parker and Metcalf, 1974). However, some cell lines, not derived from 
T cells, also produce IL-3 (Iscove et al.,1982; Metcalf et al., 1969). Activated T 
lymphocytes have the ability to produce other factors that stimulate hemopoiesis, 
e.g. GM-CSF (Cline and Golde, 1974; Gasson et al., 1984; Metcalf and Johnson, 
1978; Pluznik et al., 1986; Staber et al., 1982). The production and/or release of 
these growth factors (IL-3 and GM-CSF) by T lymphocytes may be regulated by 
different (so far unknown) mechanisms, since IL-3 production is inhibited by 
cyclosporin-A while GM-CSF production is not affected (Pluznik et al., 1986). 
Furthermore, T lymphocytes have been implicated in regulation of seeding, prolifera-
tion and differentiation of hemopoietic stem cells and early committed progenitors 
(Goodman et al., 1980; McMillen and Simmons, 1981). These effects ofT lymphocytes 
can be interpreted as effects produced by interactions between lymphocytes and 
marrow stromal cells (Gordon et al., 1982; Wiktor-Jedrzejczak et al., 1981). Although 
not essential for in vitro bone marrow hemopoiesis, T lymphocytes may play a 
role in regulating both early and mature stages of erythroid differentiation (Estrov 
et al., 1986; Goodman and Shinpock, 1972; Keller et al., 1983; Lipton et al., 1983; 
Lord and Schofield, 1973; Lu et al., 1986; Torok-Storb ·et al., 1981; Wiktor-Jedr-
zejczak et al., 1977). In addition, hemopoiesis in long-term cultures with a splenic 
stromal layer are dependent on the presence of T lymphocytes, while the T lympho-
cytes appear to play no role in the maintenance of hemopoietic activity in LTBMC 
(Keller et al., 1983). Recently, two separate thymocyte populations have been 
isolated, one of which stimulated in vitro erythropoiesis, while the other (larger) 
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population inhibited erythroid colony formation (Sharkis et al., 1986). In humans it 
has been shown that bone marrow cultures with lymphocytes from patients with 
Diamond-Blackfan syndrome (Hoffman et al., 1976) or aplastic anemia (Ascensao et 
al., 1976; Hoffman et al., 1977; Torok-Storb et al., 1980) can inhibit erythroid 
and/or myeloid colony formation. Lymphocytes from a patient with acquired amega-
karyocytic thrombocytopenic purpura are capable to inhibit megakaryocyte formation 
(Gewirtz et al., 1986). Furthermore, some patients with granulopoietic failure (low 
blood neutrophil counts and low CFU-GM colonies in bone marrow) had steroid-
sensitive T lymphocytes in their bone marrow inhibiting CFU-GM formation (Bagby 
et al., 1983b), again suggesting a role forT lymphocytes in (dys)regulating hemato-
poiesis. 
In conclusion, within the HM a variety of different cell types participates 
in the regulation of hemopoiesis by producing HGFs and other stimulating or 
inhibiting substances. These accessory cells also produce immunoregulatory cytokines 
(IL-l, IL-2) which stimulate cells in their proximity to produce HGFs (Bagby et 
al., 1983a; Kasahara et al., 1983). Thus, a complex mechanism of interacting marrow 
cells and locally produced humoral factors appears to regulate hemopoiesis. The 
extramedullary produced HGFs also exert their effects locally, as suggested by the 
observation that in response to an infection, HGFs attract and activate the cells 
which can eliminate micro-organisms initiating the response. Only in severe infec-
tions HGF levels are high enough to stimulate the bone marrow (Metcalf, 1985). 
13 ASSAYS TO STUDY THE HEMOPOIETIC STROMA 
Several assays have been developed to assess the functional activity of the 
hemopoietic stroma. The functional activity of the hemopoietic stroma, with respect 
to the assays used, and other factors determining the test results can be separated 
into: (a) the proliferative status of stromal cells; (b) the hemopoietic supportive 
function of stromal cells, e.g. the production of growth factors or (c) a combination 
thereof. 
Under normal conditions the hemopoietic stroma shows little proliferative 
activity (Caffrey et al., 1966; Haas et al., 1969; Kaneko et al., 1982; Meyer-Hamme 
et al., 1971). However, when there is an extra demand for functional cells (e.g. 
infection or blood loss) regeneration and remodelling of the hemopoietic stroma 
does occur, including proliferation of stromal cells, in addition to increased pro-
liferation of hemopoietic progenitors (Da et al., 1986; Hashimoto, 1962; McClugage 
and McCuskey, 1970; McCuskey et al., 1971). The application of assays in which 
stromal cells are induced to proliferate can be used to measure proliferative defects 
and to estimate the capacity of the hemopoietic stroma to respond to stress-induced 
proliferation or to replace non-functional stromal cells in vivo. In some mouse 
strains this reserve capacity of splenic and femoral stromal cells to proliferate 
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attenuates with increasing age although these cells do not show evidence of in 
situ failure during the normal life-span of the animal (Hotta et al., 1980; Ploe-
macher, 1981; Wolf and Arora, 1982). However, this diminution of stromal cell 
reserve capacity may be expected to become apparent when a destructive agent 
causing reduction of the stromal cells is followed by a demand for these cells to 
replicate. Examples for this hypothesis will be discussed later. 
Indications to justify separation of the stromal functions are demonstrated 
by several authors. They all show that a defective proliferative capacity of the 
stroma is not necessarily accompanied by a defective stromal ability to support 
hemopoiesis in vivo and in vitro (Laver et al., 1986; Naparstek et al., 1985; 1986; 
Ploemacher et al., 1983). The assays used to determine stromal function in the 
experiments described in this thesis will be discussed briefly below. 
13.1 QUANTIFICATION OF PERIPHERAL BLOOD CELLS AND 
HEMOPOIETIC PROGENITORS IN SPLEEN AND BONE 
MARROW 
Quantification of peripheral blood cell numbers (leucocytes and erythrocytes) 
and hemopoietic progenitor cell numbers (CFU-s, BFU-E and CFU-GM) in the 
hemopoietic organs (spleen and femur) can be used to determine the in vivo stro-
mal capacity to maintain hemopoiesis, on the condition that the quantity and the 
quality of the PHSC is normal. The usefulness of quantification of peripheral 
blood cells to estimate stromal function is limited. Changes in the production rate, 
and compensatory proliferation from committed progenitors do occur (Cronkite et 
al., 1985) and mask damage.· to the hemopoietic stroma. However, since immediate 
survival of the individual is .dependent upon the presence of normal functional end 
cells, determination of these cells after cytotoxic treatment is necessary to control 
the acute effects of cytotoxic treatment. Quantification of CFU-s or CFU-GM has 
been used often to determine the damage to the hemopoietic stroma caused by 
radiation (Kedo et al., 1976; Nelson et al., 1977; Ploemacher et al., 1983), cytostatic 
agents (Fried and Barone, 1980) or a combination of both (Gregory et al., 1971; 
Wathen et al., 1981, 1982). This assay gives information about the total functional 
activity of the in situ hemopoietic stroma and in contrast with almost all other 
stromal assays discussed below, stromal cells are not forced to proliferate. However, 
any conclusions on possible functional insufficiency of specific stromal cell popula-
tions can not be made. 
132 ECfOPIC IMPLANTATION OF BONE MARROW OR SPLEEN 
Femurs (with both ends cut off) and spleens, or marrow plugs and spleen 
fragments, can be implanted in the subcutaneous tissue of the abdomen or under 
the kidney capsule. The implanted organs show extensive regeneration with accom-
panying partial restoration of hemopoiesis over a period of a few weeks. 
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In contrast with other organs, like kidney or liver, the bone marrow tissue 
does not undergo coagulation necrosis after subcutaneous implantation (Tavassoli, 
1976; Tavassoli and Crosby, 1970, 1971). The marrow tissue has an angiogenic 
potency. Within 12 hours after implantation newly formed host-derived capillaries 
pierce into the implant and make contact with the donor capillaries and sinus-
aids. This revascularization is necessary for the survival and regeneration of the 
hemopoietic stroma. The hemopoietic stroma is sensitive to lack of vascular supply 
and if this is interrupted for more than 12 hours, e.g. by transferring the implant 
to a new site during the first day, the implant does not survive (Tavassoli, 1976). 
If the vascular supply is restored in time, marrow regeneration can be divided 
into four phases: (1) loss of hemopoietic cells and proliferation of the surviving 
stromal cells to form a monotonous tissue resembling primitive mesenchym within 
4-6 days after transplantation; (2) formation of primitive sinusoids of donor origin 
and cancellous bone between 6- 10 days; (3) maturation of sinuses and ( 4) active 
hemopoiesis from 2 weeks after transplantation. The maximal hemopoietic activity 
is achieved 4 to 6 weeks after implantation (10-25% of the activity in a non-trans-
planted femur) and this remains constant for the rest of the animal's life (Sahe-
bekhtiari and Tavassoli, 1978; Tavassoli, 1984b ). 
In contrast to the bone marrow transplant, the spleen transplant undergoes 
coagulation necrosis like subcutaneous transplants from kidney or liver, but a 
small peripheral rim of splenic stromal cells survives and subsequently reconstructs 
the stromal compartment in the necrotic center of the spleen and restoration of 
hemopoietic activity occurs within a few weeks (Chamberlin et al., 1974; Ploe-
macher et al., 1982; Tavassoli, 1976; Tavassoli et al., 1973a). 
The growth of the implanted organs is under influence of host factors. Implant 
growth, in particularly that of the splenic implants, is stimulated by irradiation of 
the host before implantation, or by bleeding or hypertransfusion of the host during 
growth of the implants (Chamberlin et al., 1974; Molineux et al., 1987; Ploemacher 
et al., 1982). Furthermore, growth of the implants is dependent on the sex of the 
recipients. Female mice do not stimulate the growth as well as male recipients. 
This suppressive effect in female mice is partly strain-dependent and can be reduced 
considerably by sublethal irradiation of the female recipients before implantation. 
In addition, radiation chimeras with bone marrow of male origin support the growth 
of implants better than those recipients in which the bone marrow is of female 
origin (Schofield, 1986a). An explanation for these observations has not been 
provided. 
The stromal cells (fibroblasts, osteoblasts, endothelial cells, adventitial reticular 
cells and bone-forming cells) of the implant are mainly from donor origin and the 
majority of the hemopoietic cells (CFU-s and CFU-GJM) are host derived (Amsel 
and Dell, 1971; Fried et al., 1973a; Friedenstein et al., 1968; Hotta et al., 1983; 
Maniatis et al., 1971; Sahebekhtiari and Tavassoli, 1978; Tavassoli and Khademi, 
1980). Thus, the total amount of hemopoietic cells and/or hemopoietic progenitors 
(CFU-s, BFU-E and CFU-GJM) accumulated in the implants 6-8 weeks after 
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implantation can be used to estimate the stromal regenerative capacity or stromal 
function of the in situ hemopoietic stroma from the implant donors. 
The hemopoietic activity in the ectopic implants is qualitatively comparable 
with the activity at the place of origin. Thus, yellow marrow implants remain 
yellow and red marrow implants show hemopoietic activity comparable with red 
marrow (Bigelow and Tavassoli, 1984). As mentioned in a previous chapter, marrow-
derived fibroblasts implanted beneath the kidney capsule can also produce hemo-
poietic active ossicles, with similar hemopoietic activity as seen in the place of 
origin (Bainton et al., 1986; Patt et al., 1982). Furthermore, when hemopoietic 
organs from mice with a congenital anemia caused by a hemopoietic stromal defect 
(mice of the Sl!Sld genotype with a severe macrocytic anemia (Bernstein et al., 
1968; McCulloch et al., 1965; Russell, 1979), and the SP/ + mutant mouse strain 
with a mild macrocytic anemia (Mintz and Cronmiller, 1978), are implanted into 
normal hosts with normal stem cells, they remain deficient in their capacity to 
stimulate hemopoiesis (Fried et al., 1973b; Ploemacher and Brons, 1984; Tavassoli 
et al., 1973b). An excellent demonstration of conservation of an implants functional 
background is the observation that the stromal defect in Sl!Sld mice can only be 
cured following transplantation of normal stroma (Bernstein, 1970; Wolf, 1974) and 
not after injection of normal BMC (McCulloch et al., 1965; Sutherland et al., 
1970). Normal implants do not affect the macrocytic anemia in W/Wv mice, which 
have an inherited stem cell defect (Tavassoli et al, 1973b). There are indications 
that in some mouse strains the proliferative capacity of hemopoietic stroma de-
creases during aging, resulting in a decreased hemopoietic activity in the implants 
(Hotta et al., 1980; Ploemacher, 1981; Wolf and Arora, 1982). Thus, the growth of 
implants may be considered as a functional test for the hemopoietic stroma. The 
above mentioned experiments also indicate that the stroma of the implants is from 
donor origin and that the normal stromal cells or cell products from the host do 
not migrate to establish normal stromal function in the implants from donors with 
an inherited stromal defect. However, recently it has been suggested that the 
recipient may in some way contribute to the development of the stromal microen-
vironment of the (femoral) implants and may be able to improve hemopoietic activity 
in the implants derived from mice with the Sl!Sld genotype (Ebbe et al., 1977; 
Schofield et al., 1987). The latter observations indicate that measurement of 
impaired stromal function using the implant assay may be underestimated. 
The development of hemopoietic activity in implants derived from mice with 
a virus-induced leukemia transplanted into normal mice is not impaired but after 
normal hemopoietic reconstitution the implants are rapidly invaded by leukemic 
cells transplanted together with the implant (Levy et al., 1976; Ratzan et al., 
1973). This observation suggests a normal stroma in this experimentally induced 
leukemia. The treatment of leukemia with radiation or chemotherapy, however, can 
damage the regenerative capacity of the subcutaneously implanted organs. Radiation 
with 5 Gy or more diminishes the regenerative capacity of femoral and splenic 
implants and they show no sign of recovery up to at least 1 year after irradiation 
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(Chamberlin et al., 1974; Fried and Adler, 1985; Fried et al., 1976; Piersma et al., 
1983a; Ploemacher and van Soest, 1979; Ploemacher et al., 1983). The alkylating 
agents CTX and busulfan (BU) are also capable to diminish the regenerative capacity 
(Adler and Kuznetsky, 1984; Fried and Barone, 1980; Fried et al., 1977). Within 24 
weeks after CTX but not after BU injection, normalization of the implant regenera-
tion is found (Fried and Adler, 1985). These authors suggest qualitative differences 
in damage caused by CTX, BU, or irradiation. The question as to which cell 
population is most vulnerable for these cytotoxic treatments remains unsolved. 
Some other cytostatic agents, e.g. bleomycin, do not damage the regenerative 
capacity of the femoral stroma (Adler and Kuznetsky, 1984). These observations 
make it likely that only radiation and a small group of cytostatic agents, interfering 
with DNA structure, and perhaps some other drugs like chloramphenicol (Nara et 
al., 1982), are capable of suppressing the regenerative ability of hemopoietic stroma. 
133 IN VITRO CULTURE OF FIBROBLASTOID STROMAL CELLS 
This chapter deals with the quantitative and qualitative differences in fibro-
blastoid colony formation during disease and following treatment with radiation or 
drugs in both animals and humans. 
In vitro culture of bone marrow-derived fibroblastoid cells is described for 
the first time by Carrel and Burrows (1910). Populations of cells from hemopoietic 
organs (spleen and bone marrow) formed adherent colonies in in vitro cultures. 
The predominant cell type in these adherent colonies are fibroblast-like cells. The 
fibroblastoid nature is further identified by their capacity to synthetize collagen 
type I and fibronectin (B~ntley and Foidart, 1980; Reincke et al., 1982a). The 
clonal nature of these fibroblastoid cell colonies has been demonstrated by Frieden-
stein et al. (1974a) and many others (Castro-Malaspina et al., 1980; Gordon and 
Gordon-Smith, 1981; Greenberg et al., 1981; Nagao et al., 1981). Friedenstein et al. 
(1974a) also has introduced the concept of the fibroblastoid colony-forming unit 
or CFU-F, a stromal precursor cell capable of extensive proliferation, and of 
formation of a stromal tissue characteristic of the organ of origin and capable to 
produce, in in vitro culture, colonies of at least 50 cells. 
Hemopoietic organ fibroblasts of several different mouse strains with hemo-
poietic deficiencies have been studied. The number of CFU-F colonies is normal in 
the bone marrow of mice with the Sl!Sld genotype (Brockbank and Ploemacher, 
1983; Wiktor-Jedrzejczak, et al., 1983; Wilson and O'Grady, 1976) and the SP/ + 
genotype (Brockbank and Ploemacher, 1983). The increased content in splenic 
CFU-F found in Sl!Sld mice is not specific for a stromal· defect but related to a 
general response to chronic anemia (Brockbank and Ploemacher, 1983; Brockbank 
et al., 1985). So far, the only mouse strain studied which may have a defect in 
CFU-F quantity (low femoral CFU-F numbers) and quality (interaction with other 
stromal cells or growth factor production) is the mouse strain with congenital 
osteopetrosis, the op/op mouse. This defect is characterized by an absence of 
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functional osteoclasts (Marks and Lane, 1976) and a defective macrophage matura-
tion accompanied with normal granulocyte numbers (Wiktor-J edrzejczak et al., 
1982). The defect in these mice can not be cured after a BMT with normal BMC, 
but BMC from op/op mice can reconstitute lethally irradiated mice in a normal way. 
BMC from op/op mice differentiate into mature macrophages in vitro when provided 
with CSA from normal mice and it has been reported that an intraperitoneal injec-
tion of op/op mice with conditioned medium from normal fibroblasts results in the 
production of mature macrophages (Wiktor-Jedrzejczak et al., 1982). Under normal 
culture conditions the fibroblast colonies are contaminated with macrophages and 
it has been suggested that macrophage progenitor cells (which are present in the 
cell suspensions used to culture CPU-F) are stimulated to proliferate by the fibro-
blastoid cells and overgrow the fibroblastoid colonies (de Jong et al., 1987; Wiktor-
Jedrzejczak et al., 1983). The contamination of CFU-F colonies with macrophages 
(high in normal mouse CFU-F cultures) is very low in op/op mouse, presumably 
because of the lack of growth factor production (Wiktor-Jedrzejczak et al., 1982). 
These observations are very suggestive for a functional defect in fibroblastoid 
cells from op/op mouse resulting in insufficient monocyte/macrophage differentia-
tion. 
Femoral CFU-F content has been studied also in leukemic mice. In a murine 
myeloid leukemia models the CPU-F content has been observed to decrease with 
increasing tumor load (Ben-Ishay et al., 1984, 1985). This decreased CFU-F colony 
formation can also have resulted from inhibitory factors produced by leukemic 
cells during in vitro CFV-F colony formation (Ben-Ishay et al., 1984). Furthermore, 
Nagao et al. (1983a, 1983b) have demonstrated that human leukemia cells also can 
produce factors that inhibit CFU-F colony formation. Using another murine leukemia 
mode~ it was demonstrated that the femoral CFU-F content declines in the early 
stages of viral leukemogenesis while hemopoietic progenitors were not affected 
(Zipori and van Bekkum, 1979). In addition, Zipori and Bol (1979) suggested that 
fibroblastoid cells stimulated leukemic cells in vitro. 
Sublethal irradiation of mice with 5-9 Gy severely decreases the CFU-F 
content of hemopoietic organs (Friedenstein et al., 1976, 1981; Greenberger et al., 
1982; Piersma et al., 1983a, 1985b; Ploemacher et al., 1983; Xu et al., 1983). Follo-
wing irradiation recovery of the CFU-F population is very slow and incomplete 
for a period of 3 up to 18 months after irradiation (Greenberger et al., 1982; Piersma 
et al., 1983a, 1985b; Ploemacher et al., 1983; Xu et al., 1983). Repopulation of 
CPU-F in the bone marrow can be enhanced after a second stromal damage e.g. 
LPS injection (Piersma et al., 1985b ). From these observations it has been suggested 
that the irradiated stroma still contains the majority of viable fibroblastic cells, 
but that they have lost their proliferative capacity to form colonies in vitro due 
to latent radiation damage. Thus, radiation-damaged CFU-F that are not capable 
to form colonies in vitro, are possibly replaced by surviving CFU-F after LPS-
induced CFU-F proliferation. However, a decreased proliferative capacity of stromal 
cells does not necessarily imply a decreased in situ functional activity (e.g. to 
18 
produce colony-stimulating activities) of these cells sUTVlvmg the irradiation as 
has been shown for femoral stromal cells (Laver et al., 1986; Naparstek et al., 
1985; 1986; Song and Quesenberry, 1984; Zuckerman et al., 1986a) and thymic 
stromal cells (Hirokawa and Sado, 1984). 
In addition to irradiation, injection of some cytotoxic agents have also been 
reported to induce an acute decrease in CPU-F colony formation. A diminished 
femoral CFU-F content has been found after injecting mice with the alkylating 
agents BU or CTX. Following this initial decline the CFU-F population size slowly 
returns to suboptimal levels (McManus and Weiss, 1984; Molineux et al., 1986a, 
1986b; Testa et al., 1985). The combination of radiation and either BU (Wathen et 
al., 1982) or CTX (Wathen et al., 1981) also causes a long-term defect in the 
marrow CFU-F population size. In contrast, injection of Ara-C and adriamycin in 
normal or leukemic mice enhances the femoral CFU-F content (Ben-Ishay et al., 
1985). Sofar no explanation is available for the lather observation. 
In humans CFU-F quantity and to a lesser extent CFU-F quality has been 
studied in several hematological disorders like myelofibrosis, aplastic anemia, 
myelodysplastic syndromes and leukemia. The CFU-F colony formation has been 
studied also after irradiation and/or cytotoxic agent treatment for leukemia and 
other malignancies. 
The CFU-F population size and the functional activity of the cultured CFU-F 
from almost all patients studied with "idiopathic myelofibrosis" are within normal 
ranges (Castro-Malaspina and Jharwar, 1984; Castro-Malaspina et al., 1982; Hotta 
et al., 1985a). In most myelofibrotic patients an increased content of myeloid 
and/or megakaryocytic progenitors is found (Hotta et al., 1985a; McCarthy, 1985). 
It has been suggested that abnormal megakaryocytes release platelet -derived growth 
factor (PDGF) (Castro-Malaspina et al., 1981b; Groopman, 1980). PDGF stimulates 
collagen production and it is a potent mitogen for fibroblast proliferation. Although, 
the number of CFU-F in the bone marrow is not affected, PDGF enhances the 
CFU-F colony size (Hirata et al., 1985). The current opinion is that. marrow fibrosis 
is not the result of an intrinsic CFU-F disturbance but is the response to an 
abnormal or excessive release of (a) factor(s) that stimulate fibroblasts to proli-
ferate and secrete collagen. Further support for a reactive origin of myelofibrosis 
are the observations that myelofibrosis occurs in the rare "grey platelet" syndrome 
with excessive release of PDGF (Coller et al., 1983; Drouet et al., 1981), and that 
myelofibrosis in leukemia patients disappears after treatment of the leukemia 
(Manoharan et al., 1979; Mehta et al., 1983; Myers et al., 1974; Obion et al., 1983; 
Wolf et al., 1982). 
The results of CPU-F quantification in patients with aplastic anemia or 
leukemia and in patients treated for leukemia with irradiation and/or cytotoxic 
agents can be seen in Table !.1 CFU-F colony numbers in the bone marrow of 
patients with aplastic anemia are variable and this may be due to the heterogeneity 
in origin of aplastic anemia, i.e. a defective PHSC, autoimmune mechanisms (Ascen-
sao et al., 1976) or stromal defects (Ershler et al., 1980). There are some indications 
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that a small group of patients may have developed aplastic anemia because of a 
defective HM expressed as a decreased marrow CFU-F content (Reynolds and 
McCann, 1985; Vladimirskaya et al., 1981). At diagnosis of acute leukemia and 
after relapse CFU-F colony formation is decreased, in most patients, but increases 
after chemotherapy treatment and returns to normal after achievement of complete 
remission (Table I.l). The suppression of CFU-F colony formation during leukemia 
could be the result of an inhibitory factor produced by leukemic cells (Nagao et 
al., 1983a). Furthermore, severe treatment of leukemia with chemotherapy and/or 
irradiation has been reported to reduce the CFU-F content significantly for a 
period upto 40 months after cessation of treatment (Da et al., 1986; Haworth et 
al., 1982). 
Table 1.1. CFU-F quantity in human bone marrow during disease or after 
leukemia treatment 
anemia or leukemia 
before or after 
treatment 
CFU-F number Reference 
aplastic anemia normal 
increased 
decreased 
leukemia at diagnosis normal 
or relapse 
decreased 
leukemia in complete (sub )normal 
remission after 
chemotherapy 
decreased 
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Gordon and Gordon-Smith, 1981 
Kaneko et al, 1982 
Nagao et al., 1981 
Juneja et al., 1984 
Reynolds and McCann, 1985 
Vladimirskaya et al., 1981 
Greenberg et al., 1981 
Bruzzone and Minguell, 1985 
Nagao et al., 1983a, 1983b 
Vladimirskaya et al., 1981 
Bruzzone and Minguell, 1985 
Nagao et al., 1983a, 1983b 
Vladimirskaya et al., 1981 
Da et al., 1986 
Haworth et al., 1982 
Data on the qualitative aspects of the CFU-F colonies from patients with 
hematological disorders are limited. In some patients with aplastic anemia it is 
suggested that they have developed the anemia because of a defective functional 
activity of the fibroblasts, i.e. the inability of the CFU-F colonies to stimulate 
hemopoiesis in vitro (Gordon and Gordon-Smith, 1983; Hotta et al., 1985b; Juneja 
and Gardner, 1985; Juneja et al., 1984). In a few patients with a myelodysplastic 
syndrome the defect may be the result of a disturbed hemopoietic regulatory 
activity of the fibroblasts (Zipori et al., 1985). 
In general, quantitative CFU-F determinations in the individual patient are 
of limited usefulness due to the large variation in normal values, although in large 
groups of patients some general conclusions can be made (see above). As has been 
shown in animal experiments, CFU-F quantification may predict the reserve capacity 
of the stroma to regenerate and to replace damaged stromal cells after chemo-
therapy or irradiation-induced damage (Friedenstein et al., 1976; Hotta et al., 
1983; Tavassoli et al., 1973a). More important, however, may be the assessment of 
the ability of CFU-F derived cells (i.e. fibroblasts) to produce hemopoietic growth 
factors to study the effects of disease and chemotherapy or radiation treatment. 
13.4 WNG-TERM BONE MARROW CULTURES 
The long-term bone marrow culture (LTBMC) system has been introduced by 
Dexter and Lajtha (1974) and is sofar the best in vitro representative for in vivo 
hemopoiesis. For an overview of the technique the reader is referred to excellent 
reviews by Dexter et al. (1984) and Eastment and Ruscetti (1984). Briefly, murine 
or human marrow cells are. inoculated in flasks and an adherent stromal layer is 
allowed to develop for 2-4 weeks. This stromal layer is essential for the develop-
ment of long-term hemopoietic activity. Using optimal culture conditions the 
hemopoietic progenitors survive during the initial growth phase of the adherent 
layer and 2-4 weeks after initiation of the culture maintenance and production of 
hemopoietic progenitors can be measured. This is the so called "one phase" LTBMC 
(see fig.I.l A). A serious disadvantage is that only unseparated BMC can be used 
as these contain both the precursors for development of the stromal layer and for 
the initiation of hemopoiesis. If the LTBMC is set up from BMC derived from 
previously cytotoxic agent-treated mice, hemopoietic activity may be diminished 
due to hemopoietic progenitor damage. This LTBMC system can be supplemented 
with normal hemopoietic progenitors without stromal cells at the time of inoculation 
to "overrule" the presumptive cytotoxic agent damaged hemopoietic progenitors. It 
is assumed that the production of hemopoietic cells in the latter LTBMC system 
is solely dependent upon stromal integrity (see fig.I.1 B). Using the "two phase" 
LTBMC system (see fig.I.l C), a tissue culture flask is inoculated with BMC and 
after establishment of the stromal layer hemopoietic activity is achieved by addition 
of a second inoculum of hemopoietic progenitor cells. Before addition of the second 
inoculum of hemopoietic cells the established stromal layer may be irradiated to 
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~->/-> ~ weeks ~ -> -> hemopoietic A cell production ~ ~ + BMC weeks ~ -> ~ -> hemopoietic B cell production 
f· I BMC 
~1-2weeks v ~ weeks ~ -> -> -> hemopoietic c cell production 
Figure Ll The long-tenn bone marrow culture system. See text for explanation 
eradicate the hemopoietic progenitors that may have survived during the initial 
growth phase of the stromal layer. Hemopoietic activity can be observed for at 
least one year depending on the species used. 
The relation between hemopoietic and marrow stromal cells has been studied 
extensively in this culture system both morphologically and functionally (see also 
the previous chapter). The stromal elements in the adherent layer of LTBMC 
include endothelial cells, reticulum cells, adipocytes, fibroblasts, T lymphocytes, 
macrophages and 'blanket cells' (Allen, 1981; Dexter, 1982; Dexter et al., 1984; 
Shibata and Inoue, 1986). The existence of endothelial cells in murine LTBMC is 
still controversial (Allen, 1981, Zuckerman and Wicha, 1983), but they have been 
demonstrated in human LTBMC (Keating and Singer, 1983; Toogood et al., 1980). 
The adipocytes in LTBMC are most likely not derived from macrophages as sug-
gested by Tavassoli (1984a), but are derived from other cells, e.g. the fibroblastic 
reticulum cell (Simmons et al., 1983). The blanket cell, recently characterized by 
Dexter et al. .(1984) and also suggested to be of reticulum cell origin, is a large 
well-spread polygonal cell, alkaline phosphatase-positive, and capable to produce 
extracellular fibronectin and laminin (Allen and Dexter, 1984). This cell type owns 
its name to the association with granulopoietic cobblestone areas, which occur 
beneath the blanket cell layer (Dexter et al., 1984). Maintenance of hemopoiesis is 
also possible from spleen cell-derived adherent layers, although hemopoietic activity 
has not been observed beyond week 6 of culture. Splenic stem cells seeded onto a 
bone marrow-derived adherent layer, however, maintain hemopoiesis as well as 
BMC (Keller et al., 1983). These authors have suggested that the long-term main-
tenance of hemopoiesis in bone marrow-derived adherent layers is the result from 
a particular BMC class necessary for the regulation of extensive self renewal and 
maintenance of stem cells. These cells are apparently not present in spleen-derived 
adherent layers. 
The most primitive hemopoietic progenitors in LTBMC are found within the 
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adherent layer. The self renewal capacity of adherent stem cells is much higher 
than that displayed by their non-adherent derivatives (Coulombe! et al., 1983a; 
Crouse et al., 1984; Mauch et al., 1980; Reincke et al., 1985; Sharp et al., 1985). 
Furthermore, maintenance of primitive stem cells is dependent upon close cell-cell 
interactions with stromal cells and it has been suggested that also in vitro, 
primitive stem cells reside in "niches" (Sharp et al., 1986), as has been proposed 
for in vivo stem cell maintenance (Schofield, 1978). The existence of such niches 
in vitro is stressed by the observations of Sharp et al. (1986), who have been 
demonstrated that a tissue culture flask can only support a limited number of 
stem cells, and that saturation of the adherent layer with stem cells occurs after 
repeated refeedings with fresh bone marrow. The hemopoietic progenitors proliferate 
and differentiate continuously, resulting in long-term production of all hemopoietic 
progenitors including CFU-s (Dexter et al., 1977b), CFU-C (Dexter et al., 1977b; 
Williams et al., 1977), BFU-E (Eaves et al., 1979; Eliason et al., 1979), CFU-Meg 
(Williams et al.,1978) and lymphoid progenitors (Dexter et al., 1977b; Jones-Ville-
neuve and Philips, 1980; Schrader and Schrader, 1978). 
Hemopoietic activity in LTBMC occurs focally. In murine LTBMC, granulo-
poiesis is in close association with adipocytes and an increased adipocyte content 
is associated with increased granulopoiesis (Greenberger, 1978). In contrast, adipo-
cytes in human LTBMC have no stimulatory effect on hemopoiesis and increased 
fat cell formation is correlated with a decreased hemopoietic activity in vitro 
(Touw and Lowenberg, 1983), as has been observed in vivo in humans (Tavassoli, 
1984a). Normally, mature erythrocyte production is not observed in LTBMC,' but 
can be induced by supplementing the cultures with anemic mouse serum and EPO 
(Dexter et al.,1981). Within 2-3 weeks after addition of anemic mouse serum and 
EPO, erythropoiesis is induced and granulopoiesis inhibited, accompanied with a 
marked decrease in adipocyte numbers. Erythroid activity is found in areas separate 
from the previously active granulopoietic regions (Allen, 1981). Long-term bone 
marrow cultures produce colony stimulating factors, but their role in these cultures 
has not yet been elucidated (Gualtieri et al., 1984; Lipschitz et al., 1987a; Shadduck 
et al., 1983). 
The LTBMC system has been used to study the effects of aging upon the HM. 
The results obtained from these investigations are controversial and vary between 
no effect of aging of the microenvironment upon hemopoietic activity (Schofield 
et al., 1986; Williams et al., 1986), increased stimulation of hemopoietic activity of 
the aged HM (Matthews and Crouse, 1981) or decreased stimulatory activity of the 
aged stroma (Lipschitz et al., 1987b; Mauch et al., 1982). The latter observation is 
comparable with the results from Hotta et al. (1980) using the subcutaneous 
implantation technique (see previous chapter). 
Some examples in which the LTBMC system has been helpful to monitor the 
effects of disease and/or treatment with cytotoxic agents upon the HM are dis-
cussed below. Long-term cultures established from bone marrow of anemic SVSld 
mice with a genetically determined defective HM or from anemic W /W" mice with 
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a genetically determined stem cell defect, reproduce the anemias in vitro (Dexter 
et al., 1977a; Keller and Philips, 1984; Keller et al., 1983; Petursson and Chervenick, 
1985; Zuckerman et al., 1986b). Zuckerman et al. (1986b) have suggested that the 
stromal defect in SI!Sld mice is due to a local inhibitory effect which can be 
partially eliminated in vitro by irradiation of the SI!Sld stroma. Ershler et al. 
(1980) have presented experimental evidence for the existence of a congenital 
hemopoietic stromal defect in humans. Culture of bone marrow fragments from an 
anemic patient have resulted in decreased hemopoietic progenitor proliferation and 
erythropoietic differentiation, despite a normal progenitor content. Long-term bone 
marrow cultures of some aplastic anemia patients have revealed the existence of a 
functional defective microenvironment (Hotta et al., 1985b). Establishment of 
long-term marrow cultures from mice with a spontaneous thymic lymphoma, which 
heavily infiltrated the bone marrow, results in an almost complete disappearance 
of the leukemic population (Hays and Hale, 1982). A similar observation has been 
made in man after establishment of LTBMC from patients with Ph' chromosome 
positive chronic myeloid leukemia or acute myeloid leukemia (Coulombel et al., 
1983b; Eaves et al., 1985). Some LTBMC from acute myeloid leukemia patients, 
however, have mail:_ltained abnormal leukemic cells for a long period of time (Eaves 
et al., 1985). LTBMC from leukemic patients, sofar, do not present evidence for 
the existence of a severely abnormal functional HM although some changes in 
CFU-F quality and/or quantity may occur (see previous chapter). Treatment of 
leukemias and other malignancies with radio- and/or chemotherapy, however, have 
the capacity to damage the HM as has been demonstrated by establishment of 
LTBMC from cytostatic agent-treated mice (Anderson et al., 1982; Hays et al., 
1982) or from in vitro cytostatic agent-treated or irradiated LTBMC (Greenberger 
et al., 1984; Horikoshi and Murphy jr., 1985; Laver et al., 1986; Naparstek et al., 
1985; Reincke et al., 1982b). It has been observed that the proliferative capacity 
of stromal progenitors is quite sensitive to in vitro irradiation, while the hemo-
poietic supportive function and growth factor production is relatively resistant to 
the effects of radiation (Laver et al., 1986; Naparstek et al., 1985; Song and 
Quesenberry, 1984; Tavassoli, 1982; Zuckerman et al., 1986a). Which cells or cell 
activities of the hemopoietic stroma are most vulnerable to cytotoxic treatment 
remains to be determined. 
135 LIPOPOLYSACCHARIDE-INDUCED INCREASED SPLENIC 
HEMOPOIESIS 
LPS injection induces a huge increase in the level of circulating CSF's 
(Metcalf, 1971; Quesenberry et al., 1972). Various cell types (macrophages and 
endothelial cells) increase synthesis of CSF after LPS injection (Sheridan and 
Metcalf, 1972). Following LPS injection an increased splenic hemopoietic activity 
is found with a massive accumulation of hemopoietic progenitors in the spleen 
with highest numbers between 3 and 6 days after LPS injection depending on the 
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amount of LPS injected (Vos et al., 1972). The increased accumulation of splenic 
CFU-s after LPS injection is both a result of local CFU-s proliferation (McCul-
loch et al., 1970), and immigration of bone marrow-derived CFU-s (Ploemacher 
and Brons, 1987). The increase of splenic CFU-s numbers depends on a normal 
splenic stromal environment, apart from a normal CFU-s proliferative capacity 
(Ploemacher et al., 1983). Quantification of hemopoietic progenitors in the spleen 
after LPS injection can be used to estimate stromal integrity of the spleen, provided 
a normal proliferative capacity of the stem cell pool exists. The increased hemo-
poietic activity is accompanied with stromal cell proliferation (CFU-F) (Brockbank 
et al., 1983a) and endothelial cell proliferation (Reidy and Schwartz, 1983). Stromal 
cell proliferation also occurs in the other above mentioned assays to detect stromal 
function. This assay demonstrates the existence of a defective hemopoietic stromal 
compartment in Sl!Sld mice although these mice have a normal production of 
humoral regulators (McCulloch et al., 1970; Ploemacher et al., 1986). The other 
mouse strain with a genetically determined hemopoietic stromal defect, the SP I+ 
mice, displays a normal splenic accumulation of hemopoietic progenitors following 
LPS injection (Ploemacher et al., 1984a; Ploemacher and Brons, 1987). Irradiation 
induces a severely impaired reaction following LPS injection, which lasts upto one 
year after irradiation and cannot be restored by a transplantation of normal BMC 
(Ploemacher et al., 1983). 
13.6 GROWTH KINETICS OF NORMAL BONE MARROW CELLS 
IN AN1MALS WITH A NORMAL OR DEFECTIVE MICRO-
ENVIRONMENT 
A lethal total body irradiation (TBI) which eradicates all hemopoietic stem 
cells must be followed by a BMT if hemopoiesis is to be re-established. The growth 
kinetics of intravenously injected normal hemopoietic cells in the different hemo-
poietic organs can be followed. Because a normal hemopoietic stroma is mandatory 
for optimal stimulation of hemopoiesis after lethal TBI a comparison of the rate 
of regeneration of the intravenously injected normal BMC and the maximal hemo-
poietic activity achieved in normal irradiated mice and in mice with a supposedly 
defective microenvironment can be used to get an impression of the functional 
activity of the hemopoietic stroma. Differences in regeneration kinetics are assumed 
to result from differences in the ability of the hemopoietic stroma to support the 
injected normal hemopoietic progenitors. In contrast with the other assays men-
tioned above, the determination of the growth kinetics of normal BMC is assumed 
to be largely independent of stromal cell proliferation . .Under normal conditions 
and after irradiation of bone marrow (and other organs) some proliferation of 
stromal cells does occur, e.g. endothelial and reticular cells (Adamson and Bowden, 
1983; Caffrey et al., 1966; Meyer-Hamme et al., 1971) or CFU-F (Da et al., 1986), 
but it is assumed that the regeneration of hemopoietic progenitors during the first 
weeks is dependent on the existing stroma. 
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The use of this assay to study stromal function is very sparse. It was applied 
to study the microenvironmental defect in genetically anemic mice and to study 
the short-term effects of cytostatic agents and irradiation. The growth kinetics of 
CFU-s and CFU-GM from normal BMC in genetically anemic SL/Sld mice has been 
shown to be delayed in both spleen and femur (McCulloch et al., 1965; Sutherland 
et al., 1970). Comparison of Sli/ + mice (with a mild microenvironmental defect) 
with normal mice revealed no differences between the two groups concerning the 
growth of committed progenitors (CFU-GM and BFU-E) although Sli/ + mice were 
deficient in their ability to support macroscopic spleen colony formation (Ploe-
macher et al., 1984b ). Six weeks after CTX treatment a delayed hemopoietic 
recovery is found after irradiation with 3.0 Gy as compared with non CTX-treated 
mice and although the proliferative potential of the CFU-s is decreased, the delayed 
hemopoietic recovery is suggested to be the result of stromal damage (Fried and 
Barone, 1980). Using a comparable experimental design, Kedo et al. (1976) has 
demonstrated a delayed recovery of CFU-s in mice exposed to 300 rads after 
having recovered from 950 rads TBI followed by a BMT. 
1.4 LATE EFFECTS OF RADIATION AND CHEMOTHERAPY 
Chemotherapy and radiation used in cancer chemotherapy have both the 
potential for injury, since antineoplastic therapy is not specific for tumor cells 
but affects normal cells as well. The efficacy of cancer chemotherapy is still 
improving, which results in increased survival time and cure rates. This encouraging 
situation, however, permits the occurrence of late therapy-related sequelae, which 
had heretofore been obscured or precluded by early recurrence of tumor. The late 
effects of radiation and chemotherapy will be discussed below with special attention 
to the late effects on the bone marrow compartment. 
In general, cell death due to radiation is linked to mitosis and occurs only 
when the cell divides. Some cell types, e.g. lymphocytes, also show interphase cell 
death. The effects of radiation can be divided in acute and late effects and depend 
on the cell renewal characteristics of the irradiated tissue (Rubin, 1984; Wheldon 
et al., 1982). The different tissues can be separated according to cell renewal 
characteristics of their parenchymal cell compartment, determined by the lifetime 
of mature cells. Most epithelial tissues and the bone marrow are examples of 
tissues with rapid cell renewal characteristics. These tissues have stem cell com-
partments that rapidly proliferate and differentiate in a mature cell, which can 
not display mitotic activity. Tissues with slow cell renewal characteristics are 
described by a parenchymal cell compartment that turns over slowly and is capable 
to regenerate and/or proliferate to a certain stimulus e.g. microvasculature in 
wound healing, bone after a fracture or liver after partial resection. In non-
proliferative tissues, with very little or no regenerative capacity of parenchymal 
cells e.g. muscle and the central nervous system, lost cells are replaced by fibrotic 
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tissue. The slow- or non-proliferative tissue types can be described as cell popula-
tions where either all cells are in a long cell cycle and occasionally divide, or the 
majority of cells are quiescent with others in a short cell cycle. 
Regeneration of the different tissues after irradiation is dependent on the 
type of tissue, radiation dose, and the irradiated organ volume, i.e. the surviving 
fraction of stem cells or cells capable to proliferate. If the surviving fraction of 
stem cells is not sufficient to reconstitute the tissue, overt damage will occur. 
The latency period before the expression of gross tissue injury is determined by 
the renewal characteristics of the stem cell compartment and it is dose-dependent 
except after very high doses, when virtually all mitotic activity is abolished. In 
tissues with rapid renewal characteristics e.g. most epithelial tissues and the bone 
marrow the latency period will be very short and in slow-, occasional-, or non-
proliferating tissues e.g. bone and connective tissue, liver, and the central nervous 
system the latency period will be much longer (Reinhold, 1984; Rubin, 1984; Wheldon 
et al., 1982). Another important component of late radiation damage in (almost) all 
organs is the effect upon the blood vessels, resulting in irregular dilatation and 
constriction of the vessels and reduction in the size of the capillary bed (Hopewell, 
1975; Hopewell et al., 1986; Reinhold, 1984). If these vascular changes always 
affect the tissues, of which they are part has not been fully elucidated yet (Hope-
well et al., 1986; Knospe et al., 1960; 1968). 
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Figure L2 The mechanism of action of some chemotherapeutic agents 
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The cytotoxic agents are usually classified according to their mechanism of 
action during a specific phase in cell cycle (see fig.1.2). Antimetabolites for example 
are cell cycle specific and react during S phase. Alkylating agents and antitumor 
antibiotics, however, are not cycle specific and react with DNA irrespective of 
the cell cycle (among others reviewed by Chabner and Myers, 1982). 
During the frrst decades after the introduction of cytotoxic agents it has 
been thought that, in contrast with the use of radiation, late effects due to the 
use of anticancer agents are absent. In the early seventies the first reports have 
appeared about late effects associated with the prolonged use of anticancer agents 
in man (reviewed by D'Angio, 1976). It has been believed that tissues composed of 
mature and non-dividing cells are spared for the damaging effect of chemotherapy, 
however, this has appeared not to be true. Good examples for the effect of an 
anticancer drug upon mature cells, are the toxic effect of adriamycin on cardio-
myocytes (Bristow et al., 1978) and the effect of cis-platinum on renal tubular 
cells (Gonzalez-Vitale et al., 1977). The exact nature of how cytotoxic agents 
exert these late effects is not known but in general the toxic effects of chemo-
therapeutic agents are dependent upon the cell's capacity to absorb, concentrate, 
or metabolize these agents and it may be dependent or independent of cell cycle 
or maturation. In contrast with radiation, chemotherapeutic agents will spare the 
vascular system (Rubin, 1984), with a few exceptions e.g. bleomycin (Adamson et 
al., 1974; Lazo, 1986). 
There is ample experimental evidence that both radiation and some cytotoxic 
agents, mainly the alkylating agents, are capable to decrease the regenerative 
potential of the stem cell compartment. The depletion of stem cell reserve or 
loss of normal potential of reserve stem cells is described by the term "stem cell 
senescence" or "accelerated aging" (Botnick et al., 1979; Fried and Adler, 1985; 
Hellman and Botnick, 1977; Rubin, 1984; Schofield, 1986b). In conclusion, both 
quantity and quality of the hemopoietic stem cells are affected by the above 
mentioned treatment modalities. A comparable effect may injure the cells responsible 
for stromal regeneration after a cytotoxic insult. The stromal compartment, includ-
ing the vascular system is regenerating slowly (Caffrey et al., 1966; Haas et al., 
1969). Apart from normal replacement, remoulding of the hemopoietic stroma can 
occur after certain stimuli e.g. severe blood loss. This is accomplished by prolifera-
tion of the stromal compartment and especially the vascular system (McClugage et 
al., 1971). Accordingly; the bone marrow can be seen as a slow renewal tissue 
intermingled with a fast renewal tissue i.e. the stromal compartment and the 
hemopoietic stem cells, respectively. Irradiation affects fast and slow regenerating 
tissues in a comparable fashion but at a different time scale. A reduction in stromal 
stem cell quality and quantity will result in a less optimal reaction towards stress-
induced proliferation and in a slackening or incomplete renewal of the stromal 
compartment. As mentioned in the previous chapters, normal hemopoiesis is impos-
sible without a normal stromal compartment, and a defective stromal compartment 
may result in permanent aplasia. 
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Several authors have presented indications that long-term hemopoietic (and 
stromal) stem cell defects occur in man after irradiation and/or chemotherapy 
(Haworth et al., 1982; Lohrman and Schreml, 1988; Rubin, 1984; Schreml, 1985; 
Testa et al., 1985; Vellenga et al., 1987). The decreased stem cell quality becomes 
overt as a limited reserve capacity after a challenge e.g. another treatment with 
irradiation or cytotoxic agents or an infection and blood loss (Rubin, 1984). 
Recently, an impaired reserve capacity of the hemopoietic stem cell compartment 
in man has been demonstrated also after the injection of recombinant growth 
factors following chemotherapy treatment for carcinoma (Gabrilova et al., 1988) 
and following high-dose chemotherapy and autologous BMT for treatment of breast 
cancer or melanoma (Brandt et al., 1988). The increase in peripheral blood leuco-
cytes is diminished in those patients treated previously with pelvic irradiation 
(this is approximately 50% of the bone marrow volume with active hemopoiesis in 
adults) (Gabrilova et al., 1988) or intensive chemotherapy (Brandt et al., 1988). 
The experimental data concerning late effects of chemotherapy and radiation 
are already mentioned in previous chapters. The following paragraph will give 
some general remarks concerning late effects and regeneration of the bone marrow 
after treatment with cytotoxic agents. Late effects of radiation and/or chemo-
therapy in other organs have among others been reviewed by D'Angio (1976), 
Brady (1981), Byrd (1985), Chessels (1983), Deeg et al. (1984), Hendry (1988), and 
Rubin (1984) and will not be included here. 
The acute marrow aplasia after irradiation is the result of stem cell damage 
and the second, permanent, aplasia is the result of stromal damage, especially the 
vascular system (Knospe et al., 1960; 1968). The recovery of hemopoietic activity 
is preceded by restoration of the stromal integrity (Knospe et al., 1960; 1968; 
Werts et al., 1980; and previous chapters). With respect to the response of the 
bone marrow to radiation or cytotoxic agents the marrow must be seen as one 
functional unit. The bone marrow is a diffuse organ and is found in almost all 
skeletal bones. The occupation of the bone marrow with active hemopoiesis depends 
upon species and age. The skeletal bones in mice are completely filled with hemo-
poietic active marrow and in a normal adult human the bones with active hemo-
poiesis are the vertebrae, pelvis, and femoral head and neck (Custer and Ahlfeldt, 
1932; Hashimoto, 1962). Cytotoxic agents will react with the entire bone marrow 
organ but radiation will only affect a certain volume of the bone marrow depending 
on the irradiation fields used. Regeneration of the bone marrow (infield or outfield) 
is dependent on dose and irradiated bone marrow volume (reviewed by Parmentier 
et al.,1988; Rubin, 1984; Scarantino et al., 1984). The main regulating factor is the 
irradiated volume and the radiation dose. Regeneration is almost nonexistent when 
the irradiated marrow volume remains below 20-30% and using doses above 20 Gy. 
After irradiation of 40-50% of the bone marrow volume acute reactions are generally 
more severe and it has been observed that the unirradiated bone marrow may 
have a decreased hemopoietic activity also ( abscopal effect on unirradiated bone 
marrow), most likely due to an increased rate of differentiation in the unirradiated 
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marrow (Parmentier et al., 1988). The irradiated field shows no signs of regeneration 
when less than 50% of the marrow volume is irradiated but the unirradiated 
hemopoietic marrow may show an increased activity and this may remain active 
for many years. Subtotal bone marrow irradiation (50-75% of the bone marrow 
volume) results in a very complex reaction. The unirradiated marrow becomes 
active and hemopoietic activity is also found in normally not active bone marrow 
or extramedullary which may lasts for decades. In contrast with irradiation of 
small fields (20-30% ), infield regeneration after subtotal irradiation can be found 
after use of higher doses upto 40 Gy (fractionated dose regimens). Infield regenera-
tion is particularly evident in younger persons (Sacks et al., 1978). Above mentioned 
data are from studies in man. The data from mice (or other small rodents) can in 
general not be used to predict the regeneration patterns of the irradiated bone 
marrow in man, because of the different dose regimens used (in animal studies 
usually single high-dose exposures and in humans fractionated protocols) and the 
different distribution of hemopoietic activity in the bones. However, a comparable 
regeneration pattern of the bone marrow after irradiation as was observed in man 
has been demonstrated in a rodent model (Rubin et al., 1977; Scarantino et al., 
1984). 
Human data about late effects and regeneration of the bone marrow after 
cytotoxic agents are rare, and usually include reports from combination treat-
ments (see above). For some cytotoxic agents, however, experimental evidence 
exists that stromal damage can occur (see chapter 1.3). 
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CHAPTER n 
INTRODUCTION TO THE EXPERIMENTAL WORK 
The objectives of the experimental work as described in the appendix papers 
can be separated into four main topics: 1. a study to compare the different assays 
to detect stromal integrity with respect to extent and kinetics of stromal damage 
and recovery after radiation or chemotherapy treatment (chapter III-VI), 2. a 
study of the late effects of chemotherapy (especially cis-platinum) and radiation 
upon the hemopoietic stroma (chapter III-VI), 3. a study to compare the effects of 
cytotoxic treatment of young or old mice upon the HM (chapter III-V), and 4. a 
study of the effects of cis-platinum upon the lymphopoietic system (chapter VII). 
The assays or parameters used to study hemopoietic integrity in the ex-
perimental work of this thesis (chapter III-VI) are: (a) the quantification of 
peripheral blood cells and hemopoietic progenitors in spleen and bone marrow, 
(b) the quantification of hemopoietic progenitor cell recovery in regenerated 
ectopically implanted bone marrow or spleen, (c) quantification of fibroblastic 
colony-forming units in femur or spleen, (d) long-term bone marrow cultures, (e) 
measurement of splenic hemopoietic stem cell accumulation in response to bacterial 
LPS-induced hemopoietic stress, and (f) comparison of growth kinetics of normal 
hemopoietic progenitor cells following lethal irradiation of mice with a normal or 
(supposedly) defective microenvironment The above mentioned assays are discussed 
in chapter I.3. 
Sofar these different assays have not been compared to determine the extent 
and kinetics of stromal damage. As discussed in chapter I.3 some of these assays 
determine the proliferative capacity of stromal cells (especially b, c, d, and e) and 
some determine the hemopoietic supportive function of stromal cells (especially a, 
b, d, e, and f) or a combination of these two. A comparison of these assays may 
therefore give a better understanding of which cell (fibroblast or other stromal 
cell) and cell function (proliferation or the support for hemopoiesis) is most 
susceptible to chemotherapy or radiation. 
The increasing use of effective chemotherapy and irradiation is reflected in 
increasing cure rates and prolongation of survival after many different types of 
malignancy, both in adults and children. However, it also increases the appearance 
of delayed complications after these treatment modalities (chapter I.4). The latter 
has increased the importance to determine the occurrence of late sequelae of both 
irradiation and chemotherapy as is described in chapter III-VI. 
Data on the late effects after chemotherapy are scarce and during the first 
decades after the introduction of chemotherapy it has been believed that chemo-
therapy regimens lack late effects as can be seen from the duration of the studies 
in the drug developing program in the USA which only last 180 days, prior to 
allowing the test compound to be introduced to man (DeVita et al., 1979). After 
clinical indications of long-term effects after chemotherapy treatment, the ex-
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perimental research for late sequelae increased (chapter 1.4). Cis-platinum is an 
increasingly and successfully used agent in chemotherapy treatment protocols for 
many different malignancies (Loehrer and Einhorn, 1984; Schilcher et al., 1984). 
The mode of action of cis-platinum is not fully understood but it is suggested to 
be comparable with alkylating agents (Pascoe and Roberts, 1974; Zwelling et al., 
1981). It is known that some of the alkylating agents e.g. BU and CTX, exhibit a 
long-lasting effect on both hemopoietic progenitors and the hemopoietic stroma 
(chapter 1.3 and 1.4). It has already been demonstrated by several authors that 
cis-platinum has an acute toxic effect upon hemopoietic progenitors (Nowrousian 
and Schmidt, 1982) and induces a long-lasting defect in response to anemic stress 
produced by bleeding (Braunschweiger et al., 1982). However, whether cis-platinum 
has an effect upon hemopoietic stromal integrity remains to be solved and this 
has been the main objective for the studies described in chapter V and VI. The 
investigations described in chapter VII have been performed to expand knowledge 
concerning the effects of cis-platinum upon the lymphopoietic system treated 
during growth. 
The late effects after irradiation have been studied extensively (see chapter 
!.3 and 1.4) but the majority of the studies has been carried out in adult ex-
perimental animals or . man. Since the early and late effects of irradiation of an 
expanding HM during growth are unknown, such studies have been included (see 
chapter III). The stromal compartment in murine bone marrow increases during the 
first 8 weeks of life as determined by the femoral CFU-F content (Brockbank et 
al., 1983b). The mice have been irradiated at 4 weeks of age, during the expansion 
of the femoral CFU-F content, and several assays have been used to estimate the 
stromal integrity upto one year after irradiation which is approximately 1/3 to 1/2 
of the life expectancy of mice. 
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CHAPTER m 
RADIATION SENSITIVITY OF HEMOPOJETIC STROMA: LONG-
TERM PARTIAL RECOVERY OF HEMOPOJETIC STROMAL 
DAMAGE IN MICE TREATED DURING GROWTH 
Peter G.J. Nikkels, Johannes P. de Jong and Rob E. Ploemacher 
Department of Cell Biology and Genetics, Erasmus University, Rotterdam, 
The Netherlands 
Radiation Research 109, 330-341, 1987 
ABSTRACf 
We studied the ability of the hemopoietic organ stroma to recover from 
damage inflicted by 5 or 7 Gy gamma radiation administered during a period of 
stromal growth in 4-week-old mice. Irradiation resulted in an immediate depletion 
of femoral colony-forming fibroblastic progenitors (CFU-F) down to 10-20% of age-
matched control values. A full recovery to normal numbers occurred between 120 
and 240 days after irradiation and was followed by a secondary decrease 1 year 
after irradiation. This secondary decrease was accompanied by a decrease in the 
femoral CFU-s and CFU-e content. Femoral CFU-F attained normal numbers and it 
was demonstrated to occur from surviving CFU-F and could not be enhanced or 
prolonged following infusion of unirradiated BMC after irradiation. During the 
transient CFU-F recovery the hemopoietic stroma remained severely damaged as 
judged by the regenerative. capacity of spleen and femur stroma after subcutaneous 
implantation, and the ability of the spleen to accumulate CFU -s in response to 
lipopolysaccharide injection. We have reported earlier that in similarly irradiated 
adult mice, no restoration of femoral CFU-F was observed. This difference be-
tween 4-week-old and adult mice could not be explained by a difference in in 
vitro radiosensitivity of CFU-F or in their in vivo regeneration kinetics following 
irradiation and subsequent lipopolysaccharide injection. We conclude from these 
observations that (a) the recovery kinetics of the CFU-F population are different 
in young and adult irradiated mice, (b) infused CFU-F d~ not contribute to CFU-F 
regeneration in an irradiated femur, (c) CFU-F are not the sole determinants of 
stromal regeneration in femur and spleen following irradiation. 
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lNTRODUCTION 
Radiation-induced damage of hemopoietic stem cells and bone marrow stroma 
is one of the dose limiting factors in cancer therapy. Stromal injury after radiation 
has been reported in both animal models and humans (Chamberlin et al., 1974; 
Fried et al., 1976; Knospe et al., 1960; Rubin et al., 1973; Sacks et al., 1978; Sykes 
et al., 1964; Testa et al., 1985; Wolf, 1982). Knospe et al. (1960) showed that local 
irradiation of rat bone marrow with a single dose of 40 Gy or more resulted in 
permanent aplasia due to loss of sinusoidal structures. Permanent aplasia was also 
found in human sternal marrow after doses about 30 Gy (Sykes et al., 1964). Sacks 
et al. (1978) demonstrated, using radioisotope scanning procedures, that the extent 
of bone marrow regeneration is related to the irradiated bone marrow volume if 
radiation doses do not exceed 50 Gy. Using a subcutaneous organ implantation 
technique, which measures the ability of the regenerating donor stroma to support 
the accumulation and maintenance of host -derived stem cells (Fried et al., 1973a; 
Hotta et al., 1983), stromal damage was detected at far lower radiation doses, 
i.e., 4 Gy or more (Chamberlin et al., 1974; Fried et al., 1973a; Fried et al., 1976; 
Piersma et al., 1983a; Ploemacher and van Soest, 1979; Ploemacher et al., 1983). 
This stromal insult showed no recovery for at least 9 weeks after treatment 
(Chamberlin et al., 1974). Quantification of a stromal progenitor cell class (CPU-F) 
also revealed persistent stromal damage using doses of 5 Gy or more (Piersma et 
al., 1983a; Ploemacher et al., 1983), with recovery to control levels when lower 
radiation doses were employed (Xu et al., 1983). 
Recently, our laboratory reported that the prolonged depletion of the femoral 
CPU-F population after lethal TBI could recover to normal numbers following in-
jection with LPS (Piersma et al., 1985b ). It was suggested that the irradiated 
stroma still contained the majority of functionally viable fibroblastic cells, but 
that they had lost their in vitro colony-forming capacity due to latent radiation 
damage. Thus, the LPS-induced depletion of the CPU-F population in the femur of 
these mice stimulated repopulation of the stroma with fibroblastic cells still capable 
to form colonies of at least 50 cells. On the basis of this assumption, we hypo-
thesized that recovery of the CPU-F population in irradiated developing stroma of 
young mice could be expected without LPS treatment, since the CFU-F population 
is still expanding in such mice (Brockbank et al., 1983b) and do not have to be 
forced to proliferate in situ to replace latent damaged CPU-F. This led us to 
study the effects of gamma radiation on the developing hemopoietic stroma in 
comparison to fully developed adult stroma over a one year period. For this purpose 
we used the subcutaneous organ implantation technique, quantification of the 
stromal fibroblastic progenitor cells (CPU-F), hemopoietic progenitor cells (CFU-s 
and CPU-c) and peripheral blood parameters. We also studied the splenic CPU -s 
accumulation 5 days after injection of LPS as a measurement of the stromal 
integrity of the splenic stroma as described previously (Ploemacher et al., 1983). 
In addition, we investigated whether transplantation of marrow cells was a pre-
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requisite of CFU-F recovery m irradiated mice. 
MATERIALS AND METHODS 
Mice. Female F1(CBA/RijxC57BL/Rij) mice, 4 weeks of age and weighing 14-16 g 
(young mice), 12 weeks old and weighing 26-30 g (adult mice), and male or female 
mice 8 to 30 weeks old were used as recipients for CFU-s determination. The 
animals were purchased from the Laboratory Animals Center of the Erasmus Univer-
sity, Rotterdam, The Netherlands, or from the Radiobiological Institute, TNO, 
Rijswijk, The Netherlands. 
Irradiation.. Mice received a dose of 5, 7 or 9 Gy total-body irradiation using a 
137Cs gamma source (Gamma cell 40 Atomic Energy of Canada Ltd., Ottawa, Canada) 
with a dose rate of 1.27 Gy/min. 
Cell preparation.. Single cell suspensions of femoral marrow and spleen were pre-
pared and diluted in a buffered saline solution (BSS). Nucleated cells and red 
blood cells were counted with a Coulter Counter Model B. Hematocrits were deter-
mined using a microcentrifuge. 
CFU-s assay. The number of CFU-s was determined by the spleen colony assay of 
Till and McCulloch (1961). Cell suspensions were injected i.v. into 7-10 lethally 
irradiated recipients. Seven to eight days later spleens were fixed in Telleyeszniz-
ky's solution and macroscopic surface colonies counted. 
CFU-c and CFU-F assay. CFU-c and CFU-F were quantified in a semisolid culture 
medium (10% concanavalin A-stimulated mouse spleen conditioned medium was used 
as CSF source for CFU-c cultures as described previously (Brockbank et al., 1983b). 
CFU-c colonies were counted at day 7 of culture and contained at least 50 cells. 
CFU-F colonies were flXed at day 10 of culture and stained with Giemsa. Only 
colonies containing at least 50 fibroblastoid cells were counted. 
Lipopolysaccharide treatment. Endotoxin of Salmonella typhosa (LPS) (Sigma) 
prepared by the Boivin method was dissolved in BSS to the appropriate dilution 
and injected i.v .. 
Regeneration assay. Spleens and femurs of previously irradiated and control mice 
were subcutaneously implanted into adult syngeneic hosts as has been described 
previously (Piersma et al., 1983b). Host mice received 5 Gy TBI 1 day before 
implantation to stimulate splenic regeneration (Chamberlin et al., 1974). Radiation 
of host mice had no effect on femoral regeneration. Six to eight weeks later the 
implants were removed and their CFU-s content was assayed. 
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Assay of splenic stroma function. Five days after injection of 300 1-Lg LPS the 
CFU-s content of the spleen was determined. The LPS-induced accumulation of 
CFU-s in the spleen was used as an indication of the splenic stromal function 
(Ploemacher et al., 1983). 
RESULTS 
Survival, body weight, Ht, erythrocyte, and leucocyte counts 
During the 12-month study body weight of both 5 and 7 Gy irradiated 4-
week-old mice was 10-20% less than that of age-matched nonirradiated controls 
(data not shown). Following 5 Gy TBI the first mice died 240 days after irradia-
tion, and survival gradually declined to 90% at one year. Seven Gy TBI resulted in 
a first death after 120 days and a 75% 1-year survival (data not shown). The 
cause of death remained unexplained since no autopsies were done. Ht and erythro-
cyte counts fluctuated around 95% (5 Gy) and 85% (7 Gy) of age-matched control 
values (data not shown). Leucocyte counts were severely decreased 1 week after 
both 5 and 7 Gy TBI (down to 7-11% ), returned slowly to (sub )normal levels 
(80-100%) at 45 days and remained at this level during the 1-year observation 
period (data not shown). 
Cellularity and hemopoietic and stromal progenitor content in the spleen 
One week following 5 Gy TBI, the splenic cellularity decreased down to 12% 
of unirradiated control mice (Fig.ITI.l). Splenic cellularity was restored to subnormal 
levels within 45 days and continued to be (sub)normal during the observation period. 
After 7 Gy TBI splenic cellularity remained below the 5 Gy TBI data except for 
the 240-day point. Furthermore, splenic cellularity showed a tendency to a second 
decrease at 1 year after 7 Gy TBI. The initial decrease of CFU -s numbers (Fig.Ill. 
2A) was followed by a recovery at 45 days up to 90% (5 Gy) and 60% (7 Gy) respec-
tively, and remained at 60 and 40%, respectively, between 120 and 360 days. CFU-
c numbers showed a smaller recovery in comparison to CFU-s but reached com-
parable values 240 and 360 days after irradiation. CFU-F numbers did not show 
much recovery in the spleen during the 1-year observation time. 
Cellularity and hemopoietic and stromal progenitor content in the femur 
Following the initial decrease 1 week after irradiation, the femoral cellularity 
(Fig.Ill.1) and progenitor content (CFU-s, CFU-c, and CFU-F) (Fig.Ill.2B) returned 
to normal or subnormal values. During the first 45 days following irradiation, 
CFU-s and CFU-c numbers showed a comparable recovery to approximately 60% of 
age-matched controls after 5 or 7 Gy TBI, while CFU-F numbers showed no sign 
of recovery. Femoral progenitor cell numbers CFU-s and CFU-c, recovered to 
(sub)normal and CFU-F numbers to (supra)normal 120 to 240 days after 5 or 7 
Gy TBI. However, a secondary severe decrease in the hemopoietic progenitor 
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Figure llLl Nucleated cells of femoral bone ma"ow and spleen after 5 or 7 Gy 
TBI. All data are expressed as percentage of age-matched non-i"adiated controls 
± standard e"or of 2 or 3 individual experiments. Each experiment consisted of 
three individual assayed mice per point. Control cellularities averaged 2.38 x lOS 
nucleated cells per spleen and 3.83 x 107 nucleated cells per femur. 
"' 
A 
0 140 ;:; 
c 
0 120 u 
1J 
"' .c 1 DO u 
"' E 80 
"' 01 
"' ~ 60 
0 
"' 01 40 2 
c 
"' u 20 ... 
"' 0. 
45 120 240 360 
days after irradiation 
SGy 7Gy 
CFU-5 e o 
CFU-C • 
CFU-F Ao. 
B 
45 120 240 360 
days after irradiation 
"' 14o E 
c 
0 
120 u 
1J 
"' 100 "§ 
ro 
E 
80 
"' 01 ro 
60 ~ 
0 
"' 40 01 ro 
c 
20 "' ~ 
"' 0. 
Figure llL2 Hemopoietic and stromal progenitor content in spleen (A) and femur 
(B). Hemopoietic stem cells (day 8 CFU-s), granulocyte/macrophage colony-fanning 
units (CFU-c) and stromal fibroblastoid colony-fanning units (CFU-F) content 
after 5 or 7 Gy TBI. All data are expressed as percentage of age-matched noni"a-
diated controls ± standard e"or of 2-3 individual experiments. Each experiment 
consisted of three individual assayed mice per point. Averaged control numbers: 
day 8 CFU-s: 2700 per spleen and 7800 per femur. CFU-c: 7800 per spleen and 
37,500 per femur. CFU-F: 340 per spleen and 1270 per femur. 
population size was observed at 1 year after 7 Gy TBI, while CFU-F numbers 
decreased following both 5 and 7 Gy TBI. The data in the figures were selected 
from mice which showed no sign of overt disease, i.e., a supranormal peripheral 
blood count and spleen size. One year after 7 Gy TBI approximately 30% of the 
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surviving mice showed the above mentioned symptoms. 
Regeneration assay and splenic CFU-s accumulation after LPS injection 
Following irradiation, both spleen and femur showed an immediate and sus-
tained diminished capacity to regenerate and support CFU-s maintenance after 
subcutaneous implantation into syngeneic hosts (Fig.Ill.3), while no significant 
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after 5 or 7 Gy TBL The CFU-s content per organ was used as a quantification 
of the stromal regenerative capacity after irradiation-induced damage. All data are 
expressed as a percentage of the CFU-s content per age-matched nonirradiated 
subcutaneous implanted control organ ± standard error of 2 or 3 individual ex-
periments. Each experiment consisted of 3 or 6 pooled spleens or femurs per 
point. Averaged control numbers: 183 CFU-s per splenic implant and 1100 CFU-s 
per femoral implant. 
differences were observed between the 5 and 7 Gy irradiated groups. As has been 
shown previously (Ploemacher et al., 1983), the LPS-induced accumulation of CFU-
s in the spleen could be used as an indication of splenic stromal function. The 
irradiated spleens showed a reduced ability to accumulate CFU -s in response to 
LPS injection (Fig.III.4). This dose-dependent stromal lesion did not recover during 
the 1-year observation period. 
CFU-F survival after in vitro irradiation of young or adult normal bone marrow 
cells 
From Fig.Ill.2 it appeared that femoral CFU-F from mice irradiated when 4 
weeks old showed a transient recovery to (supra)normal values. This observation 
was at variance with previous data from adult irradiated mice (Piersma et al., 
1985b), in which femoral CFU-F showed almost no recovery during 18 months after 
irradiation. In an attempt to explain these differences, we compared the in vitro 
radiation sensitivity of CFU-F from 4- and 12-week-old mice and determined the 
surviving fractions in 4- or 12-week-old mice. As can be seen from Fig.III.5, no 
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significant difference in CFU-F radiosensitivity was observed. 
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Figure lliA Splenic CFU-s accumulation at 5 days following injection of 300 1.1.g 
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LPS-induced CFU-F recovery in normal and irradiated mice 
In a previous observation (Piersma et al., 1985b) we demonstrated that the 
long-term depletion of CFU-F numbers in 9 Gy TBI mice could be completely 
restored to non-irradiated control numbers within 4 to 6 weeks following injection 
of a high dose of LPS. This beneficial effect of LPS was explained by the assump-
tion that after BMT the irradiated stroma still contained viable fibroblastic cells 
with a limited proliferative capacity to form colonies in vitro as a result of latent 
radiation-induced DNA damage. LPS-induced depletion of CFU-F from the bone 
marrow presumably stimulated repopulation of the hemopoietic stroma with surviving 
and/or injected donor-derived colony forming fibroblastic cells. The data in Fig.III.6 
indeed demonstrate that LPS injection in normal non-irradiated mice leads to a 
dose-dependent decrease in CFU-F content and femoral cellularity, which is followed 
by a regenerative period between 7 and 15 days after the LPS injection. 
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Figure IIL6 Nucleated cells of nonnal adult femoral bone marrow (A) and femoral 
CFU-F content (B) following injection of 10 J.Lg LPS, 150 )J.g LPS or 500 J.Lg LPS. 
All data are expressed as percentage of age-matched non-LPS-treated controls ± 
standard error of 3 individual assayed mice. See legends to Figs.l1I.1 and 11!.2 for 
control numbers. 
Subsequently we compared the ability of the CFU-F ·population to regenerate 
in mice that had been irradiated at 4 or 12 weeks of age. The mice were injected 
with either 10 or 150 J.Lg of LPS at 3 months after irradiation. As can be seen from 
Figs.III.7B,D, LPS treatment induced a recovery of femoral CFU-F in most groups 
to values exceeding the femoral CFU-F numbers in non-LPS-injected mice. The in-
complete CFU-F normalization in the 12 week, 7 Gy + BMC group (Fig.III.7) may 
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Figure IIL7 Nucleated cells of femoral bone marrow (A and C) and femoral CFU-F 
content (B and D) following injection of 10 ~J.g LPS (A and B) or 150 ~J.g LPS (C 
and D) 3 months after 7 or 9 Gy irradiation of 4- or 12-week-old mice. All data 
are expressed as percentage of age-matched non-LPS-treated controls ± standard 
error of 3 individual assayed mice. See legends to Figs.11I.l and 111.2 for control 
numbers. 
have been due to the rather short regeneration time of 4 weeks in this experiment. 
It is also evident from Fig.III.7B,D that the recovery of the femoral CFU-F 
numbers in irradiated mice lagged behind that of control mice, indicating that the 
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regeneration of the CFU-F in irradiated mice is retarded in comparison to the 
unirradiated CFU-F. It also appears from Fig.III.7 that transfusion of unirradiated 
BMC immediately after irradiation did not prevent the postirradiation depletion of 
the CFU-F population, nor did it facilitate normalization of the CFU-F population 
following LPS injection. These data demonstrate that transfusion of unirradiated 
BMC is not a prerequisite for the normalization of the femoral CFU-F population 
in previously irradiated mice following LPS treatment. Finally, no significant 
differences were found between the regeneration kinetics of CFU-F following LPS 
injection in 4- and 12-week-old mice. This strongly suggests that the transient 
normalization of femoral CFU-F in irradiated 4-week-old mice (Fig.III.2B) results 
from a CFU-F population with a low regenerative ability similar to that of CFU-F 
in mice irradiated at 12 weeks of age. 
DISCUSSION 
It appears from the present study that the femoral but not the splenic CFU-F 
population size in mice irradiated at 4 weeks of age shows a transient recovery to 
a normal level following 5 or 7 Gy TBI. Previously it has been reported that 
irradiation of adult mice leads to a severe and long- term depletion of femoral 
and splenic CFU-F with doses exceeding 5 Gy (Piersma et al., 1985b; Ploemacher 
et al., 1983; Xu et al., 1983). These observations suggest that the CFU-F population 
in young mice is less radiosensitive as compared to that in adult mice. However, 
when BMC from 4- and 12-week-old mice were irradiated in vitro no significant 
differences in radiosensitivity were measured (Fig.III.5). This indicates that the 
transient normalization of the CFU-F population in mice irradiated at 4 weeks of 
age is probably due to a difference in in vivo CFV-F kinetics following radiation. 
To study this possibility, mice were injected with LPS 3 months after 7-9 Gy TBI. 
Since LPS injection partly depletes the CFU-F population in unirradiated (Fig.ill.6) 
and previously irradiated mice (Figs.IIL7B,D), subsequent normalization of the 
femoral CFU-F number must be accomplished by surviving CPU-F. Such a normaliza-
tion was indeed observed both in mice irradiated at the age of 4 and 12 weeks. No 
significant differences in the regeneration kinetics after enforced LPS-induced 
proliferation were observed between the two age groups. In both groups the 
proliferative ability of the CFU-F population was similarly delayed as compared to 
that of LPS-treated unirradiated control mice. These observations can be explained 
by assuming that latent damaged CFU-F, not able to form colonies in vitro, are 
replaced by surviving CFU-F in young mice, due to normal growth of the femur 
(Brockbank et al., 1983b ). The replacement of latent damaged CFU-F in non growing 
adult femurs could be accomplished only by forcing CFU-F to proliferate, e.g., by 
using LPS. 
The secondary decrease of the femoral CFU-F numbers following doses 
exceeding 5 Gy was accompanied by a secondary decrease of hemopoietic progenitor 
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cell numbers in the femur. These observations are in line with previous reports on 
the effects of irradiation in mice, rats and dogs ( Cowall et al., 1981; Croizat et 
al., 1979; Knospe et al., 1960; Ploemacher et al., 1983; Xu et al., 1983). In our 
experiments also approximately 30% of all mice surviving 1 year after 7 Gy TBI 
had high blood leucocyte counts and occurrence of splenomegaly. Since postirradia-
tion blood abnormalities have been observed to precede the development of leukemia 
(Cowall et al., 1981), it is suggested that a part of these mice in the present 
study had developed leukemia. In addition, it might be speculated that the secondary 
femoral hypoplasia in irradiated mice may represent a preleukemic or myelodysplastic 
syndrome (Michels et al., 1985). No experimental proof was obtained for these 
suggestions since no autopsy was performed on these mice. 
Transfusion of unirradiated BMC directly following irradiation of young and 
adult mice did not ameliorate the postirradiation depletion of the CFU-F popula-
tion, nor did it improve the post-LPS recovery of femoral CFU-F numbers. Pre-
viously, it was reported by Piersma et al. (1983b) that infused CFU-F have a 
remarkably high capacity to lodge into the irradiated femur of mice and are 
maintained in this site for months. The present data indicate, however, that 
transfusion of unirradiated BMC is not a prerequisite for the normalization of the 
irradiated CFU-F population. 
The radiosensitivity of CFU-F from 4- and 12-week-old mice (Do was 1.59 
and 1.65 Gy, respectively) was comparable with previous reports (Garnett et al., 
1982; Werts et al., 1980; Xu et al., 1983), but was greater than was found by 
Wilson et al. (1974). The radiosensitivity of CFU-F is comparable to or even less 
than that of the hemopoietic progenitors CFU-s (Do range from 0.8 to 1.2 Gy) 
and CFU-c (Do range from 1.6 to 2.4 Gy) (Testa et al., 1985; Xu et al., 1983). 
However, in previously irradiated mice the CFU-F recovery lagged behind that of 
hemopoietic progenitors (Fig.III.2B), indicating that the recovery of CFU-F following 
irradiation shows other regeneration kinetics than hemopoietic progenitors. 
It is of interest to note, that both the regenerative capacity of implanted 
femurs and spleen (Fig.III.3) and the LPS-induced CFU-s accumulation in the spleen 
(Fig.III.4) were severely decreased following irradiation of 4-wk-old mice with 5 or 
7 Gy TBI, but, in contrast with femoral CFU-F, did not normalize during the 
1-year observation period. Although the immediate radiation toxicity has been 
reported to be the same for femoral regenerative capacity following implantation 
and for femoral CFU-F (Piersma et al., 1983a), these assays of stromal integrity 
(Fried et al., 1973; Fried et al., 1976; Hotta et al., 1983; Ploemacher et al., 1983) 
apparently measure different stromal components. 
The observation of near normal peripheral blood parameters in the presence 
of a decreased progenitor content in both spleen and femur indicate a compensatory 
proliferation (Hendry et al., 1983) or an increased cycling rate (Croizat et al., 
1979; Hendry and Lajtha, 1972) of the committed progenitors to produce enough 
functional blood cells. The presented data also indicate that near normal femoral 
hemopoiesis could occur within a severely (latent) damaged stroma. All stromal 
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assays used in this study are dependent on proliferation and a decreased prolifera-
tive capacity does not necessarily have to imply a decreased function of the stromal 
cells surviving the irradiation (Laver et al., 1986; Naparstek et al., 1986; Song and 
Quesenberry, 1984). In line with a previous report (Piersma et al., 1985b) we show 
here that the diminished CFU-F population after irradiation could be replaced by 
normal proliferating CFU-F after a second, LPS-induced, stromal damage. This 
recovery apparently can occur from CFU-F surviving the irradiation, although its 
kinetics is delayed as compared with that of CFU-F in nonirradiated mice. Further- · 
more, we found that the kinetics of LPS-induced CFU-F recovery was similar in 
mice irradiated at 4 or 12 weeks of age and could not be enhanced by a bone 
marrow transplant. In a previous report we showed that donor-derived stromal 
cells could be detected in the recipient (Piersma et al., 1983b), and Werts et al. 
(1980) showed that n;tarrow stromal cells could migrate from an irradiation protected 
site into an irradiated femoral bone marrow. However, apparently these cells do 
not contribute to the ultimate CFU-F population size which may depend on other 
microenvironmental factors, e.g. the endothelial cells from the sinusoids (DeGowin 
et al., 1976; Knospe et al., 1960). 
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Department of Cell Biology and Genetics, Erasmus University, Rotterdam, 
The Netherlands 
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ABSTRACT 
We have compared four assays to detect hemopoietic stromal damage induced 
by various cytostatic agents in young ( 4-week old) and adult (12-week old) mice. 
These assays included: (a) quantitation of the hemopoietic stem cell content of 
subcutaneously implanted spleens and femurs, (b) quantitation of fibroblastic 
colony-forming units per femur and spleen, (c) quantitation of the growth of 
normal hemopoietic progenitor cells in irradiated cytostatic drug-treated mice, and 
(d) measurement of splenic hemopoietic stem c~ll accumulation in response to 
bacterial lipopolysaccharide-induced hemopoietic stress. 
Busulfan caused a short- and long-term hemopoietic stromal defect. However, 
the four assays used showed different kinetics and severity of the stromal damage. 
Cyclophosphamide treatment resulted in a short-term stromal damage which was 
repaired within one week to three months, depending on the assay used. Methotre-
xate and vincristine did not cause long-term stromal damage as measured by the 
four assays used, whereas a short-term splenic stromal damage was detected using 
the subcutaneous implantation technique. No significant differences in stromal 
sensitivity to drug treatment were observed between young and adult mice. The 
presented data suggest that the 4 assays used to study stromal integrity measure 
different components of the HM, and indicate that the use of a single assay may 
well lead to erroneous interpretations. 
INTRODUCTION 
With the increasing use of effective cancer chemotherapy it has become 
important to determine and evaluate the risks of late complications. Recently some 
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investigators reported a long-term hemopoietic insufficiency after chemotherapy. 
This long-term insufficiency following antineoplastic agents in adults and children 
(Haworth et al., 1982; Matsuo et al., 1985; Testa et al., 1985) and experimental 
animals (Ben-Ishay et al., 1985; Botnick et al., 1981; Braunschweiger et al., 1982; 
Fried and Barone, 1980; Fried et al., 1977; McManus and Weiss, 1984; Morley et 
al., 1975; Trainor and Morley, 1976) may be caused by a failure of hemopoietic 
stem cells or by a defective support capacity of the hemopoietic stroma or a 
combination thereof. 
In order to study the effects of various cytostatic agents on the integrity of 
the hemopoietic stroma, we employed a series of assays, which are assumed to 
detect different components of the stroma or combinations thereof, and distin-
guish between a (latent) proliferative defect or a functional stromal defect. This 
may be helpful in predicting long-term damage inflicted by cytostatic agents. A 
functional damage in stromal cells may result in an acute and long-lasting dis-
turbance in hemopoietic regulation. On the other hand, a proliferative defect does 
not result in an acute stromal defect in situ, but may decrease the reserve capacity 
of the slow regenerating hemopoietic stroma when responding to stress-induced 
proliferation. In addition it has been reported that late toxicity induced by chemo-
therapy may not only occur from damage to rapidly proliferating cells, but also 
may result from damage to non-cycling cells (D' Angio, 1976; Billingham, 1979; 
Goorill et al., 1981; Weiss and Muggia, 1980). The mechanism by which antineoplastic 
agents cause damage to the organ stroma are not fully understood. It is also 
unclear which stromal cells are most vulnerable for cytotoxic treatment: 
In the present study we used 2 assays that permit detection of a latent 
proliferative defect. These assays are the quantitation of the fibroblastoid colony 
forming unit ( CFU-F) and the quantitation of the regenerative capacity of the 
implanted spleens or femurs. In these assays the stromal cells are forced into 
mitosis (Fried et al., 1973a; Friedenstein et al., 1974b; Hotta et al., 1983). 
In order to detect functional stromal defects under conditions where stromal 
cell proliferation is limited we quantitated the growth of non::iJ.al BMC in previ-
ously drug-treated mice. In addition, an assay was used to measure the functional 
activity of the hemopoietic stroma and progenitors at the same time, i.e. quantita-
tion of the CFU-s accumulation in the spleen following lipopolysaccharide (LPS) 
injection. In the absence of detectable defects in the proliferative activity of the 
CFU-s compartment, this assay can be used as an indication of the splenic stromal 
function (Ploemacher et al., 1983). However, defects in the capacity of CFU-s to 
migrate and/or proliferate in the spleen may also lead to a decreased splenic 
response to LPS. Finally quantitation of peripheral blood parameters (hematocrit, 
leucocytes, and erythrocytes) and hemopoietic progenitor content per spleen or 
femur under nonnal steady state conditions was used as an indication of the 
combined functional activity of hemopoietic progenitors and stroma. This study was 
also undertaken to compare the usefulness of. the different assays used to detect 
stromal integrity. 
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The cytostatic agents, chosen on the basis of their use in the treatment of 
malignancies in children, were busulfan (BU), cyclophosphamide (CTX), methotrexate 
(MTX) and vincristine (VCR). BU was chosen since latent hemopoietic stem cell 
and stromal damage has been reported in adult treated mice (Fried et al., 1977; 
McManus and Weiss, 1984; Morley and Blake, 1974) and because of its clinical use 
in preparation of children with congenital bone marrow disorders for BMT (Park-
man et al., 1984). CTX, MTX, and VCR are clinically used in treatment of children 
with acute lymphoblastic leukemia, the most common childhood malignancy. 
MATERIALS AND METHODS 
Animals. Female (CBNRij x C57BL/Rij)F1 mice, .four weeks old (young) and weigh- . 
ing 14-16 g., and female mice, 12 weeks old (adult) and weighing 25-30 g., and male 
or female mice 8-30 weeks old were used as recipients for CFU-s determination. 
The animals were purchased from the Laboratory Animals Center of the Erasmus 
University, Rotterdam, The Netherlands, or from the Radiobiological Institute 
TNO, Rijswijk, The Netherlands. 
Drug treatment. Vincristine (VCR) (Eli-Lilly), cyclophosphamide (CTX) (Asta), and 
methotrexate (MTX) (Lederle) were dissolved in phosphate-buffered saline (PBS). 
Ten milligrams of busulfan (BU) (Wellcome) were first dissolved in 1 ml of acetone 
and further diluted with 67 ml of PBS to the appropriate dilution. The acetone 
concentration was 15 J..LVml. VCR was injected i.v. twice weekly for 3 consecutive 
weeks in a total dose of 1.5 mg!kg body weight (BW). BU (total dose 45 mg!kg 
BW) or MTX (total dose 67.5 mg!kg BW) were injected i.p. three times a week for 
three consecutive weeks. CTX was injected i.p. once a week (CTX. 3x100mg) (total 
dose 300 mg!kg BW) or three times a week ( CTX. 9x30mg) (total dose 270 mg!kg 
BW) for three consecutive weeks. 
Regeneration· assay. The regenerative capacity of spleens and femurs were deter-
mined by assaying their CFU-s content at 6 weeks following subcutaneous implanta-
tion. Four spleens and 8 femurs derived from 4 experimental donor mice per group 
were implanted subcutaneously in 4 isologous host mice as has been described 
previously (Ploemacher et al., 1982). Implants were pooled for CFU-s determination. 
Adult syngeneic host mice for splenic and femoral implants received 5 Gy TBI 1 
day before implantation to stimulate splenic regeneration (Chamberlin et al., 1974). 
Radiation of host mice had no effect on femoral regeneration. 
Irradiation. Whole body irradiation was performed with a cesium-137 source (Gamma-
cell 40, Atomic Energy of Canada Ltd., Ottawa, Canada) at a dose rate of 1.27 
Gy/min. 
47 
Cell preparation. Single cell suspensions of femoral marrow and spleen were 
prepared and diluted in alpha medium (alpha modification of Dulbecco's minimum 
essential medium). Nucleated cells and red blood cells were counted with a Coulter 
Counter model B. Hematocrits were determined using a microcentrifuge. 
CFU-s assay. CFU-s were assayed as described by Till and McCulloch (1961). Cell 
suspensions were injected i.v. into 7-10 lethally (9 Gy) irradiated recipients. Spleens 
were fixed 7 days later and macroscopic surface colonies were counted. Radiation 
control mice contained an average of less than 0.2 colonies per spleen. 
CFU-G/M and CFU-F assay. CFU-G/M and CFU-F were quantitated in a semi solid 
culture medium (0.8% methylcellulose) as described previously (Brockbank et al., 
1983b ). All colonies counted contained at least 50 cells. 
CFU-s accumulation in the spleen. Endotoxin of Salmonella typhosa (LPS) (Sigma) 
prepared by the Boivin method was used. Five days after i.v. injection of 300 p.g 
of LPS per mouse, the increase in splenic cellularity and CFU-s were determined 
as an indication of the splenic stromal ability to support proliferation and accumula-
tion of CFU-s (Ploemacher et al., 1983). However, it may also detect defects in 
the CFU-s compartment with respect to proliferative activity, migration or spleen 
homing ability. 
Growth curves. One year after cessation of cytotoxic treatment, mice received 
lethal (9 Gy) total body gamma irradiation. Within 2 hours after irradiation, the 
mice were injected i.v. with 4 x 106 syngeneic normal BMC. At 4, 7, 11 and 33 
days after irradiation the splenic and femoral cellularity and CFU-G/M content of 
3 mice per point were determined. The growth of CFU-G/M was used to determine 
the stromal ability to support hemopoiesis one year after cytotoxic agent treatment. 
Statistics. Values for all parameters in the figures are expressed as arithmetic 
means in percentage of age-matched controls ( ± 1 SEM). Each point in figure 1, 
3, 4 and 5 was determined in 2-5 separate experiments while each experiment 
consisted of 3-4 mice per experimental group. At each time point age-matched 
controls were also assayed. Statistical analysis was done using the Student t test. 
RESULTS 
Young mice 
Busulfan treatment 
Immediately after the last BU injection animals showed a transient anemia and 
neutropenia (data not shown). The cellularity of spleens and femurs remained 
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Figure IV.l. The effect of BU on splenic and femoral cellularity (A), CFU-G/M 
content (B), CFU-F content (C), regenerative capacity of spleen and femur and 
CFU-s accumulation in spleens after LPS treatment (D). All data are expressed as 
percentage of age-matched controls ± SEM of 2-5 experiments. The 1 year data 
indicated 'A' are from mice treated at 12 weeks of age, the other data are from 
mice treated at 4 weeks of age. Control cellularities averaged from 1.99 x 10S 
nucleated cells per spleen at the 1 day point to 2.57 x 10S at 1 year and from 
3.10 x 107 nucleated cells per femur at the 1 day point to 4.56 x 107 at 1 year. 
Averaged control numbers: CFU-G/M: 7,600 per spleen and 43,700 per femur. CFU-F: 
320 per spleen and 1,570 per femur. Regeneration assay: 115 CFU-s per splenic 
implant and 930 CFU-s per femoral implant. Splenic CFU-s accumulation after LPS 
treatment: 110,300 CFU-s per spleen. * p < 0. 05, **p < 0. 01. 
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Figure W.2 Growth kinetics of nonnal CFU-G/M in spleen and femur of lethally 
i"adiated mice, 1 year after they received the first of a series of cytostatic drug 
injections at 4 weeks of age. Each point represents the pooled data of 3 mice in 
1 experiment. Co (e), BU (•), CTX 3 x 100 (.6.), MTX (0) and VCR (D). 
below control values during the time period studied, except for a transient restora-
tion in the femur at one week after cessation of treatment (Fig.IV.lA). Both in 
spleen and femoral marrow hemopoietic (CFU-G/M) (Fig.IV.lB) and stromal param-
eters (CFU-F, Fig.IV.lC; regenerative capacity, Fig.IV.lD) were severely decreased 
immediately after treatment. 
Femoral and splenic CFU-F numbers (Fig.IV.lC) showed a transient normaliza-
tion between 1 and 90 days, which was followed by a secondary decrease down to 
50-80% of control values. An essentially similar pattern was observed for the 
femoral regenerative capacity (Fig.IV.lD) and CFU-G/M content (Fig.IV.lB). How-
ever, these parameters indicated different levels of BU-induced damage when 
assayed at comparable time points, indicating that the assessment of a single 
parameter may yield insufficient information on hemopoietic and stromal integrity. 
Splenic regenerative capacity and CFU-G/M content did not show a transient 
return to normal values within this period, but a slow restoration occurred up to 
60-80% at the one year time point. One year after cessation of BU treatment all 
femoral hemopoietic and stromal parameters were significantly below normal. 
The post-BU kinetics of the regenerative capacity, the LPS response and the 
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Figure W.3 The effect of CTX on splenic and femoral cellularity (A), CFU-G/M 
content (B), CFU-F content (C) regenerative capacity of spleen and femur and 
CFU-s accumulation in spleens after LPS treatment (D). All data are expressed as 
percentage of age matched controls ± SEM of 2-5 experiments. The 1 year data 
indicated 'A' are from mice treated at 12 weeks of age, the other data are from 
mice treated at 4 weeks of age. CTX was injected i.p. once a week ( CTX (3 x 
100mg)) or three times a week (CTX (9 x 30mg)) for three consecutive weeks. For 
control numbers see legend Fig. 1. *p < 0.05. **p < 0.01. 
CFU-G/M, but not CFU-F, content showed a good correlation in the spleen. The 
growth pattern of normal CFU-G/M in the femur of mice at one year after BU 
treatment (Fig.IV.2) suggests that at this late time point their femoral stroma may 
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indeed be less capable to stimulate growth of hemopoietic progenitors. Since only 
3 mice per experimental point are used in this assay no definite conclusions can 
be made. 
Cyclophosphamide treatment 
CTX induced a moderate decrease of the splenic and femoral cellularity 
(Fig.IV.3A) and CFU-G/M content (Fig.IV.3B) immediately after treatment, followed 
by almost complete restoration within one week. These data correlate well with 
the transient damage of the hemopoietic stroma as measured by the CFU-F assay 
(Fig.IV.3C) and regenerative capacity (Fig.IV.3D), which showed recovery to normal 
values within 7-90 days. Only splenic regenerative capacity of CTX-treated mice 
remained below that of age-matched controls. Fractionation of the CTX dose 
induced a decreased acute stromal toxicity (Fig.IV.3D). The decreased growth of 
normal CFU-G/M observed beyond day 7 in lethally irradiated recipients previously 
treated with CTX (Fig.IV.2) suggest that CTX had also decreased the functional 
capability of the stroma to support hemopoiesis. 
Methotrexate and vincristine treatment 
Transient increases in splenic cellularity (Fig.IV.4A) and in splenic and femoral 
CFU-G/M content (Fig.IV.4B) were evident immediately after cessation of MTX 
treatment. VCR treatment induced a transient increase in splenic CFU-G/M (Fig. 
IV.SB). In the spleen of both MTX- and VCR- treated mice, CFU-F numbers (Fig.IV. 
4C and IV.SC) increased after cessation of treatment and remained above normal 
from 90-180 days; normal levels were found after one year. In femurs of these 
mice, CFU-F were transiently increased one week after the last MTX- or VCR-
injection. The regenerative capacity of spleens and femurs of the MTX- and VCR-
treated mice (Fig.IV.4D and IV.SD) fluctuated around normal values during the 
observed time period of one year. Due to the large variability of the stromal 
assays no definite conclusions can be drawn. Only at one week was the splenic 
regenerative capacity significantly decreased. The ability of these mice to ac-
cumulate CFU-s following LPS-injection appeared unchanged over the year following 
treatment. MTX and VCR treatment resulted in a small stromal defect as judged 
by the growth kinetics of normal BMC in lethally irradiated MTX- or VCR-treated 
recipients. At 12 and 33 days a decreased CFU-G/M content was found although 
the growth during the first 7 days was normal (Fig. IV.2). 
Adult mice 
At one year following cessation of treatment with BU, CTX, MTX or VCR, 
adult mice did not show significant differences in sensitivity of the hemopoietic 
stroma to these agents in comparison to young mice (Fig.IV.l, IV.3-5). In contrast 
to young BU-treated mice that had a 50% decrease in femoral CFU-G/M, the 
CFU-G/M content of adult BU-treated mice did not differ from age-matched 
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controls one year after the last BU injection (Fig.IV.lB). Also adult VCR-treated 
mice differed from young VCR-treated mice with respect to their splenic CFU-G/M 
content (Fig.IV.SB). 
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Figure W.4 The effect of MTX on splenic and femoral cellularity (A), CFU-G/M 
content (B), CFU-F content (C) regenerative capacity of spleen and femur and 
CFU-s accumulation in spleens after LPS treatment (D). All data are expressed as 
percentage of age matched controls ± SEM of 2-5 experiments. The 1 year data 
indicated 'A' are from mice treated at 12 weeks of age, the other data are from 
mice treated at 4 weeks of age. For control numbers see legend Fig. 1. *p < 0.05, 
**p < 0.01. 
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Figure IV.5 The effect of VCR on splenic and femoral cellularity (A), CU-G!M 
content (B), CFU-F content (C) regenerative capacity of spleen and femur and 
CFU-s accumulation in spleens after LPS treatment (D). All data are expressed as 
percentage of age matched controls ± SEM of 2-5 experiments. The 1 year data 
indicated ~' are from mice treated at 12 weeks of age, the other data are from 
mice treated at 4 weeks of age. For control ·numbers see legend Fig. 1. *p < 0.05 
**p<O.Ol. 
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DISCUSSION 
Our study clearly demonstrates that the data from 3 stromal assays used, i.e. 
CFU-F, regenerative capacity, and splenic LPS response, do not correlate with 
respect to the extent and kinetics of stromal damage inflicted by treatment with 
cytostatic agents. This notion implies that the use of a single stromal assay can 
lead to erroneous interpretations of the stromal function after cytotoxic treat-
ment. Moreover, it seems that the stromal defects induced by cytostatic agents 
are not necessarily accompanied by impaired hemopoiesis and therefore suggest a 
latent defect in the proliferative capacity of the stroma, rather than a defect in 
in situ stromal function (Fig.IV.1B, IV.1D and IV.2). The proliferative defect that 
was measured by the implant regeneration assay in the first weeks after BU 
treatment (Fig.IV.1D) is most likely caused by the small number of surviving stromal 
cells. Between 90 and 180 days the regenerative capacity of the femoral stroma had 
reached control levels which suggested a normalization of the number of stromal 
cells responsible for the maintenance of hemopoietic activity in implanted femoral 
grafts. It is unlikely that the subsequent secondary decrease observed in the femoral 
regeneration after BU treatment is also caused by a deficient number of stromal 
cells. Rather, it ma:y be explained by the assumption that the proliferative poten-
tial of the stroma was exhausted during and after BU treatment. This notion of a 
limited proliferative potential (Hayflick, 1976) seems to be supported by the obser-
vation that a decreased regenerative capacity may also occur with ageing of some 
mouse strains (Hotta et al., 1980; unpublished observations). The existence of a 
proliferative defect in otherwise normally functioning stromal cells was also 
observed in long-term bone marrow cultures following in vitro irradiation (Laver 
et al., 1986). 
Our laboratory reported recently a similarity between the immediate radiation 
toxicity for femoral CFU-F and the regenerative capacity of the femur following 
subcutaneous implantation (Piersma et al., 1983a). In the present study we found 
that a severely decreased regeneration of spleen and femur implants 7 days after 
the last BU injection was accompanied by a normal CFU-F content, while the 
opposite was observed in the femur at 180 days following cessation of BU treatment 
(Fig.IV.1C and IV.1D). Apparently both assays determine the regenerative ability of 
different entities of the HM. The data strongly suggest that BU affects regenera-
tion of another stromal component, e.g. endothelial cells, than CFU-F, while gamma 
radiation at least severely decreases the regenerative ability of CPU-F. These 
observations indicate that quantitation of CFU-F numbers can not be used to 
estimate the functional activity of the in situ hemopoietic activity or predict 
long-term effects of cytostatic agents upon hemopoietic stroma. This conclusion is 
essentially supported by a recent report of Dr. Molineux and his colleagues (1986a), 
who demonstrated different extent and kinetics of a BU-induced long-term stromal 
lesion as assayed by the femoral CFU-F numbers and regenerative capacity. This 
study was performed in adult mice using comparable total doses of BU as were 
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used in the present report. 
Our results on the delayed toxic effects of BU and CTX in young mice are 
in agreement with and extend previous studies using adult mice (Adler and Kuz-
netsky, 1984; Fried and Adler, 1985; Fried and Barone, 1980; Fried et al., 1977; 
McManus and Weiss, 1984). The improvement in regenerative capacity after BU 
(Fig.IV.1D), which was not observed in adult mice (Fried and Adler, 1985), appears 
to be at difference with our study. Our data do not show long-term hemopoietic 
stromal or stem cell damage after MTX or VCR treatment and fully support the 
previous studies by Trainor and Morley (1976) with respect to the effects of MTX 
and vinblastine (a VCR-related drug) upon the stem cell compartment. 
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ABSTRACf 
We studied the short- and long-term effects of a fractionated injection of 
cis-diamminedichloroplatinum (II) (CDDP) upon the haemopoietic stroma and the 
haemopoietic precursor cell compartment of young and adult mice. The integrity of 
the stromal microenvironment was investigated using three different assays in-
cluding quantification of (a) the fibroblastoid progenitor cell compartment, (b) the 
regenerative capacity after subcutaneous implantation of spleen and femur, and (c) 
the growth of normal bone marrow progenitors in kthally irradiated CDDP-treated 
mice. 
CD DP treatment induced a slight anaemia which -lasted for the observation 
period of 1 year, and could not be restored by infusion of normal BMC. The 
population size of hemopoietic progenitors was severely decreased immediately 
after CDDP treatment and the CFU-s recovery in the bone marrow was slow and 
temporary. Stromal function was significantly decreased and normalization occurred 
within approximately 40 d, depending on the stromal parameter measured. Subse-
quently, the regenerative capacity of the stroma showed a second decrease which 
was still detected at 1 year. This pattern of stromal damage has not been reported 
for any other cytostatic agent. Since the other two assays did not detect a second 
decrement in stromal integrity it is implied that the three stromal assays used 
detect different stromal functions. We conclude that CDDP treatment of both young 
and adult mice results in severe short-term damage and a late occurring secondary 
regenerative defect of the haemopoietic organ stroma. 
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INTRODUCTION 
It has been demonstrated that cis-diamminedichloroplatinum (II) (CDDP) has 
significant antineoplastic activity against a variety of solid tumors and lymphomas 
in both experimental animals (Rosenberg, 1985) and man (Loehrer and Einhorn, 1984; 
Schilcher et al., 1984). The increase in the percentage of long-term survivors 
(Loehrer and Einhorn, 1984) emphasized the necessity to study the long-term side 
effects of CDDP. 
Methods to minimize the severe nephrotoxicity (Corden et al., 1985; Jacobs 
et al., 1984) in order to enable the use of higher doses of CDDP resulted in an 
increase of response rates, but also enhanced the incidence of myelotoxicity (Khan 
et al., 1982; Ozols et al., 1983). CDDP treatment has also been reported to increase 
the sensitivity of the bone marrow for other cytostatics (Haim et al., 1984) or 
radiotherapy (Keizer et al., 1984). Human and murine studies already indicated a 
severe short-term CDDP-induced damage of all haemopoietic progenitors, the ery-
throid progenitor (BFU-E) being most sensitive (Jenkins et al., 1981; Nowrousian 
and Schmidt, 1982; Rothman and Weick, 1981). Recently Braunschweiger et al. 
(1982) reported a long lasting defect in the ability of CDDP-treated mice to respond 
to anaemic stress induced by bleeding. 
In view of this we have used three different assays to determine long-term 
stromal integrity in young ( 4 weeks old) and adult (12 weeks old) mice, i.e. (1) 
Quantification of the fibroblastoid colony forming unit (CPU-F), a single stromal 
progenitor class in the haemopoietic stroma (Blackburn and Patt, 1977; Frieden.Stein 
et al., 1974a; Tsai et al., 1986). (2) Quantification of the regenerative capacity of 
spleen and femur after subcutaneous implantation. This assay measures the ability 
of the regenerating donor-derived stroma to accommodate host-derived CFU-s 6-8 
weeks after implantation (Fried et al., 1973a; Hotta et al., 1983). (3) Quantification 
of the growth of normal haemopoietic progenitors in irradiated CDDP-treated 
mice. The first 2 stromal assays listed depend on proliferation of stromal cells 
(Friedenstein et al., 1974b; Piersma et al., 1985b; Tavassoli et al.; 1973a). Recently, 
it has been shown that a defective proliferative capacity of the stroma is not 
necessarily accompanied by a defective stromal ability to support haemopoiesis 
(Laver et al., 1986; Naparstek et al., 1986; Ploemacher et al., 1983). The third 
assay is assumed to measure the in situ stromal integrity under circumstances that 
do not induce immediate large-scale proliferation of stromal cells. 
MATERIALS AND METHODS 
Mice. Female (CBA/Rij x C57BL/Rij)F1 mice, 4 weeks old (weighing 14-16 g), and 
female Fl mice 8 to 35 weeks old (22-34 g), were purchased from the Radiobio-
logical Institute TNO, Rijswijk, The Netherlands, and kept under clean conventional 
conditions. 
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Drug treatment. Cis-diamminedichloroplatinum(II) (a gift from Bristol-Meyers 
Company, New York, N.Y.) was dissolved in phosphate-buffered saline (PBS) at a 
concentration of 0.3 mglml and injected i.p. at a dose of 10 mg!kg body weight 
(BW). This dose is equivalent to a dose of about 30 mg/m2 in man based on the 
conversion factors of Freireich et al. (1966). The LDSO of this drug for mice is 14 
mg!kg BW (Penta et al., 1979). 4 or 12 weeks old F1 mice were injected three 
times at weekly intervals. Control mice were injected with the same volume of 
PBS. There was less than 10% mortality during the observation period. 
Colony assays. The CFU-s assay was carried out using the technique of Till and 
McCulloch (1961). At least 8 recipient mice per point were exposed to a lethal 
dose of 9.0 Gy total body irradiation (TBI) using a Gammacell40 J..37 Cs irradiation 
unit (Atomic Energy of Canada Ltd., Ottawa, Canada) at a dose rate of 1.27 Gy/min. 
Irradiated control mice contained an average of 0.2 day-8 colony per spleen. These 
mice were i.v. injected with appropriate dilutions of the cell suspensions to be 
tested. Macroscopic surface colonies were counted 8 d later after ftxation of the 
spleen in Telleyesznizky's solution. CFU-c, BFU-E and CFU-F were quantifted in 
a semi solid culture medium as previously described (Brockbank et al., 1983b). 
Subcutaneous implantation technique. Spleens and femurs of 4 experimental mice 
per group were removed after killing the donors with CO:z. Host mice received 5 
Gy TBI one day before implantation to stimulate splenic regeneration (Chamberlin 
et al., 1974). In each recipient mouse two femurs and one spleen were implanted 
subcutaneously on the ventral abdominal side under Avertin anaesthesia. Six to 8 
weeks later the implants were removed and CFU-s per implanted organ assayed. 
Growth of normal bone marrow cells in CDDP-treated mice. At different times 
after cessation of CDDP-treatment, mice received a lethal TBI followed by i.v. 
injection of 4 x 106 syngeneic normal BMC. The repopulation kinetics of spleen 
and femur concerning cellularity and CPU -c was determined 4-30 days after TBI 
and reconstitution as an indication of the stromal ability of spleen and femur to 
support haemopoiesis. 
Growth of bone marrow cells from CDDP-treated mice in normal mice. Normal non-
CDDP-treated mice received a lethal TBI and were injected with 4 x 106 BMC from 
mice at certain times after cessation of CDDP treatment. The femoral cellularity 
and CFU-c repopulation kinetics in the spleen and femur of these recipients was 
measured up to 11 days after TBI, as an indication of the regenerative ability of 
CDDP-treated BMC. 
Statistics. Values for all parameters are expressed as arithmetic means, and presen-
ted as per cent of age-matched controls unless stated otherwise. SEMs of these 
data were calculated by converting the absolute SEMs of experimental and control 
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data in percentages, and taking the square root of their quadrated sum. Thus, the 
SEMs include both the variance of the means of the control and experimental 
groups. Determinations for the control and treated group were always performed 
on the same day to exclude day to day variations. Statistical analysis was done 
employing the Student t test and using the absolute numbers of both control and 
treated groups. Statistical difference was assumed at the 95% confidence limits. 
RESULTS 
Since no significant differences were observed between data from mice treated 
at 4 or 12 weeks of age, only data from 4-week-old CDDP-treated mice will be 
presented. 
Body weight and peripheral blood 
CDDP treatment resulted in a decrease in body weight (BW) with a nadir at 
1 week after the last injection (65% of normal). The BW lagged behind that of 
age-matched control mice until it reached control levels at one year after cessation 
of treatment (data not shown). Erythrocyte numbers and haematocrit remained 
significantly below age-matched control numbers between 20 and 360 days after 
CDDP treatment (Fig.V.1). Further investigation indicated that the anaemia was 
normochromic and normocytic. 
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Figure V.l Changes in leucocytes ( .&. ), erythrocytes ( 0) and hematocrit (e) after 
three CDDP injections of 10 mg/kg given at weekly intervals. Data were converted 
to per cent of age-matched controls. Data represent the arithmetic means ( ± 1 
SEM).Each point consisted of six to 18 individually assayed mice. Vertical bars 
indicate SEM. Control values for leucocytes 9.9 X 109 /l, erythrocytes 8.72 x 1022/l 
and hematocrit 0.49 l/l. * p < 0.05, ** p < 0.01. 
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Figure V.2 Hemopoietic and stromal progenitors in spleen (A) and femur (B) after 
three CDDP injections of 10 mg/kg given at a weekly interval. Data were converted 
to per cent of age-matched controls. Each point consisted of six to 18 individually 
assayed mice. Vertical bars indicate 1 SEM. Control numbers of primitive progeni-
tors in the spleen were: CFU-s 2900, CFU-c 6100, and CFU-F 290 per organ. 
Control values for the femur; CFU-s 6400, BFU- E 8600, CFU-c 27 200, and CFU-F 
1010 per organ. * p < 0.05, ** p < 0.01. 
Cellularity and haemopoietic and stromal progenitor cell content of spleen and femur 
CDDP treatment elicited a large decrease do'Yfi to 30-40% of control values 
in the splenic and femoral cellularity, which normalized within 40 days (data not 
shown). In the spleen the number of the progenitor cells (CPU-s, CPU-c and 
CPU-F) (Fig.V.2A) were far below control numbers (1-18%) during the first week 
after cessation of treatment. Subsequently, a fast recovery of CPU-s was observed, 
followed by restoration of CPU-c and CPU-F. Only at the one year point was the 
splenic CPU-F content significantly below normal. In the femur the progenitor 
content (CPU-s, BPU-E, CPU-c and CPU-F) (Fig.V.2B) was also severely decreased 
immediately after CDDP treatment (1-10% of control). The recovery of the CPU-s 
population size in the femur was severely delayed as compared with that in the 
spleen. After day 140 the femoral CPU-s content showed a secondary decline 
down to 60% of control values. The femoral CPU-F population recovered much 
faster from the CDDP-induced depletion than the splenic CPU-F population. 
Regeneration of spleen and femoral marrow after subcutaneous implantation 
The donor-derived femoral marrow capacity to regenerate and support host-
derived CPU-s, 6 weeks after subcutaneous implantation into syngeneic hosts (Fig.V. 
3), was severely depressed immediately after cessation of treatment but returned to 
normal at 40 days, followed by a second decrease between 140 and 360 days. The 
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splenic regenerative capacity was less damaged as compared to that of femoral 
marrow, and showed a second decrease between 80 and 360 days (Fig.V.3). 
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Figure V3 Regenerative capacity of spleen and femur after subcutaneous implanta-
tion. At different times after cessation of CDDP-treatment femurs or spleen were 
subcutaneously implanted in syngeneic hosts. Quantification of the CFU-s content 
per implanted organ 6-8 weeks after implantation (data converted to per cent of 
age-matched controls) was used to estimate stromal function. Data represent ,the 
arithmetic mean of 2-4 individual experiments(± I SEM) and each experiment 
consisted of three to eight pooled spleens or femurs per point. Control spleen 
implants contained an average of 100 CFU-s. Control femur implants 1100 CFU-s. 
* p < 0.05, ** p < 0.01. 
Growth of normal femoral CFU-c in CDDP-treated, lethally irradiated mice 
We investigated the in situ stromal integrity in CDDP-treated mice by studying 
the stromal ability to support the growth of injected normal syngeneic BMC after 
lethal irradiation. Twenty days after the last CDDP injection the femoral and 
splenic haemopoietic stroma showed a severely decreased capacity to stimulate the 
growth of normal haemopoietic progenitors (CPU-c) (Fig.V.4A-D), but near normal 
CFU-c growth occurred in mice at 40 and 220 days after CDDP treatment. At 
difference with this was the incomplete restoration of nucleated cells in the spleens 
of these mice at 20 and 40 days after CDDP injection. Femoral cellularity was 
insufficiently restored at 20, 40 and 220 days. From Table 1 it appears that 
transplantation of 4 x 106 normal BMC into irradiated CDDP-treated mice ( 40 days 
after CDDP) could not restore the normocytic anaemia induced by CDDP as meas-
ured at 70 days after BMT. 
Growth of CDDP-treated bone marrow cells in normal syngeneic mice 
In order to investigate whether CDDP treatment would induce a residual 
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Figure VA Growth kinetics of normal BMC in normal (e) or CDDP-treated mice. 
At 20 ( 0 ), 40 (D) and 220 (b..) d after CDDP-treatment, mice were lethally 
i"adiated and reconstituted with 4 x 1()6 normal BMC. Data represent arithmetic 
means ( ± 1 SEM) of nine individually assayed mice per point in the control group 
and three individually assayed mice per point in the CDDP-treated groups. * p < 
0.05, ** p < 0.01. 
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stem cell defect we determined the proliferative capacity of CDDP-treated BMC, 
measured as the number of nucleated cells and CFU-c per femur, and compared 
this to that of normal BMC in lethally irradiated (9 Gy) but otherwise normal 
mice. In general, CDDP-treated BMC produced less nucleated cells (Fig.V.5A) and 
CFU-c (Fig.V.5B) in the femur of the recipients than did BMC from control mice. 
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Figure V.S Growth kinetics of normal and CDDP-treated BMC in normal recipients 
expressed as nucleated cells (A) or CFU-c (B) per femur. Normal i"adiated mice 
were grafted with 4 x 106 normal BMC ( •) or 4 x 106 CDDP-treated BMC from 
mice 20 (0), 40 (£::,.,), 80 (v), 140 (D) or 360 (()) dafter cessation of treatment. 
Data represent arithmetic means ( ± I SEM) of 15 individually assayed mice per 
point for the control group and three individually assayed mice per point for the 
CDDP-treated groups. * p < 0.05, ** p < 0.01. 
DISCUSSION 
Fractionated doses of CDDP induced a long-lasting mild normocytic and 
normochromic anaemia and transient leucocytosis. Anaemia may be one of the 
adverse side effects of CDDP treatment in both mice (Nowrousian and Schmidt, 
1982) and in man (Getaz et al., 1980; Khan et al., 1982; Ozols et al., 1983; Rothman 
and Weick, 1981; Wood and Hrushesky, 1984), and may be caused by a decreased 
erythropoietin production due to nephrotoxicity of CDDP (Wood and Hrushesky, 
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1984). It has been reported that a comparable fractionated regimen of CDDP as 
used in the present study induced a long-lasting qualitative and small but significant 
quantitative defect of the CFU-s population in mice (Dumenil et al., 1982). In 
difference with this, our observations on the growth potential of CDDP-treated 
BMC in normal irradiated recipients (Fig.V.5) indicate that CDDP only temporary 
(day 20) influenced the proliferative ability of the surviving primitive haemopoietic 
precursors. This suggests that the CDDP-induced anaemia is not the result of an 
ineffective stem cell compartment but rather is caused by a stromal insult. Suppor-
tive evidence for this notion is formed by our observation that infusion of 4 x 
106 BMC from normal or CDDP-treated mice led to comparable restoration of the 
radiation-depleted erythroid compartment, in normal mice, while 4 x 106 normal 
BMC could not cure the CDDP-induced anemia (Table V.1). 
Table V.l Haematocrit and erythrocyte numbers in CDDP-treated and normal mice 
before and after transplantation of CDDP-treated or normal BMC. 
10 weeks after transplantation of:" 
1 hr before BMT normal BMC CDDP-BMC 
Recipient Ht Ery<= Ht Ery Ht Ery 
Normal 49.4d 8.84 49.0 8.88 48.7 8.65 
(0.4) (0.15) (0.7) (0.18) (0.9) (0.16) 
CDDP- 42.1 7.42 40.0 7.37 n.d. n.d. 
treatedb (1.1) (0.21) (0.9) (0.19) 
a. Recipients received 4 x 106 BMC from either normal mice, or from mice 40 d 
after the last CDDP injection. 
b. 40 d after cessation of CDDP treatment. 
c. Number of erythrocytes x 10-9 /ml blood obtained by cardiac puncture under 
ether anaesthesia. 
d. Arithmetic mean (1 SEM) of 10 individually assayed mice. 
It appears that the developing stroma (Brockbank et al., 1983b) in 4-week-old 
mice has a similar sensitivity for CDDP as the full grown stroma of 12-week-old 
mice. Both the regeneration assay (Hotta et al., 1983; Tavassoli et al., 1973a) and 
the CFU-F assay (Friedenstein et al., 1974b) are sensitive measures of latent 
residual damage, since the stromal cells are forced to proliferate and damaged 
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cells may consequently not survive. In contrast, the establishment of growth curves 
of BMC in previously CDDP-treated and irradiated mice is assumed to measure the 
in situ functional stromal integrity under circumstances that do not induce imme-
diate large scale proliferation of stromal cells. All three assays (see Fig.V.3, 2, and 
4, respectively) detected an early severe injury of the haemopoietic stroma of 
both spleen and femur and the subsequent restoration of stromal integrity within 
approximately 40 d after cessation of CDDP treatment. A late secondary stromal 
defect was detected by the implant regeneration method, but not by the other two 
stromal assays. We interpret these findings as follows. CDDP induces an immediate 
and transient functional and proliferative defect of the haemopoietic stroma. The 
late secondary loss of the regenerative ability may be explained by assuming that 
the proliferative potential of the surviving stromal cells was exhausted during and 
after the early recovery phase. Thus an acceleration may have occurred of the de-
cline in regenerative capacity that has been reported to occur with ageing (Hotta 
et al., 1980). Apparently, this did not apply to CFU-F, since both in spleen and 
femur normal levels were found between 80 and 360 days except for the splenic 
CFU-F content at 1 year. These considerations suggest that a residual damage in 
other stromal cell types, e.g. endothelial cells, may have caused a loss of stromal 
regenerative capacity, a situation which is reminiscent of the effect of gamma-
radiation on the stroma of 4-week-old mice (chapter III). 
The doubling time of the haemopoietic precursors in femur and spleen during 
recovery after CDDP-induced damage was much longer than was observed for 
normal or CDDP-treated precursor cells injected in normal lethally irradiated mice 
(Fig.V.8 and Vos, 1972). In the light of the present data we propose that this 
slow recovery of haemopoietic precursors in CDDP-treated mice both may have 
resulted from the presumptive stem cell damage which we observed at day 20, and 
from the observed dysfunction of the hemopoietic organ stroma before day 40. 
The decrease in the femoral CFU-s population size between d9-y 220 and 360 
suggests a defect in the ability of the stroma to maintain sufficient numbers of 
early precursors, and remarkably coincides with the secondary loss of the femoral 
regenerative potential as assessed by the implant method. 
Our study on the growth of normal BMC in previously CDDP-treated mice 
may have clinical relevance with respect to the increased use of high-dose chemo-
therapy and subsequent autologous bone marrow transplantation in the treatment 
of solid tumors. We show here that the growth of normal BMC was severely delayed 
in the femur and spleen of mice, that were treated with CDDP 3 weeks before 
BMT, as compared to that of non-CDDP-treated mice (Fig.V.S). This·may lead to a 
prolonged and intensified risk of bleeding and infections. 
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ABSTRACT 
The short- and long-term effects of a fractionated cis-diamminedichloro-
platinum (II) (CDDP) administration on the ability of the murine femoral stroma to 
support hemopoiesis was tested using long-term bone marrow cultures. Furthermore, 
the femoral content of fibroblastoid colony-forming units, committed hemopoietic 
progenitors (granulocyte/ macrophage colony-forming units) and pluripotent stem 
cells (spleen colony-forming units) was studied. 
One week after cessation of treatment the stromal and hemopoietic precursors 
were significantly reduced in number. Normal values were observed at 12 weeks 
after cessation of the CDDP injections. Long-term bone marrow cultures established 
from femurs of mice at one week after CDDP administration showed a reduction 
in their cumulative production of non-adherent cells and granulocyte/macrophage 
colony-forming.units. This reduction was due to a decreased number of hemopoietic 
progenitor cells present at initiation of culture since it could be ameliorated by the 
addition of a sufficient number of non-adherent normal hemopoietic progenitor 
cells. Long-term bone marrow cultures established twelve weeks after CDDP admi-
nistration produced normal numbers of granulocyte/macrophage colony-forming 
units when compared with control cultures, but the total cell production was 
slightly decreased. These results demonstrate that CDDP does not damage the 
capacity of stromal cells to establish an in vitro functional microenvironment. 
INTRODUCTION 
Since the discovery of the antitumor activity of cis-diamminedichloroplatinum 
(CDDP) in animals (Rosenberg and Van Camp, 1970; Rosenberg et al., 1969), this 
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compound is included in several clinical protocols. Its use as a single agent, or in 
combination with other cytostatic drugs, has markedly improved treatment of 
head, neck and ovarian cancers and resulted in a high cure rate for advanced 
testicular cancer (Einhorn and Donahue, 1977; Williams and Whitehouse, 1979; 
Wiltshaw and Kroner, 1976). The major dose limiting effect of the drug is nephro-
toxicity (Madias and Harrington, 1978), but hydration, mannitol and/or furosemide 
induced diuresis, new administration routes and new dosage schedules have been 
reported to reduce the degree of renal dysfunction (Chiuten et al., 1983; Hayes et 
al., 1977; Vogl et al., 1980). Because of this, higher CDDP doses can be used and 
other side effects like anemia and myelosuppression have become dose-limiting 
(Blumenreich et al., 1985; Chary et al., 1977; Ozols et al., 1984). Although the 
exact mode of action is not completely understood, it is suggested that CDDP 
inhibits DNA synthesis by forming both DNA interstrand and intrastrand crosslinks 
(Pascoe and Roberts, 1974; Zwelling et al., 1981) comparable with. those formed by 
alkylating agents. It is known that some of these agents, e.g. busulfan and cyclo-
phosphamide, exhibit a long-lasting toxic effect on both hemopoietic progenitor 
cells and the HM (Fried et al., 1970; Molineux et al., 1986a; Morley and Blake, 
1974). The use of CDDP in murine models already demonstrated its dose-related 
and cumulative toxicity for early progenitors, particularly BFU-E and CFU-s 
(Jenkins et al., 1970; Nowrousian and Schmidt, 1982). Furthermore, Braunschweiger 
et al. (1982) observed that CDDP-treated mice have a long lasting defect in respon-
se to anemic stress induced by bleeding. 
In this study we used a clinically relevant treatment protocol of fractionated 
CDDP administration to investigate the ability of the stromal compartment to 
support hemopoiesis in long-term bone marrow cultures derived from CDDP-treated 
and control mice. In addition, we studied the toxic effects of this drug on hemo-
poietic and stromal progenitor cell classes. 
MATERIALS AND METHODS 
Drug treatment. Young (4-wk-old) male (CBA!Rij x C57BL!Rij)F1 mice were pur-
chased from the Radiobiological Institute TNO, Rijswijk, The Netherlands, and 
kept under conventional conditions. CDDP (a gift from Bristol-Meyers Company, 
New York, N.Y.) was dissolved in PBS (8.1 mM Nad!P04.2H:z0, 2.2 mM &J>04, 2.7 
mM KCl and 0.14 M NaCl) at a concentration of 0.3 mg CDDP/ml. Mice received 
10 mg of CDDP/kg body weight weekly for a total of three weeks. The total dose 
is equivalent to a dose of about 90 mg/m2 in man based on the conversion factors 
of Freireich et al. (1966). One or twelve weeks after cessation of drug treatment 
mice were killed by cervical dislocation and both femurs were removed using a 
sterile technique. 
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Preparation of nylon wool filtered non-adherent bone marrow cells. Nylon wool 
columns were prepared by filling 6 ml syringes with nylon wool from Leuko-pak 
leukocyte filters (Fenwal). Columns were incubated at 37°C with ex-medium (ex-
modification of Dulbecco's minimal essential medium) supplemented with 20% fetal 
calf serum (FCS: KC Biological lot no. 300361) for 30 minutes before use. Bone 
marrow suspensions in ex-medium plus 20% FCS (maximal2 x 108 BMC per column) 
were then layered on the column and allowed to adhere on the nylon wool. After 
45 minutes of incubation at 37°C non-adherent cells were eluted with 50 ml of ex-
medium plus 20% FCS at a flow rate of 1 ml per minute. Nonadherent cells were 
tested for the presence of fibroblastoid, granulocyte-macrophage and early hemo-
poietic (day 7 and day 12 CFU-s) progenitor cells. 
Long-term bone marrow cultures (LTBMC). Bone marrow was flushed from the femur 
of control or CDDP-treated mice with a 23 gauge syringe needle using 3 ml of ex-
medium supplemented with 10% horse serum (Boehringer, lot no. 1309200), 10% 
FCS, 10-5 M hydrocortisone hemi-succinate (Sigma), 10-4 M mercaptoethanol (Merck) 
and transferrin (500 1-Lg/ml; Behringwerke) into 25 cm2 Costar screw-capped culture 
tissue flasks. Cultures were maintained at 33°C in a humidified atmosphere consis-
ting of 10% C02 in air. At weekly intervals, the total non-adherent cell fraction 
was removed and 3 rill of fresh medium were added to the cultures. The non-adher-
ent cells were counted with the aid of a Coulter particle counter and assayed for 
granulocyte-macrophage progenitors. 
Spleen colony assay. The CFU-s assay was performed as described by Till and 
McCulloch (1961). Groups of 8 recipient mice received a lethal dose of 9 Gy total 
body gamma-radiation using a 137Cs-gamma-source (Atomic Energy of Canada Ltd., 
Ottawa, Canada) at a dose rate of 1.23 Gy/min, and were subsequently transfused 
with appropriate dilutions of BMC. After 7 or 12 days spleens were removed and 
fixed in Telleyesnizky's solution. The number of macroscopically visible spleen 
colonies was counted. 
Fibroblast colony-forming units (CPU-F). BMC were cultured in alpha-medium 
containing 0.8% methylcellulose and 20% FCS. One ml aliquots of culture medium, 
containing 5 x 105 cells, were plated in 35 mm Costar culture dishes and incu-
bated at 37°C in a humidified atmosphere consisting of 10% C02 in air. All deter-
minations were performed in triplicate. On day 10 of culture the cells were washed 
with PBS, fixed with methanol and stained with 10% Giemsa. Fibroblastoid stromal 
cell colonies containing at least 50 fibroblastic cells were counted with an inverted 
microscope. 
Granulocyte-macrophage colony-forming units (CFU-GIM). BMC were cultured in 
alpha-medium (5 x 104 nucleated cells/ml medium) containing 0.8% methylcellulose, 
10% FCS, 1% BSA and 10% con-A stimulated mouse spleen conditioned medium. Cells 
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were cultured for 7 days under the same conditions as described for CPU-F. All 
determinations were performed in duplicate. Granulocyte-macrophage colonies, 
containing at least 50 cells, were counted with an inverted microscope. 
Experimental design. In this study we used the production of non-adherent cells 
and granulocyte/macrophage precursor cells in LTBMC from femurs of CDDP-treated 
and control mice as parameters for the toxic effects of CDDP. A CDDP-induced 
reduction of these parameters could be due to (a) a reduction in the number of 
hemopoietic and/or stromal cells per explanted femoral plug, (b) a functional or 
proliferative defect in hemopoietic and/or stromal cells, or (c) a combination of 
these possibilities. To investigate the first possibility, we compared the production 
of non- adherent cells and CFU-G/M in control cultures with the production of 
those cells in cultures set up with half a femoral plug. In order to study the 
CDDP toxicity for stromal cells, we attempted to reinoculate non-hemopoietic 
stromal layers from femurs of CDDP-treated and control mice with adherent cell 
depleted normal BMC. Non-hemopoietic stromal layers were initially obtained using 
the system of Cohen et al. (1980) in which no horse serum and hydrocortisone 
was added to the medium. However, re-addition of hydrocortisone and horse serum 
led to a resumption of the hemopoietic cell production in such cultures indicating 
that resting stem cells were still present. As a consequence of this, we chose 
another approach. Cultures derived from whole femurs of treated animals and those 
derived from halved control femurs were supplemented with an excessive number 
of adherent cell-depleted normal BMC at initiation of culture. This complement of 
untreated hemopoietic cells is known to be unable to form an adherent stromal 
layer. This assay therefore aUowed us to study a possible stromal defect induced 
by CDDP. 
RESULTS 
Hemopoietic and stromal progenitors 
One week after cessation of treatment a reduction of the number of BMC to 
approximately 50% of control numbers was observed. All progenitor cell types were 
significantly reduced and the greatest reduction was observed in the CFU-F and 
CFU-s numbers, which were 17-18% of control values (Table VI.1). Twelve weeks 
after cessation of treatment all parameters measured had returned to normal values. 
Nylon wool filtration 
Nylon wool filtration of normal BMC effectively removed CFU-F and resulted 
in a slight enrichment in the incidence of day 7 and day 12 CFU-s. Relative 
numbers of BFU-E and CFU-G/M remained normal (Fig.VI.1). The recovery of the 
total cell number after nylon wool adherence was 26.2 ± 2.4 percent (mean ± 1 
SE, n=8). 
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Table VI.l Stromal and hemopoietic progenitor cell content of the femur after 
CDDP treatment. 
cells/femur CFU-GM/femur CFU-F/femur CFU-s/femur 
X 107 x103 x102 x102 
day 7 
Controls 
1 wk 28.5±1.3a 36.6±6.2 15.7±1.4 75.6±16.9 
(100)b (100) (100) (100) 
n=24c n=24 n=15 n=9 
12 wk 34.0±1.4 33.9±3.3 9.1±4.0 55.9±9.8 
(100) (100) (100) (100) 
n=9 n=S n=3 n=6 
CDDP-treated 
1 wk 15.1±1.9 11.9±2.7 2.9±0.7 13.3±5.1 
(53) (33) (18) (18) 
n=24 n=24 n=15 n=9 
p<O.OQ2d p<0.002 p<0.002 p<0.002 
12 wk 31.9±1.4 32.6±5.0 9.7±4.1 45.7±9.4 
(94) (96) (107) (82) 
n=9 n=6 n=3 n=6 
n.s. n.s. n.s. n.s. 
a. Arithmetic mean ± 1 SE. 
b. number in parentheses, percentage of control values. 
c. n, number of mice assayed. 
d. level of significance determined by Mann-Whitney U-test. 
n.d. not determined. 
n.s. not significant. 
day 12 
58.7±8.9 
(100) 
n=9 
n.d. 
10.1±2.6 
(17) 
n=9 
p<0.002 
n.d. 
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Figure VI..l Effect of nylon wool adherence on the frequency of hemopoietic and 
stromal progenitor cells. Data are expressed as progenitor cell numbers present in 
the non-adherent fraction relative to that of non-filtered normal bone marrow. Each 
column represents the mean of five replicate experiments (%), except for the 
CFU-s columns, which are based on three replicate experiments.· 
Long-term bone marrow cultures. 
To determine whether CDDP administration leads to a functional damage of 
the HM, LTBMC were prepared from whole femurs of CDDP-treated or control 
mice one week after cessation of treatment. Although no morphological changes in 
the composition . of the stromal layer could be observed between cultures derived 
from treated or control mice, both the total production of non-adherent cells and 
CFU-G/M were severely reduced in LTBMC of treated mice (Fig.VI.2A and VI.3A). 
Two approaches were followed to investigate whether this reduction was due to 
either a quantitative or qualitative defect of the hemopoietic and/or stromal cells 
(see Materials and Methods: experimental design). Firstly, we prepared LTBMC of 
halved control femurs and secondly we supplemented part of the cultures with 
adherent cell-depleted normal BMC. Such cell suspensions contain all hemopoietic 
progenitor cell classes but no CFU-F (Fig.VI.l) and were not able to establish 
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Figure VL2 Cumulative non-adherent cell production in LTBMC established one 
week after CDDP administration from a whole femur of control (e) and CDDP-
treated (•) mice, and in LTBMC established from half a control femur (A). fVhole 
ma"ow plugs from CDDP-treated mice or halved ma"ow plugs from control mice 
were either not (A) or immediately supplemented with 5 x ]()6 (B) or 2 x 107 (C) 
nylon wool-filtered BMC. Data are expressed as the mean of three replicate 
experiments. Non-adherent cells derived from control LTBMC are expressed in 
absolute numbers and experimental groups are expressed as a fraction of these 
control cultures. In each experiment groups contained six cultures derived from 
six individual mice. 
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Figure VL3 The cumulative CFU-G/M production in LTBMC established one week 
after CDDP administration from a whole femur of control (e) and CDDP-treated 
(•) mice and in LTBMC established from half a control femur (J,..). Whole marrow 
plugs from CDDP-treated mice or halved marrow plugs from control mice were 
either not (A) or immediately supplemented with 5 x ]()6 (B) or 2 x 107 (C) nylon 
wool-filtered BMC. Data are presented as indicated in Figure 2. 
adherent layers which could maintain hemopoiesis (data not shown). 
LTBMC established from half a normal femur plug showed a similar reduction 
in the cumulative production of non-adherent cells and CFU-G/M as cultures 
established from whole femurs of treated mice (Fig.VI.2A and VI.3A). Both in 
cultures established from half a normal femur and a whole CDDP-treated femur, 
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Figure V/.4 The cumulative non-adherent cell (A) and the cumulative CFU-G/M (B) 
production in LTBMC established from a control femur either not (e) or immedia-
tely supplemented with 2 x 107 ( 0) nylon wool-filtered BMC. Data are presented 
as indicated in Figure 2. 
the reduced cell production could not be restored by adding 5 x 106 nylon wool 
filtered cells (Fig.VI.2B and VI.3B). Addition of four times as many nylon wool 
filtered cells increased the total non-adherent cell numbers, but control values 
were not achieved (Fig.VI.2C). A comparable effect was seen for the CFU-G/M 
numbers in matrow cultures derived from the content of half a normal femur (Fig. 
VI.3C). In difference with this, CFU-G/M numbers in LTBMC of CDDP-treated mice 
were even increased to 120% of control values (Fig.VI.3C). These observations 
demonstrated that in LTBMC of treated mice, the ratio between produced CFU-G/M 
and non-adherent cell numbers was altered. This· alteration was not due to the 
CDDP treatment because it was also seen in cultures of a whole control femur 
which were inoculated with 2 x 107 nylon wool filtered cells (Fig.VI.4). Three 
months after cessation of treatment the production of CFU-G/M in marrow cultures 
of CDDP-treated mice was normal compared with control cultures but the cellularity 
was reduced (Table VI.2). 
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Table VI.2 Production of non-adherent cells and CFU-GM in LTBMC of CDDP-
treated and control mice twelve weeks after cessation of treatment. 
Controls CD DP-treated 
wk cells/ CFU-GM/ CFU-GM/ cells/ CFU-GM/ CFU-GM/ 
of flask flask 5.104 flask flask 5.104 
cult. x105 x102 cells xlOS x102 cells 
1 16.2±15" 18.9±1.6 62±9 15.4±0.88. 10.3±1.3 33±3 
2 13.4±1.1 33.3±4.4 122±9 10.4±1.8 19.5±6.9 97±4 
3 110.8±15.1 113.2±21.4 57±10 96.8±10.9 84.2±19.7 46±13 
4 94.2±5.8 60.4±11.5 32±6 81.6±5.1 68.7±28.5 44±19 
5 119.2 ± 13.4b 66.4±14.8 27±3 87.6±13.2 61.1±12.0 35±7 
6 102.5 ± 14.5b 52.7±15.3 25±4 62.9±3.8 71.5±14.2 56±8 
7 122.0c 58.0 24 64.1±4.8 66.3±19.3 52±16 
a. arithmetic mean ± 1 SE of 5 flasks. 
b. arithmetic mean ± 1 SE of 3 flasks. 
c. one flask 
DISCUSSION 
One week after cessation of CDDP-treatment all femoral stromal and hemo-
poietic progenitor cell types were reduced significantly (Table VI.l). CDDP had a 
greater toxicity for CFU-F and CFU-s than for CFU-G/M. These short-term effects 
of CDDP are in accordance with other reports (Dumenil et al., 1982; Jenkins et 
al., 1981; Nowrousian and Schmidt, 1982; Wierda and Pazdernik, 1979a). Twelve 
weeks after cessation of treatment we observed a normalization of CFU-F and 
CFU-G/M numbers. At this time day 7 CFU-s numbers were at subnormal values al-
though not sigurncantly different from control numbers. A small and long-lasting 
reduction of early hemopoietic progenitors was also demonstrated by Dumenil et al 
(1982). Furthermore, a defective response to anemic or other hemopoietic stress 
situations after CDDP injections has been reported (Braunschweiger et al., 1982; 
Kovacs et al., 1986). 
Little is known about the effects of CDDP administration on the HM. In this 
study we demonstrated a considerable reduction of CFU-F one week after cessa-
tion of treatment (Table VI.1), which indicates that the proliferative capacity of at 
least one stromal cell class was reduced. Since it has been shown that a reduced 
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proliferative capacity of the stroma not necessarily is accompanied by a defective 
stromal ability to support in vitro hemopoiesis (Laver et al., 1986; Naparstek et 
al., 1986), LTBMC were prepared to investigate a CDDP-induced stromal dysfunction. 
Other studies already indicated that LTBMC were useful to demonstrate stromal 
damage in irradiated mice and in mice treated with busulfan or BCNU (Anderson 
et al., 1982; Cohen et al., 1980; Hays et al., 1982; Tavassoli, 1982). Reinoculation 
of non-hemopoietic layers with a complement of untreated non-adherent BMC would 
represent the most direct assessment of stromal integrity. Unfortunately, we did 
not succeed in the establishment of pure stromal layers. Since irradiation of LTBMC 
to remove hemopoietic activity as described by others (Quesenberry et al., 1984a) 
cannot be recommended because this may interfere with CDDP-toxicity, we decided 
to mask the toxic effects of CDDP on hemopoietic progenitor cells by addition of 
an excess of nylon wool-filtered cells. Such cell suspensions are depleted of 
adherent cells and contained normal number of progenitor cells (Fig.V1.1), which 
are assumed to compete with presumptively CDDP-damaged progenitor cells and 
thus compensate for CDDP toxicity on hemopoietic cells. 
We observed no difference in the production of nonadherent cells and CFU-
G/M in LTBMC of CDDP-treated mice and those achieved from half a femur (Fig. VI. 
2A and VI.3A). This was unexpected because in CDDP-treated marrow early hemo-
poietic progenitor cells were reduced to 18% of control numbers, which is three 
times less than in marrow derived from half a femur. These results can be ex-
plained if we assume that a pre-CFU-s exists for which CDDP is less toxic than 
for day 7 and day 12 CFU-s. The existence of such a cell type has been proposed 
by Chertkov et al. (1986) who demonstrated that hemopoiesis still occurred in 
LTBMC from CFU-s-depleted BMC obtained from hydroxyurea-treated mice. In 
addition, it has been demonstrated that BMC, highly enriched for day 10 CFU-s 
were not able to maintain hemopoiesis in LTBMC (Spooncer et al., 1985). The 
assumption of a low incidence of such pre-CFU-s in normal bone marrow would 
explain why a supplement of 5 x 106 nylon wool-filtered cells did not improve 
CFU-G/M and cell numbers in LTBMC (Fig.VI.2B and VI.3B). Interestingly, with 
larger cell numbers inoculated, non-adherent cell production was rather constant 
regardless of the initial cell number (Fig.VI.2C and VI.4A). Crouse et al. (1984) pro-
posed that this phenomenon, called "flask homeostasis" is caused by regulation of 
the number of differentiated progeny produced. In contrast, CFU -G/M production 
showed good correlation with initial cell numbers (Fig.VI.3 and VI.4B). These 
fmdings implicate that both the extent of differentiation, expressed as the number 
of non-adherent cells produced per CFU-G/M, and, with higher cell numbers 
produced, flask cellularity do not reflect the capacity of the stroma to support 
hemopoiesis. 
We conclude therefore that CDDP does not affect the capacity of the hemo-
poietic stroma to establish a functional in vitro microenvironment. The observed 
reduction in the cumulative production of non-adherent cells and CFU-G/M in 
LTBMC of CDDP-treated mice probably is due to the reduced number of hemopoie-
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tic progenitor cells at initiation of culture since it could be ameliorated by addition 
of a sufficient number of non-adherent normal BMC. These results demonstrate 
that one should be careful to interpret data obtained from LTBMC when including 
femoral marrow from mice following an ablative protocol. Furthermore, we have 
demonstrated that a reduction of femoral CFU-F numbers does not correlate with 
the capacity of the hemopoietic stroma to establish an in vitro functional micro-
environment. This observation indicates that quantification of CFU-F numbers can 
not be used as a reliable parameter to estimate the functional capacity of the 
hemopoietic stroma. This conclusion is in agreement with a previous report from 
our laboratory (appendix paper 2) demonstrating that regeneration of spleen and 
femur implants of busulfan-treated mice did not correlate with the initial CFU-F 
content of these implants. 
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SUMMARY 
The effect of CDDP upon the murine immune system was investigated. CDDP 
injections dramatically decreased the number ofT cells and the functional activity 
of the cellular immune system as measured in a delayed type hypersensitivity 
(DTH) assay immediately after cessation. These parameters returned to normal 
within 3 to 6 weeks after cessation of treatment. The serum Ig levels, RBC and 
WBC counts, and hematocrit did not show major changes during the observation 
period. 
INTRODUCTION 
CDDP has been shown to be an effective antineoplastic agent for solid tumors 
in experimental animals (Rosenberg and Van Camp, 1970) and man (Prestayko et al., 
1979). CDDP represents a new class of cytostatic drugs: it reacts with DNA to 
form both DNA interstrand and DNA intrastrand cross links as well as DNA protein 
cross links, thus preventing DNA synthesis and cell division (Roberts and Thompson, 
1979). In short-term experiments, a single CDDP injection has been shown to 
exert immunosuppressive effects (Berenbaum, 1971; Khan and Hill, 1972) and to 
inhibit T lymphocyte function to a greater extent than B lymphocyte function 
(Wierda and Pazdernik, 1979b ). Recently, CDDP has been reported to induce 
myelosuppression and anemia when given repeatedly (Corder et al., 1977). The aim 
of the present study was to investigate the immunosuppressive effects of repeated 
CDDP injections. Therefore, we determined the effects upon the functional activity 
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of the cellular and humoral immune system as well as the numbers of T lympho-
cytes in lymphoid organs. 
MATERIALS AND METHODS 
Animals. (C57BL!Rij x CBA/Rij)F1 (H-2b1q) female mice, 4 weeks old and weighing 
14 to 16 g, similar F1 female mice, 8 to 20 weeks old, and DBN2 (H-2d) female 
mice, 8 to 25 weeks old, were purchased from the Radiobiological Institute TNO, 
Rijswijk, The Netherlands. AKR (H-2k) female mice, 10 to 20 weeks old, were 
purchased from Bomholtgard, Ry, Denmark. 
Drug treatment. Cis-diamminedichloroplatinum (ll) (Bristol Meyers Company, East 
Syracuse, N.Y., USA) was dissolved in PBS at a concentration of. 0.3 mg/ml and 
injected i.p. at a dose of 10 mglkg. The LD50 of this drug for mice is 14 mglkg 
BW (Penta et al., 1979). The·· four week old F1 mice were injected once a week 
for three consecutive weeks. Control mice were injected with the same volume of 
PBS. There was less than 2% mortality during the observation period. 
Cell suspensions. Cell suspensions were prepared as described in detail elsewhere 
(Wolters and Benner, 1978). For flow cytometric analyses the cell suspensions 
were washed and resuspended in PBS with 1% bovine serum albumin (BSA), pH 
7.8. Nucleated cells and red blood cells were counted with a Coulter counter model 
B. 
Irradiation. AKR female mice received 7.5 Gy whole body irradiation. Irradiation 
was performed in a Philips MUller MG 300 X-ray machine as described previously 
(Wolters and Benner, 1978). All radiation control mice died between 14 and 21 
days after irradiation. 
Assay for delayed type hypersensitivity. CDDP-treated and control F1 mice received 
a subcutaneous immunization in the inguinal area with 1 x 107 DBN2 spleen cells. 
Six days later they were challenged in the dorsum of the right hind foot with 2 x 
107 DBN2 spleen cells. The DTH response to this challenge was measured as the 
difference in thickness of the hind feet 24 hours later. The specific increase in 
foot thickness was calculated as the relative increase in foot thickness of the 
CDDP-treated or control F1 mice minus the relative increase in foot thickness of 
control mice that only received the challenge. The foot swelling of 'the challenged 
control mice ranged from 15-25%. 
Graft-versus-Host assay. The anti-host DTH reactivity during acute Graft-versus-
Host (GvH) reactions was determined as described in detail elsewhere (Wolters and 
Benner, 1978). 
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Antisera. Antibodies directed to the Thy-1 cell surface antigen of mouse lymphoid 
cells was obtained from the tissue culture supernatant of an appropriate hybridoma. 
The origin of these anti-Thy-1 monoclonal antibodies and their use in immunofluo-
rescence has been described elsewhere (Ledbetter and Herzenberg, 1979). As a 
second step antiserum, a fluoresceinated rabbit-anti-rat immunoglobulin (RaRa-FITC) 
was used (Nordic Immunological Laboratories, Tilburg, The Netherlands; lot no. 
10-375). This serum was diluted 1:20 v/v in 1% BSA in PBS, pH 7.8. 
Flow cytometric analysis. Incubation of 100 j.Ll cell suspensions containing 1 x 107 
nucleated cells/ml with monoclonal antibodies was performed at 4<>C for 30 min in 
the presence of 1 mM of sodium azide to prevent capping of cell surface antigens. 
These cells were then centrifuged and washed twice in 1% BSA in PBS, pH 7.8. As 
a second step antiserum 50 j.Ll RaRa-FITC was applied. Incubation with this anti-
serum was done for 30 min at 4<>C in the presence of 1 mM of sodium azide. Finally 
the cells were centrifuged and washed twice in 1% BSA in PBS, pH 7.8 and their 
fluorescence analyzed with a fluorescence-activated cell sorter (F ACS II, Becton 
and Dickinson FACS systems, Sunnyvale, C.A., USA). For each sample 5 x 103 cells 
were analyzed. 
Serum Ig levels determination with an enzyme-linked immunosorbent assay (EUSA). 
A micro ELISA method was adopted to measure quantitatively mouse serum Ig levels 
of various classes. Details of this method have been described previously (Van 
Soest et al., 1984). Briefly, diluted serum samples were coated onto the bottom of 
Terasaki plates. After washing with Dulbecco 's PBS (DPBS) the plates were in-
cubated for 1 h at 37<>C with DPBS-gelatin to coat non-specific binding sites. 
Subsequently the plates were repeatedly washed with DPBS-Tween-gelatin and 
incubated for 1 h at room temperature with rabbit-anti-mouse immunoglobulin 
(RAM-Ig) or isotype-specific antisera of rabbit origin (RAM-IgM, RAM-IgG, RAM-
IgA and RAM-IgE) which were affinity-purified and found to be specific for the 
respective mouse Ig ' s by immunoelectrophoresis. Application of conjugate and 
substrate and measurement of the fluorescence were described previously (Van 
Soest et al., 1984). To quantitate the Ig levels, a reference standard of a large pool 
of normal mouse serum obtained from approximately one-year-old CBA/Rij mice 
was used on each plate (Mink and Benner, 1979). 
RESULTS 
After repeated CDDP injections the BW of the mice decreased with a nadir 
at one week after the last injection (Fig.VII.l). At 6 weeks the BW still lagged 
behind that of age-matched control mice. RBC number and Ht showed a slight 
increase during 1 week after treatment. From week 3 onwards the RBC and Ht 
decreased slowly. WBC counts oscillated around control values during the entire 
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observation period. 
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Figure VILJ Effect of CDDP treatment on various parameters. e, body weight 
(control ± 1 SEM, 17.0 ± 0.5g);•, hematocrit (control 49.5 ± 0.5);0, RBC number 
(control 8.3 ± 0.2 x 109 /ml),·O, WBC number (control 7.0 ± 1.0 x 1()6/ml);., spleen 
cellularity (control 2.0 ± 0.1 x lOS);i:::., thymus cellularity (wk 0, control 2.6 ± 0.2 
x lOS; wk 6, control 1.5 ± 0.3 x lOS). Each experimental point represent the 
arithmetic mean of 6-18 mice. Vertical bars indicate 1 SEM. 
Table VII.l Numbers ofThy-1 + cells in spleen and thymus of CDDP treated mice. 
Interval after last Spleen Thymus 
CDDP injection control CDDP control CDDP 
1 day 14.13 ± 1.26a 6.24±1.03 17.95±4.90 0.27±0.08 
1 week 10.21±0.84 4.83±1.02 15.36±0.35 0.25±0.10 
3 weeks 8.84±0.45 4.09±0.35 13.66±1.62 8.11±5.70 
6 weeks 12.47±0.54 11.95±2.05 11.83±0.49 19.80±3.18 
a Figures represent the arithmetic mean ± 1 SEM (x 107 ) of the number of Thy-
1 + cells per organ (n=3-5). 
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Spleen and thymus cellularity were considerably decreased 1 week after the 
last CDDP injection. The splenic cellularity returned slowly to control values 
whereas the thymus cellularity exceeded that of age-matched control values. This 
decreased cellularity was at least partly due to a decrease of the number of T 
cells. At 6 weeks the number of T cells in the spleen had returned to control 
values. In the thymus, on the other hand, the number of T cells exceeded that of 
age-matched controls (Table Vll.l). The influence of CDDP on cell mediated 
immunity was studied by means of a DTH assay. Thus, CDDP-treated Fl mice and 
age-matched control Fl mice were subcutaneously immunized with DBN2 spleen 
cells 3 and 6 weeks after cessation of treatment. CDDP-treated mice showed a 
severely impaired DTH response to the DBN2 alloantigens 3 weeks after the last 
injection, while the DTH reactivity was normal again at 6 weeks after cessation 
(Fig.Vll.2). One week after the last CDDP injection, spleen cells from Fl (donor) 
mice displayed decreased anti-host DTH reactivity under GvH conditions. This 
ability had returned to normal values 3 weeks after cessation of treatment (Fig. VII 
.2). 
% specific increase foot thickness 
120 in % of age-matched control 
100 - - -- - - - - - -
.80 
60 
qo 
20 
weeks after the last DDP injection 
Figure VIL2 Anti-host DTH reactivity ( 0) in lethally i"adiated AKR (H-2k) mice 
inoculated with 2 x 107 spleen cells from CDDP-treated or control (C57BL x CBA)F1 
(H-2b1q) mice. DTH responses were measured 24 h after challenge. Each ex-
perimental point represents the arithmetic mean of 6 to 8 mice expressed in % of 
control. Vertical bars indicate 1 SEM. Primary DTH responsiveness (e) of CDDP-
treated and control (C57BL x CBA)F1 (H-2b1q) mice sc immunized with 107 spleen 
cells from DBA/2 (H-2a) mice. DTH responses were measured 24 h after challenge. 
Each experimental point represents the arithmetic mean of 6 to 8 mice expressed 
in % of control. Vertical bars indicate 1 SEM. 
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The CDDP treatment did not affect the ongoing Ig synthesis as far as could 
be deduced from the serum Ig levels (Table VII.2). 
Table Vll2 Immunoglobulin concentrations in mouse serum at various intervals 
after the last of 3 weekly CDDP injections. 
Interval after the last CDDP injection 
1 day 1 week 3 weeks 6 weeks 
Control 32.6±1.6a 43.0±5.9 34.3±1.8 33.6±1.3 
IgM 
CDDP 31.2±2.7 41.7±6.5 25.3±3.2 34.8±0.7 
Control 558.9±40.4 595.6±77.2 622.0±54.5 657.0±108.1 
IgG 
CDDP 546.1±18.6 606.9±69.8 607.6 ± 127.6 629.5±38.3 
Control 141.4±4.8 139.8±13.6 136.6±5.9 129.7±16.9 
IgA 
CDDP 147.0±4.2 114.6±14.3 114.3±14.9 117.0±16.3 
Control 357±7 344±13 363±8 315±10 
IgE 
CDDP 330±6 323±18 372±17 326±10 
Control 699.9±29.9 678.5 ± 120.5 610.0 ± 43.5 748.8±22.8 
total Ig 
CDDP 789.6±29.7 773.9±83.4 740.6±98.2 737.9±44.5 
a Figures represent the arithmetic mean ± 1 SEM in mg per 100 m1 serum. The 
IgE levels, however, are expressed in J.Lg per 100 m1 (n=3-5). 
DISCUSSION 
This paper shows that a 3 week long treatment of mice with CDDP has 
profound effects on the immune system while leaving the hematologic peripheral 
blood parameters (RBC and WBC counts, and Ht values) almost unchanged. This 
extends a previous report from Nowrousian and Schmidt (1982) who described 
minor changes in hematological peripheral blood parameters after a single dose of 
12 mglkg BW. 
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The effects of CDDP on the immune system seem to be restricted to the T cell 
compartment: we did not find significant changes in the serum Ig levels. However, 
determination of serum Ig levels is an insensitive parameter for the functional 
activity of the humoral immune system (Sabbele et al., 1983). 
Table VII.l shows a markedly decreased T cell content in the spleen one week 
after cessation of CDDP treatment. As Graft-versus-Host reactions were induced 
by transplantation of 107 nucleated spleen cells, the subsequent DTH response can 
be related to the T cell content of the inoculum. Such calculations suggest a 
severely disturbed function of the remaining T cells. The latter might be due to 
the decreased proliferative capacity caused by the cross linking of DNA by CDDP. 
Such a decreased proliferative response of T cells has previously been shown in 
mice 3 days after a single CDDP injection (Wierda and Pazdernik, 1979b). Thus, it 
seems that proliferation-dependent immune reactions, as occur in DTH and following 
concanavalin A stimulation (Bloom et al., 1964; Wierda and Pazdernik, 1979b; Wolters 
and Benner, 1979), are severely but not irreversibly impaired by CDDP. 
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CHAYfER VIII 
GENERAL DISCUSSION 
The general discussion is divided in paragraphs according to the main objec-
tives mentioned in the introduction to the experimental work i.e.: L a study to 
compare the different assays to detect stromal integrity with respect to extent 
and kinetics of stromal damage and recovery after radiation or chemotherapy 
(chapters III-VI), 2. a study of the late effects of chemotherapy (especially cis-
platinum) and radiation upon the hemopoietic stroma (chapters III-VI), 3. a study 
to compare the effects of cytotoxic treatment of young or old mice upon the HM 
(chapters III-V), and 4. a study of the effects of cis-platinum upon the lympho-
poietic system (chapter VII). 
1. A comparison of the different assays to detect stromal integrity with respect 
to extent and kinetics of stromal damage and recovery after radiation or 
chemotherapy treatment. 
The parameters or assays used to determine quantitative and/or qualitative 
defects of the hemopoietic stroma are mentioned in the introduction to the ex-
perimental work and have been introduced in chapter 1.3. As discussed in chapter 
1.3 some of these assays determine the proliferative capacity of stromal cells and 
some determine the hemopoietic supportive function of stromal cells, or a combina-
tion of these two. A comparison of these assays may therefore give a better 
understanding of which cell . (fibroblast or other stromal cell) and cell function 
(proliferation or the support for hemopoiesis) is most susceptible to chemotherapy 
or radiation. In the chapters III-VI most of the above described assays have been 
applied and their significance for the measurement of stromal damage has been 
evaluated. We have shown that the different assays used to estimate stromal 
integrity do not correlate with respect to extent and kinetics of the cytotoxic 
treatment-induced stromal damage as will be discussed below. Apparently they 
detect different stromal functions or regenerating kinetics of different stromal 
cell populations. This strengthens the notion that the use of a single stromal 
assay can lead to erroneous interpretations of the stromal function after cytotoxic 
treatment. 
CFU-F 
Quantification of the in vitro clonable fibroblastoid colony-forming unit, or 
CFU-F is the only assay solely dependent on the proliferative capacity of a single 
stromal cell type i.e. the fibroblast. The fibroblasts are an important component 
of the in vivo and in vitro HM and there exists ample evidence for a regulatory 
role for fibroblastoid cells in in vitro culture systems, but their role in regulating 
hemopoiesis in the in situ marrow HM is not (yet) proved (chapter 1.2.2.3.2). As 
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has been shown in animal experiments, CFU-F quantification may predict the 
reserve capacity of the stroma to regenerate and to replace damaged stromal cells 
after chemotherapy or irradiation-induced damage (chapter !.3.3). This assay and 
the ectopic implantation technique discussed below are therefore sensitive methods 
to detect latent residual damage (Friedenstein et al., 1976; Hotta et al., 1983; 
Tavassoli et al., 1973a). The CFU-F assay, however, does not provide a functional 
assay of the (supposed) regulatory role of the fibroblasts (chapter !.2.2.3.2 and 
!.3.3). The effects of both radiation and chemotherapy upon the CFU-F can be 
separated into acute and late effects. The acute effects after cytotoxic injury are 
in general determined by dose-response relations i.e. an increasing severity of 
response with increasing dose. The late effects are determined by the recovery 
kinetics of the surviving cell population e.g. the CFU-F. 
The radiosensitivity of CFU-F (Do range from 1.59 to 1.65 Gy, chapter III) is 
comparable to or even less than that of the hemopoietic progenitors CFU -s (Do 
range from 0.8 to 1.2 Gy) and CFU-c (Do range from 1.6 to 2.4 Gy) (Friedenstein 
et al., 1976; Testa et al., 1985; Xu et al., 1983; Werts et al., 1980). Furthermore, 
the toxicity of alkylating chemotherapeutic agents (CTX derivatives and cis-pla-
tinum) to the fibroblastoid precursor cell is comparable with the toxicity to 
hemopoietic progenitors (De Jong et al., 1985; and unpublished observations). 
However, recovery of the CFU-F population in time, is in general much slower than 
the recovery of hemopoietic progenitor cells after cytotoxic injury. This indicates 
that the capacity of the stroma to support a (near) normal hemopoietic progenitor 
content per femur and (near) normal peripheral blood cell numbers, can occur 
within a stroma in which one stromal cell class has lost its proliferative capacity 
(chapters III-V). The observation of a decreased proliferative capacity and a normal 
supportive function for bone marrow stroma in vivo and in vitro has also been 
observed by several other authors (Laver et al., 1986; Naparstek et al., 1985; 
Piersma et al., 1983a; Ploemacher et al., 1983; Song and Quesenberry, 1984) and a 
comparable effect has been found for thymus stromal cells (Hirokawa and Sado, 
1984). This observation can be explained by the assumption that: 1. the irradiated 
stroma still contains viable fibroblastic cells which have retained an adequate 
hemopoietic supportive function but have lost their in vitro colony-forming capacity 
as a result of irradiation-induced damage and 2. there has been no need for 
replacement of these fibroblastic cells (see Fig.Vlii.lB)(Piersma et al., 1985b). How-
ever, after a second insult to the stromal compartment which induces stromal 
proliferation (LPS injection), recovery of femoral CFU-F numbers has been observed 
(chapter III; Piersma et al., 1985b ). This recovery after irradiation-induced damage 
has been explained by the assumption that the acute second insult induced by the 
LPS injection, subsequently stimulates the proliferation of radioresistant CFU-F to 
replace the latent damaged cells with viable cells, capable to form in vitro colonies 
(see Fig.VIII.lC and D)(chapter III; Piersma et al., 1985b). 
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in situ stroma in vitro CFU-F colonies 
-> 
Figure VIlLI A proposed mechanism for the in situ recovery of radiation-induced 
damage and the proliferative capacity of CFU-F in adult mice. Schematical presenta-
tion of the in situ hemopoietic stromal compartment and the in vitro growth of 
fibroblastoid precursors (CFU-F). The in situ hemopoietic stroma and the in vitro 
colony fonning ability of CFU-F in nonnal adult mice is schematically presented 
in A. Fig. B-D represent the effect of radiation on the stroma of adult mice. 
Following i"adiation, the stromal compartment shows a good support for in vivo 
hemopoiesis but the CFU-F with latent radiation-induced damage (hatched cells), 
die after resumption of mitosis in vitro (B). After LPS-induced damage stromal 
cells are forced to proliferate in vivo and some radioresistant cells and all the 
latent damaged (hatched) cells die (black cells) after resumption of mitosis (C), 
and are replaced by nonnal (white) cells with a nonnal capacity to stimulate 
hemopoiesis in vivo and to fonn colonies in vitro (D). 
Ectopic implantation of femur and spleen 
The quantification of the hemopoietic repopulation of ectopically transplanted 
femurs or spleens with donor-derived hemopoietic progenitors is dependent upon 
the regenerative capacity of host -derived stromal cells and the subsequent ability 
of these cells to maintain and support hemopoiesis. Differences in hemopoietic 
activity in ectopic implants are therefore dependent upon the integrity of donor 
stromal cells (chapter 1.3.2). The limiting cell type(s) that determine(s) the re-
generation of the microenvironment in ectopic implants of femur or spleen is (are) 
unknown. The CFU-F or fibroblastoid colony-forming unit is very likely not a 
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limiting factor because normal CFU-F numbers have been observed in combination 
with a severely defective hemopoietic activity in ectopic implants after irradiation 
(chapter ill) or after injection with BU (chapter IV), or cis-platinum (chapter V). 
We conclude therefore that the development of the hemopoietic stroma in the 
ectopic implants may be more dependent upon another stromal cell, e.g. endothelial 
cells. The capillaries that pierce into the ectopic femur implant are from host 
origin but the newly formed marrow sinuses in the implant are from donor origin 
and are derived from primitive mesenchymal cells or surviving endothelial cells 
(Sahebekhtiari and Tavassoli, 1978). In the developing marrow stroma of the 
implants proliferation of stromal cells, probably including endothelial cells, can be 
detected upto two months after implantation (Sahebekhtiari and Tavassoli, 1978). 
However, it remains to be elucidated whether endothelial or primitive mesenchymal 
cell proliferation is the limiting factor in reoccurrence of optimal hemopoietic 
activity in the implants. In another, comparable system using transplantation of 
marrow plugs under the renal capsule, it has been suggested that the recipient 
can contribute in some way to the stromal environment of the grafted marrow 
(Schofield et al., 1987). A similar observation of a limited host participation in 
reestablishing hemopoiesis in subcutaneous implanted femur shafts has been reported 
by Fried et al. (1973b) using mice with the Sl!Sld genotype as donors and their 
normal littermates aS recipients. However, in both systems the stromal defect has 
not been ameliorated and it is suggested that the contribution of the host is very 
limited. With respect to the interpretation of the ectopic transplantation data in 
the chapters III-V, the contribution of the host will, at most, result in an under-
estimation of the cytotoxic treatment-induced stromal damage. 
The slow recovery of hemopoietic activity in the ectopic implants after 
chemotherapy-induced damage may be explained by a similar mechanism as is 
proposed for the CFU-F recovery after irradiation and LPS injection. The stromal 
cells (apart from CPU-F) not capable to proliferate in vivo and in the ectopic 
implants, due to cytotoxic agent-induced damage, are replaced by cells with a 
normal proliferative capacity during the slow turnover of the stromal compartment 
(see Fig.VIII.1 B-D) (Caffrey et al., 1966; Haas et al., 1968; Kaneko et al., 1982; 
Meyer-Hamme et al., 1971). We suggest that the slow turnover of stromal cells in 
vivo after chemotherapy is comparable with the LPS-induced proliferation of 
fibroblastic cells after irradiation. The slow hemopoietic recovery in ectopic implants 
is not observed after irradiation-induced damage. Apparently radiation induces 
another stromal damage or the in vivo recovery of chemotherapy-induced stromal 
damage follows another pattern as compared with the recovery after radiation, 
which must be forced by a second insult. The latter suggestion may be verified by 
ectopic implantation of femurs from irradiated and LPS-injected mice. Enforced 
regeneration of the stromal cells, responsible for the formation of an adequate 
implant stroma, has occurred if the hemopoietic activity returns to normal (see 
Fig.VIII.l B-D). 
The results of the subcutaneous implantation of spleens are in general com-
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parable with the results from the femur although differences in extent and kinetics 
of the stromal damage can be observed (chapters Ill-V). This may be due to dif-
ferences in regeneration patterns after subcutaneous implantation (chapter 1.3.2), 
or differences in the stromal composition between spleen and femur. Alternatively, 
these differences may be due to the different function of the spleen as compared 
to bone marrow. The mouse spleen is an organ that shows an enormous increase 
in hemopoietic activity after stress-induced hemopoiesis (e.g. severe blood loss or 
infection) because the bone marrow of the mouse is completely filled with hemo-
poietic activity and can not expand. In general, the data concerning splenic 
transplantation are not as consistent as the femoral subcutaneous implantation 
data (chapters Ill-V). This may be due to the less optimal regenerative capacity 
of the spleen as compared with femur implants and the associated problems to 
detect low stem cell numbers. Even after stimulation of the splenic regeneration 
by irradiation of the hosts prior to implantation, splenic implants contain only 
approximately 3% of the hemopoietic progenitor content of a normal spleen, while 
femoral implants contain upto 25% of the in situ organ content of hemopoietic 
progenitors (Chamberlin et al., 1974). Pretransplantation radiation of a male host 
has no effect on the total amount of hemopoietic progenitors per femur implant. 
However, the less optimal regeneration of femur implants in female hosts can be 
stimulated by irradiation of the hosts (Schofield, 1986a). These observations have 
no effect on the interpretation of the data described in chapters Ill-V as only 
hosts of the same sex have been used. 
LPS-induced increased splenic hemopoiesis 
The extent to which hemopoietic stem cells accumulate in the spleen in 
response to bacterial LPS-induced hemopoietic stress . is a measurement of the 
ability of the splenic stroma to respond to hemopoietic stress, and the proliferative 
capacity of the hemopoietic stem cells (chapter 1.3.5). The injection of LPS results 
in a very complex reaction of many different cell types. However, the assessment 
of the hemopoietic activity in the spleen can be used to estimate splenic stromal 
integrity under the condition that the stem cells have a normal proliferative 
capacity as has been demonstrated by using irradiated and unirradiated parabiosed 
mice (Ploemacher et al., 1983). The injection of LPS induces a severe damage of 
the marrow microenvironment as determined by the decrease in CFU-F and the 
decreased ability to support normal hemopoiesis (chapter III). In addition, another 
component of the stroma may be damaged after LPS injection, i.e. the endothelial 
cells (Reidy and Schwartz, 1983). The splenic hemopoietic activity increases as a 
compensatory mechanism during the bone marrow recovery- phase and is the result 
of local proliferation (McCulloch et al., 1970) and (some) migration of bone marrow 
CFU-s to the spleen (Ploemacher and Brons, 1987). Apparently LPS is less toxic 
to the splenic stroma, the CFU-F numbers are even increased after LPS injection, 
probably due to migration (Brockbank et al., 1983a). A decreased CFU-s accumula-
tion in the spleen may be the result from (a) a decreased support capacity of the 
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splenic stroma to stimulate local CFU-s proliferation and/or (b) a decreased capacity 
of the splenic stroma to lodge bone marrow-derived CFU-s an/or (c) a decreased 
bone marrow CFU-s content that limits the migration of CFU-s to the spleen. In 
the experiments described in the chapters III-V, mice treated with chemotherapy 
or irradiation have not been supplemented with normal BMC after the cytotoxic 
treatment. This may result in an overestimation of the stromal damage detected 
using this assay. 
Growth kinetics of normal bone marrow cells in animals with a normal or (sup-
posedly) defective microenvironment 
This assay determines the growth of injected normal BMC in lethally irradiated 
mice previously treated with chemotherapeutic agents and compares it with the 
growth of normal BMC in lethally irradiated mice that have not received chemo-
therapy (see Fig.VIII.2). This assay may have clinical relevance with respect to the 
increased use of (autologous) BMT in patients, previously treated with (high-dose) 
chemotherapy. 
lethal f + BMT 
3 weeks 
----> 
1 year 
4 days 
> 
30 days 
nucleated cells 
CFU-C 
Figure VIIL2 Detennination of the growth kinetics of nonnal bone marrow cells 
after lethal i"adiation and bone ma"ow transplantation in mice previously treated 
with cytotoxic agents. 
The delayed growth of normal hemopoietic stem cells in the Sl!Sld mice 
with a congenital anemia is the result from a marrow stromal defect (McCulloch 
et al., 1965; Sutherland et al., 1970). We assume that the recovery of the injected 
normal hemopoietic cells in mice (treated with chemotherapy at least three weeks 
prior to lethal irradiation and subsequent BMT), is· only dependent on the stromal 
integrity and the capacity of the stroma to stimulate normal BMC (chapters IV 
and V). Cis-platinum treatment induced a severely delayed and diminished growth 
of normal BMC upto approximately 6 weeks after its administration (chapter V). 
The other chemotherapeutic agents tested do not show a significant late defect in 
the stimulation of hemopoietic cells following BMT one year after their administra-
tion. The hypothesis as has been suggested by Blackett (1987), i.e. regulation of 
the growth of injected BMC via a· negative feedback control system from post-
mitotic cells in the bone marrow, is not a very likely explanation for the observed 
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delay in hemopoietic cell recovery after lethal irradiation and BMT in previously 
cis-platinum treated mice after a comparison with the other assays which also 
detect a disturbed stromal integrity (chapter V). This strengthens the notion that 
the use of a single stromal assay can lead to erroneous interpretations of the 
stromal function after cytotoxic treatment. 
The effects of chemotherapy treatment prior to lethal irradiation and sub-
sequent BMT are dependent upon the time between these two cytotoxic treatments. 
Sublethal chemotherapy treatment (with CTX) followed by lethal irradiation and 
subsequent BMT within four days after chemotherapy, stimulates the growth of 
injected normal BMC. This stimulatory effect is no longer detectable seven days 
after the CTX injection (Gregory et al., 1971). The acute stimulatory effect has 
been thought to result from the cytotoxic effect of CTX upon the hemopoietic 
stem cells and not as an effect upon the hemopoietic stroma. It is assumed that 
the "niches" for the hemopoietic stem cells are liberated by CTX treatment imme-
diately before lethal irradiation and subsequent BMT, and the injected stem cells 
have more "niches" available, resulting in an increased proliferation. Alternatively, 
the stimulatory effect may be due to a negative feedback control system from 
post-mitotic cells in the bone marrow (Blackett, 1987). However, mice that have 
been treated with CTX six weeks prior to irradiation, demonstrate a delayed 
endogenous hemopoietic recovery and it has been suggested to result from CTX-
induced stromal damage (Fried and Barone, 1980). We suggest that the effects of 
chemotherapy treatment within a few days prior to irradiation are the result' of 
hemopoietic progenitor cell damage while the late effects are more likely the result 
of stromal damage. 
Long-term bone marrow cultures 
Long-term bone marrow cultures (LTBMC) represent an in vitro culture system 
in which a very complex adherent layer composed of different cell types supports 
hemopoiesis (chapter !.3.4). The analysis of the role of each component in this 
system is difficult. This complex in vitro culture system for hemopoietic organs 
can be used in several different experimental set ups to estimate stromal integrity 
after cytotoxic injury i.e. "one-phase" and "two-phase" cultures. The establishment 
of a LTBMC, derived from mice previously treated with cytotoxic agents, is (see 
Fig.Vlll.3 A-C) dependent upon the proliferative ability of stromal cells, and the 
support capacity of the stromal layer to maintain hemopoiesis. Production of 
hemopoietic cells is dependent upon the survival of hemopoietic progenitor cells 
during the initial growth phase of the stromal layer in a "one-phase" culture 
system (Fig.VIII.3 A) and in the "two-phase" system, using a supplement of non-
adherent (non-stromal, and therefore hemopoietic) cells added at the initiation of 
the culture (Fig.VIII.3 B). The hemopoietic activity in the other "two-phase" system 
(see Fig.VIII.3 C) is not dependent upon the survival of hemopoietic cells during the 
initial growth phase of the stroma because the second inoculum of hemopoietic 
cells is added after establishment of the stromal layer. The established, stromal 
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Figure VIII.3 The long-tenn bone marrow culture system. See text for explanation. 
layer may be irradiated to eradicate possible surviving hemopoietic cells, before 
addition of the second inoculum of normal hemopoietic cells (Quesenberry et al., 
1984). It is assumed that irradiation of the established, confluent, non-proliferating 
stromal layer does not affect its capacity to support and maintain hemopoiesis. 
However, it has been shown that irradiation of a stromal layer modifies hemopoietic 
growth factor production (Naparstek et al., 1985). It is not known whether irradia-
tion can interfere with the initial cytotoxic agent treatment of the in situ stroma. 
Initiation of adherent layers without hemopoietic activity from cytotoxic agent-
treated marrow cells reinoculated with untreated hemopoietic cells (see Fig. VIII.3 
C, without irradiation of the stromal layer) will represent the most direct in vitro 
assessment of stromal integrity (Anderson et al., 1982; Hays et al. 1982). However, 
we have not succeeded in the production of a stromal layer depleted of hemopoietic 
activity by manipulating the nutrient composition of the media, therefore, we used 
the "two-phase" culture system as depicted in Fig.VIII.3 B, i.e. with supplementation 
of the inoculum with an abundant amount of hemopoietic cells to "overrule" the 
presumptive cis-platinum damaged hemopoietic progenitors (chapter VI). A reduced 
production of non-adherent cells in this system may be due to: (a) a decreased 
amount of stromal cells to form an adequate stromal layer, (b) a delayed growth 
of the stromal cells due to cytotoxic agent induced damage and subsequent extinc-
tion of the (normal or damaged) hemopoietic progenitors because of an insufficient 
amount of stromal "niches" for these cells, and/or (c) a decreased ability of the 
stromal cells to stimulate and maintain hemopoiesis. Using this LTBMC system we 
have not been able to detect a disturbance in stromal integrity after cis-platinum 
treatment although other stromal assays or parameters (i.e. CFU-F quantification 
and ectopic implantation) have detected stromal defects (chapter V). However, 
the proliferative capacity of the CFU-F seemed not to be disturbed much as the 
CFU-F population size has been observed to return to (supra)normal numbers 
within three weeks and to remain at this level upto one year after cessation of 
cis-platinum treatment (chapter V). Fibroblasts are an important component of the 
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stromal layer of LTBMC (chapter L3.4) and it seems that the low amount of 
fibroblast progenitor cells at time of initiation is adequate to form a stromal 
layer. An explanation for the observed differences between the two assays (i.e. 
LTBMC and ectopic implantation) maybe that the stromal compartment ofLTBMC 
and ectopic implants are different of composition (e.g. the LTBMC stroma lacks a 
true vascular compartment although endothelial cells are present), or the limiting 
cell type to establish an adequate stromal compartment may be different for these 
two assays (e.g. endothelial cells for the ectopic implants and fibroblasts for the 
LTBMC). Furthermore, it may be possible that the added non-adherent cells change 
the stromal layer, although the non-adherent cells, derived by nylon wool filtration 
of normal BMC are depleted of CFU-F and incapable to form an adherent layer 
on their own. The capacity of added non-adherent cells to change the stromal 
layer is well known from inocula obtained from LTBMC non-adherent cells, which 
could even form a new stromal layer (Hays et al., 1982; Halka et al., 1987). Further 
research is needed to determine the effects of non-adherent bone marrow cell 
supplementation upon the in vitro development of the stromal layer e.g. by the 
use of non-adherent cells derived from mice with chromosome markers, by using 
cells with morphologically recognizable differences such as the giant granules seen 
in the C57BV6 Beige mutant mice (Murphy et al., 1973), or by using non-adherent 
cells from donors with the opposite sex and subsequent identification of morphology 
and genotype by in situ hybridization (Simmons et al., 1987). 
Quantification of peripheral blood cells and hemopoietic progenitors in spleen and 
bone marrow 
In combination with other assays and in some specific experiments determina-
tion of peripheral blood Gell numbers may give information concerning stromal 
integrity. The observation that transplantation of normal BMC in lethally irradiated 
and previously cis-platinum treated mice can not correct the anemia (low erythro-
cyte numbers in the peripheral blood), while the reverse experiment i.e. reconstitu-
tion of normal (lethally irradiated) animals with cells from cis-platinum treated 
mice produce full recovery, strengthens the idea that cis-platinum treatment has the 
capacity to damage the stromal compartment (chapter V). A similar effect has 
been observed in mice with a congenital stromal defect, the SVSld mice. A BMT 
with normal cells does not cure the anemia in the SVSld mice but SVSld BMC 
produce a full reconstitution in normal lethally irradiated littermates (McCulloch 
et al., 1965). However, in general, quantification of peripheral blood cells and 
hemopoietic progenitors is of no use to estimate fundamental damage to the 
hemopoietic stem cells or stroma (Haworth et al., 1982; Hendry et al., 1983; Ma et 
al., 1987; Ross et al., 1982; Schofield, 1986b; and appendiX paper 1-3). Especially 
after irradiation but also after exposure to certain chemotherapeutic agents the 
damage to the hemopoietic stroma can be masked by compensatory proliferation of 
committed progenitors (Abkowitz et al., 1988; Cronkite et al., 1985; Hendry et al., 
1983) or by an increased cycling rate of the stem cells (Croizat et al., 1979; Hendry 
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and Lajtha, 1972). After irradiation or chemotherapy normal or near normal peri-
pheral blood cell numbers have been found with simultaneously a low hemopoietic 
progenitor content per femur and spleen (chapters III-V). Which of the two above 
mentioned factors or both have been responsible for the (near) normal peripheral 
blood cell numbers has not been explored. 
2,3. Late effects of cytotoxic treatment and a comparison of cytotoxic treatment 
in young versus adult mice. 
The data from the experiments described in the chapters III-V concerning 
late effects of radiation and chemotherapy upon the HM emphasize the necessity 
for a long follow up of patients treated with cytotoxic agents. 
The observation of normalization of the CFU-F numbers per femur in mice 
irradiated during growth (chapter III) is not noted in adult irradiated mice from 
the same strain (Piersma et al., 1983a; Ploemacher et al., 1983). This can be 
explained by the assumption that during growth replacement occurs of fibroblastic 
progenitor cells, not capable to proliferate in vivo and in vitro due to radiation-
induced damage, by cells which have the capacity to form in vitro colonies of at 
least 50 cells (see Fig.VIII.4). Thus, normal growth of the femoral stromal compart-
ment during the first weeks of life has a comparable effect as the LPS-induced 
proliferation of fibroblastic cells after irradiation in adult mice (see Fig.VIII.1 B-D). 
We have not observed any differences in regeneration between young and adult 
mice after chemotherapy treatment (chapters IV and V). 
From human data it is known that children tolerate the acute adverse effects 
of chemotherapy better than adults. The maximally tblerated dose expressed on a 
body weight or surface area basis is nearly always greater in children although 
the dose-limiting toxicity (e.g. myelosuppression) is in general the same (Bleyer et 
al., 1985; Glaubiger et al., 1982). The most susceptible tissues or organs for acute 
adverse effects after chemotherapy are in general those with high cell turnover 
rates. The precise mechanism( s) leading to less severe acute adverse effects of 
chemotherapy in· children as compared with adults is/are poorly understood. It may 
be that children have an excess metabolic or excretory rate for these drugs as 
compared with adults or the children may have different intracellular metabolic 
rates. Another hypothesis for the increased drug tolerance is that children may 
have larger numbers of stem cells per organ and per unit body weight or surface 
area. On the other hand, the growing child may be more vulnerable than the adult 
patient to the delayed or long-term sequelae of cytotoxic treatment due to the 
rapidly proliferating state of the different tissues and organs as compared with 
the mature steady state with slow cell renewal kinetics in adults. In addition, 
chemotherapeutic agents may cause late effects due to damage of cells that do 
not replicate or replicate very slowly (chapter I.4). The partial regeneration and 
recovery of the hemopoietic stroma after the cytotoxic agent-induced damage 
(radiation, cis-platinum, and BU) is similar or better in mice treated during growth 
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Figure VIII.4 A proposed mechanism for the in situ recovery of radiation-induced 
damage and the proliferative capacity of CFU-F in young mice. Schematical pre-
sentation of the in situ hemopoietic stromal compartment and the in vitro growth 
of fibroblastoid precursors (CFU-F). The in situ hemopoietic stroma and the in vitro 
colony forming ability of CFU-F in normal young mice is schematically presented 
in A. Fig. B-D represent the effect of radiation on the stroma of young mice. The 
stromal cells with a normal capacity to stimulate hemopoiesis in vivo are not 
capable to form in vitro colonies and die after resumption of mitosis due to 
radiation-induced damage (hatched cells) (B). During growth the stromal cells 
proliferate in vivo and the latent damaged (hatched) cells die after resumption of 
mitosis and are subsequently replaced by normal (white) stromal cells with normal 
in vitro colony forming capacity and a normal capacity to stimulate hemopoiesis in 
vivo (C and D). One year after irradiation (E) the stromal compartment shows a 
decreased amount of CFU-F and a defective capacity to stimulate in vivo hemo-
poiesis, probably due to the limited proliferative capacity of stromal cells and 
subsequent slow extinction of the stromal cells (black cells)(see text). 
than in adult mice. However, after the initial recovery a second decrease in stromal 
function is observed. The CFU-F numbers are again decreased 1 year after irradia-
tion and the hemopoietic activity in ectopic implants is reduced 1/2 to 1 year 
after BU or cis-platinum treatment. Furthermore, this decreased stromal function 
is accompanied with a decrease in hemopoietic progenitor content in situ after 
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all three cytotoxic agents (chapters Ill-V). This may indicate that the proliferative 
capacity of hemopoietic stromal cells is limited as is observed for skin-derived 
fibroblasts and other cells (Hayflick, 1965; 1984). Irradiation may induce senescence 
of the hemopoietic stromal cells. Since the hemopoietic system is very important 
for survival, there is an enormous proliferative reserve capacity far in excess of a 
normal individual lifespan. Thus aging of the hemopoietic system (hemopoietic 
progenitors and stroma) is difficult to observe (if at all) under normal conditions 
(Harrison et al., 1978; Schofield et al., 1986; Williams et al., 1986). Only after 
repeated stimulation of proliferation or after cytotoxic agent treatment, a decline 
in proliferative capacity has been detected in both hemopoietic stem cells and 
stromal cells (Boggs et al., 1984; Botnick et al., 1982; Horta et al., 1980; Lipschitz 
et al., 1987b; MacMillan and Wolf, 1982; Reincke et al., 1982b; Wolf and Arora, 
1982; van Zant, 1984). The decline in proliferative capacity can be due to lasting 
reproductive cell damage and will leave some daughter cells sterile after one or 
several divisions. Another explanation for the decline in proliferative capacity may 
be a decrease in the total amount of stem cells with an inherently limited mitotic 
ability (Hayflick, 1965; 1984). The experiments of Reincke et al., (1982b) support 
the latter suggestion of residual injury caused by a reduced population size with 
fully preserved high, but limited, proliferative capacity. In analogy this can be 
suggested for marrow stromal cells (e.g. CPU-F) as well. Irradiation of young mice 
results in survival of some CPU-F which repopulate the stromal compartment 
during normal growth of the organ and the CPU-F (and other stromal cells?), not 
able to proliferate due to cytotoxic agent-induced damage, are replaced by CFU-F 
with a normal proliferative capacity. Under normal conditions CFU-F numbers 
show no decline during aging (Brockbank et al., 1983b) but the presumably extensive 
proliferation of the surviving CPU-F to replace damaged cells during growth may 
be responsible for some CPU-F reaching the natural inherently (or cytotoxic agent-
induced) limit of their reproductive lifespan one year after irradiation (see Fig.VIII.4 
E). Subsequently, this may result in a decreased hemopoietically active bone marrow 
volume or a less optimal stimulation of hemopoiesis. 
A similar mechanism as described above may be responsible for the second 
decrease observed in the capacity of ectopic implants to stimulate hemopoiesis 1/2 
to 1 year after BU and cis-platinum treatment. The decrease in regenerative 
capacity of subcutaneous implants, derived from cis-platinum treated mice, after 
initial recovery to normal can not be attributed to a limited proliferative capacity 
of the CPU-F population because the CPU-F numbers are normal (chapter III). 
Another stromal cell with limited proliferative capacity must be responsible for 
this decline e.g. endothelial cells. Endothelial cells are damaged after several 
different cytotoxic agents and subsequently show an extensive proliferative activity 
after e.g. radiation, bleomycin, and CTX (Adamson and Bowden, 1974; 1983; Hopewell 
et al., 1986; Lazo, 1986). Furthermore, endothelial damage is followed by fibroblast 
proliferation and fibrosis in several different organs (e.g. lung and bone marrow) 
and will result in further damage of the (hemopoietic) stroma (Adamson and Bowden, 
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1983; Knospe et al., 1960; 1968). 
The significance of animal data to predict effects of cytotoxic agents in 
human is limited. Although different doses and/or dose regimens are used, in 
general for both radiation and chemotherapy single high-doses in animal studies 
and multiple dose regimens in humans, the maximal tolerated doses are comparable 
on a surface area basis (Freireich et al., 1966) and comparable effects are found. 
In conclusion, both radiation and alkylating chemotherapeutic agents (cis-
platinum and BU) have the capacity to decrease the regenerative ability or proli-
ferative capacity of hemopoietic stromal cells which may result in latent damage 
and may become apparent as a hypoplastic syndrome with little tendency to recover 
to normal. If this decrease is a result of a disturbed remodulation of the stromal 
compartment, a cytotoxic agent-induced limited proliferative capacity of the stromal 
cells and a subsequent insufficient remodelling and replacement of the stromal 
compartment, or a disturbed hemopoietic supportive capacity of individual stromal 
cells remains to be elucidated. These hypotheses may be answered if we know 
exactly which cells and/or cell functions are determined by the different stromal 
assays. Cytotoxic treatment during growth results in similar (chemotherapy) or 
more severe (radiation) late effects as compared with treatment of adult mice. 
The data from the experiments described in chapters Ill-VI concerning late effects 
of radiation and chemotherapy upon the HM emphasize the necessity for a long-
term follow up of patients (children and adults) treated with cytotoxic agents to 
document the adverse late effects and, to identify the etiologic agents and to 
alter treatment to give the least toxic therapy with the best quality and duration 
of survival. Meanwhile, the benefits of current cytotoxic therapy are well worth 
the potential sequelae upon the hemopoietic system. 
4. Study of the effects of cis-platinum upon the lymphopoietic system 
The aim of the study described in chapter VII has been to investigate the 
effects of repeated cis-platinum injections upon the lymphopoietic system. In 
general chemotherapeutic agents exert immunosuppressive effects. However, some 
chemotherapeutic agents, including cis-platinum, can augment immune responses 
(e.g. antibody production and delayed hypersensitivity reactions) at relative short 
intervals after injection of the cytotoxic agent (Mastrangelo et al., 1986). We 
have not observed any immunostimulatory effect or any effect upon the immuno-
globulin production after cis-platinum injections. The observed immunosuppressive 
effects of cis-platinum upon the T cell compartment may be. caused by a severely 
decreased amount of T cells capable to proliferate or by a, not irreversibly, 
decreased proliferative capacity of the T cells. Since the assays used are not 
specific to determine effects of the lymphopoietic stroma it remains to be seen 
whether cis-platinum also effects the lymphopoietic microenvironment. 
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CHAPTER IX 
SUMMARY 
Blood cell production is normally found in the bone marrow and in mice (the 
animal used for the investigations descnbed in this thesis) and other rodents to a 
certain extent also in the spleen. In principle all blood cells can be produced by a 
single cell i.e. the pluripotent hemopoietic stem cell. This stem cell and its progeny 
proliferate and differentiate in bone marrow (and spleen) to produce all hemopoietic 
cells (chapter 1.2.1). The hemopoietic organs are composed of specific stromal 
compartments that support the production of hemopoietic cells. The stromal com-
partment is not static but can be remodelled in response to certain stimuli e.g. 
severe blood loss or infection. The different hemopoietic lineages (erythroid, 
myeloid, and megakaryocytic) are not haphazardly distributed in the bone marrow 
but are found in specific places and in contact with specific cells or cell products 
e.g. macrophages and endothelial cells. The hemopoietic stem cell and the progenitor 
cell proliferation and differentiation, and release of mature functional end cells in 
the blood stream is thought to be under (partial) control of the stromal cells and 
cell products (chapter 1.2.2). 
Bone marrow damage, characterised by stem, progenitor, and/or stromal cell 
abnormalities has been observed after cytotoxic treatment, especially after radiation 
and after treatment with alkylating agents. Damage of the hemopoietic system may 
be latent and only becomes clinically manifest in situations of hemopoietic stress 
or after a second cytotoxic treatment (chapter I.4). The experiments described in 
this thesis have been perfonned to compare different assays, used to determine 
stromal integrity (chapter 1.3), and to elucidate the effects of chemotherapy and 
radiation upon the hemopoietic microenvironment. Furthermore, we compared the 
effects of cytotoxic treatment of young (growing) and adult mice. 
We have clearly demonstrated that the different stromal assays, used in the 
experiments described in chapters III-VI, do not correlate with respect to the 
extent and kinetics of stromal damage caused by treatment with chemotherapy or 
irradiation. Apparently these assays detect different stromal functions or regenera-
tion kinetics of different stromal cell populations. This notion implies that the use 
of a single stromal assay can lead to erroneous interpretations of the stromal 
function after cytotoxic treatment. 
In the chapters III-V we have demonstrated that both radiation and chemo-
therapy (cis-platinum, cyclophosphamide, and busulfan) have the capacity to diminish 
the proliferative capacity of stromal cells or diminish the capacity of the hemo-
poietic stroma to respond to stress-induced hemopoiesis. However, the in situ 
capacity to stimulate and maintain hemopoiesis by these stromal cells is preserved. 
Thus, a normal production of peripheral blood cells may be maintained by a stromal 
compartment with a defective proliferative capacity. The cytotoxic agents used 
(cis-platinum, cyclophosphamide, busulfan, and radiation) are capable to produce a 
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temporarily or sustained defect in the CPU-F colony forming ability and in the 
regenerative capacity of the hemopoietic stroma in ectopic implants. The CPU-F 
assay determines the proliferative capacity of a single stromal cell class i.e. 
fibroblastoid progenitor cells (chapter 1.3.3). The ectopic implantation assay deter-
mines the proliferative capacity of stromal cells and the ability of these cells to 
stimulate and maintain hemopoietic activity. Ectopic implantation of hemopoietic 
organs results in regeneration of the stromal compartment, which remains mainly 
of donor origin while the hemopoietic progenitor cells in these implants are of 
host origin. The hemopoietic activity found in ectopic implants is therefore depen-
dent upon the regenerative capacity of donor hemopoietic stroma (chapter 1.3.2). 
The limiting stromal cell type( s) necessary for regeneration of hemopoietic stroma 
in implanted hemopoietic organs (e.g. endothelial cells and/or mesenchymal cells) 
is/are as yet unknown. The initial severe decrease in stromal integrity after 
cytotoxic treatment is followed by recovery to sub or (supra)non;nal values. The 
recovery of stromal damage is particularly noticeable in mice treated during growth 
and in adult mice which received a second insult to the hemopoietic stroma. In 
addition, radiation, busulfan, and cis-platinum treatment induce a second decrease 
in the CPU-F colony forming ability, in the regenerative capacity of the hemo-
poietic stroma in ectopic implants, or in both. This second decrease in stromal 
integrity (1/2 to 1 year after cytotoxic treatment) is accompanied with a defective 
in situ hemopoietic activity, i.e. a low hemopoietic progenitor content per femur 
and/or spleen. 
The above mentioned effects of cytotoxic agents upon the stromal integrity 
can be explained by one "unifying hypothesis". (1) We assume that depending on 
the cytotoxic dose used, a certain amount of stromal cells die after resumption of 
mitosis due to the cytotoxic agent-induced damage while simultaneously these cells 
may demonstrate a normal hemopoietic supportive function i.e. a normal production 
of peripheral blood cells and a normal amount of hemopoietic progenitors per 
femur and spleen may be found. The cytotoxic agent-induced da.II!.age results in (a) 
low stromal cell colony numbers upon explantation in vitro (CPU-F) and/or (b) a 
reduced hemopoietic activity in ectopic implants due to a defective stromal implant 
regeneration. Whether this decrease is really a result of a disturbed remodulation 
of the stromal compartment or a disturbed hemopoietic supportive capacity of 
individual stromal cells remains to be elucidated. (2) We assume that recovery to 
(sub)normal numbers of the stromal integrity after a second insult or during growth 
is caused by forced in situ stromal proliferation (see Fig.VIII.1 and Fig.VIII.4). 
Cytotoxic agent-induced latent damaged stromal cells (which die after resumption 
of mitosis) are replaced by cells with a normal proliferative capacity that have 
survived the initial cytotoxic treatment and subsequently normal CPU-F numbers 
are found upon explantation in vitro and/or a normal hemopoietic activity in 
ectopic implants is found (see Fig.VIII.1 and Fig.VIII.4). The hemopoietic activity 
in the ectopic implants remains diminished after irradiation of young mice whereas 
CFU-F colony numbers return to normal. The fibroblastoid progenitor (CPU-F) is 
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apparently not the limiting cell type for the restoration of an adequate stromal 
compartment in the implants. The second decrease in stromal integrity (accompanied 
with a diminished capacity of the i~ situ stromal compartment to maintain normal 
hemopoietic progenitor numbers) observed after treatment with cis-platinum, 
busulfan, and radiation may be explained by the assumption that (3) the extensive 
proliferation of the surviving stromal cells necessary to replace the cytotoxic 
agent -damaged cells and the proliferation during normal grQwth and remodelling of 
the stroma is responsible for some stromal cells reaching their natural inherently 
(or cytotoxic-agent induced) limit of their reproductive lifespan. This limit in 
proliferative capacity subsequently results in a defective (slow) turnover and 
remodelling capacity of the stromal compartment and ensues in a disturbed stromal 
compartment with a less optimal maintenance of hemopoiesis (see Fig.VIII.4E). 
Treatment during growth results in similar (chemotherapy induced) or more severe 
(radiation induced) late effects as compared with treatment of adult mice. 
Extrapolation of the data described in the chapters III-VII to the clinical use 
of chemotherapy and radiation is limited. However, it can be concluded that the 
benefits of cytotoxic cancer therapy are well worth the potential late sequelae 
upon the hemopoietic system but a long-term follow up of both children and adult 
patients treated with these agents is necessary to document the adverse late 
effects, to identify the etiologic agents and to alter treatment to give the least 
toxic therapy with the best quality and duration of survival. 
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CHAPTER X 
SAMENV ATTING 
Onder normale omstandigheden wordt bloedcelvorming, of hemopoese, aileen 
aangetroffen in het beenmerg. In de muis (het proefdier dat gebruikt is voor de 
experimenten die in dit proefschrift zijn beschreven) zien we ook in de milt enige 
hemopoese. In principe kunnen aile bloedcellen gevormd worden door een enkele 
eel, de zogenaamde pluripotente hemopoetische stamcel. Deze stamcellen en hun 
nakomelingen (progenitor-cellen) prolifereren en differentieren in het beenmerg 
(en de milt) en produceren aile bloedcellen. De bloedcelvorming in het beenmerg 
vindt plaats in een voor dit orgaan karakteristieke micro-omgeving of stroma. 
Voor een goed functionerende bloedcelvorming is zowel een normale stamcel als een 
normaal stroma van de hemopoetische organen nodig. Het beenmerg stroma bestaat 
uit een dicht netwerk van dunwandige bloedvaten, de sinusoiden, met daartussen 
een matrix opgebouwd uit vezels en amorfe tussenstof. De matrix wordt gevormd 
door de stromale cellen, fibroblasten, macrofagen, vetcellen en endotheelcellen. 
Het beenmergstroma is geen statisch netwerk van vezels, cellen en bloedvaten 
maar wordt voortdurend geremodelleerd, met name in respons op bepaalde stimuli 
om de bloedcelvorming te verhogen zoals bij een infectie of bloedverlies. De 
verschillende differentiatiereeksen voor de bloedcelvorming (de erythroide, myeloide 
en megakaryocytaire reeks, respectievelijk rode en witte bloedlichaampjes en 
bloedplaatjes) zijn niet willekeurig verspreid in het beenmerg maar worden op zeer 
speciale plaatsen, namelijk in specifiek contact met stromale cellen (b.v. macrofagen 
of endotheelcellen) of celproducten gevonden. Proliferatie en differentiatie van de 
hemopoetische stamcellen en progenitorcellen, en het afgeven van volwassen, 
uitgerijpte bloedcellen aan de bloedbaan staat (geheel of gedeeltelijk) onder controle 
van de stromale cellen en de verschillende factoren die deze cellen kunnen vormen 
(hoofdstuk I.2). 
Schade aan het beenmerg, gekarakteriseerd door afwijkingen aan de hemo-
poetische stamcel, de progenitorcel en/of het stroma, is waargenomen na chemo-
therapie en/of bestraling (beide middelen worden onder andere gebruikt voor de 
behandeling van patienten met kanker). De schade aan het hemopoetische systeem 
kan latent aanwezig zijn en aileen aanleiding geven tot klinische symptomen indien 
er b.v. een extra beroep op de bloedcelvorming wordt gedaan (b.v. tijdens een 
infectie of na bloedverlies) of na een tweede behandeling met cytostatica en/of 
bestraling (hoofdstuk I.4). De experimenten die zijn beschreven in dit proefschrift 
zijn enerzijds uitgevoerd om een vergelijking te maken van de verschillende testsys-
temen, die stromale functie bepalen (behandeld in hoofdstuk I.3), en anderzijds om 
een beter begrip te krijgen van de effecten die cytostatica en bestraling hebben 
op de hemopoetische micro-omgeving. Tevens hebben we de effecten van de behan-
deling met cytostatica of bestraling van jonge (nog groeiende) muizen vergeleken 
met die van volwassen muizen. 
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De experimenten beschreven in de hoofdstukken III-VI laten duidelijk zien 
dat de verschillende testsystemen met betrekking tot de ernst van de gemeten 
schade en het verloop van herstel van deze schade na behandeling met cytostatica 
of bestraling niet met elkaar correleren. Blijkbaar bepalen deze testsystemen 
verschillende stromale functies. Dit impliceert dat het gebruik van een enkele test 
om de schadelijke effecten van cytostatica of bestraling te bepalen op de hemo-
poetische micro-omgeving tot verkeerde conclusies kan leiden. 
De experiment en in de hoofdstukken III-V wijzen erop dat zowel bestraling 
als behandeling met cytostatica (cis-platinum, cyclophosphamide en busulfan) kunnen 
leiden tot een veminderd vermogen van stromale cellen om te prolifereren in vitro 
en te regenereren in vivo en ook kunnen leiden tot een verminderd vermogen van 
het hemopoetische systeem om adequaat te reageren op stress (b.v., infectie). 
Tegelijkertijd echter is het vermogen van de stromale cellen om in situ de stam-
en progenitorcellen te stimuleren en normale aantallen bloedcellen te vormen niet 
of nauwelijks aangetast zolang het stroma niet tot deling wordt aangezet. Dit 
betekent dat een normale productie van bloedcellen kan plaatsvinden in een stroma 
met een ernstig beschadigde capaciteit om te prolifereren. Cis-platinum, cyclophos-
phamide, busulfan en bestraling kunnen een tijdelijk of blijvend defect veroorzaken 
in het vermogen van CFU-F om in vitro kolonies te vormen. Ook het regenererend 
vermogen van het hemopoetische stroma in ectopisch geimplanteerde organen 
(beenmerg en milt) is aangetast. Het bepalen van het aantal CFU-F kolonies in vitro 
is een maat voor de proliferatieve capaciteit van een enkel type stromale eel. 
Deze test geeft echter geen informatie over de ( eventuele) regulerende capaciteit 
van fibroblastaire cellen (hoofdstuk 1.2.2.3 en 1.3.3). Ectopisch (subcutaan) im-
planteren van hemopoetische organen bepaalt echter het vermogen van meerdere 
verschillende stromale cellen om te regenereren en om hemopoetische stam- en 
progenitorcellen te huisvesten en te stimuleren tot proliferatie en differentiatie. 
Het ectopisch implanteren van hemopoetische organen induceert een sterke regene-
ratie van het stroma, dat vrijwel geheel van donor-origine blijft, terwijl de hemo-
poetische stam- en progenitorcellen van gastheer-origine zijn. ·Deze normaal in het 
bloed circulerende hemopoetische voorlopercellen worden aangevoerd via de nieuw 
gevormde bloedvaten in het subcutane weefsel die contact maken met de geimplan-
teerde organen. De hemopoetische activiteit die in de geimplanteerde organen 
wordt aangetroffen is dus afhankelijk van het regenererende vermogen van het 
van de donor afkomstige stroma (hoofdstuk 1.3.2). ·De stromale celtypen die de 
beperkende factor vormen voor een goede regeneratie van de hemopoetische organen 
zijn niet bekend. De door de cytotoxische middelen geinduceerde acute stromale 
schade wordt in het algemeen gevolgd door een (ten opzichte van het hers tel van 
stam- en progenitorcellen) traag herstel tot (sub- of supra)normale waarden. Dit 
herstel wordt met name gezien in muizen die op jonge leeftijd zijn behandeld. Op 
langere termijn echter, treed na dit herstel opnieuw een stromaal defect op. Deze 
late schade (1/2 tot 1 jaar na behaildeling) gaat tevens gepaard met een daling 
van het aantal stam- en progenitor-cellen in situ. 
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Figuur Xl Een mogelijke verklaring voor de waargenomen stromale deficienties na 
bestraling van het beenmergstroma. In A is het nonnale in situ hemopoetische 
stroma in volwassen muizen schematisch weergegeven evenals de nonnale in vitro 
groei van CFU-F. Fig. B-D tonen schematisch de effecten van bestraling op het 
stroma van volwassen muizen. Na bestraling is er een goede stimulatie van hemo-
poetische stam- en progenitorcellen in vivo, maar de beschadigde CFU-F (gearceerde 
cellen) sterven af nadat ze gaan delen (B). Na het toedienen van een tweede 
schade die het stroma aanzet tot proliferatie in vivo (injectie van lipopoly-
saccharide, LPS) worden de beschadigde (gearceerde) cellen die afsterven na deling 
(zwarte cellen) vervangen door nonnale (witte) cellen met een nonnale capaciteit 
om hemopoese te stimuleren in vivo en kolonies te vonnen in vitro (D). 
De hierboven genoemde effecten van chemotherapeutica en bestraling kunnen 
als volgt worden verklaard. (1) De stromale cellen worden door de cytotoxische 
middelen beschadigd maar ze zijn nog wel in staat om de productie van bloedcellen 
te stimuleren. Als de beschadigde cellen echter gaan delen (in vitro of in vivo) 
sterven ze af. Dit gebeurt in bepaalde assays, waarin het stroma tot deling wordt 
aangezet, zoals in de CPU-F assay en de ectopische orgaan transplantatie ( zie 
Fig.X.lA en B en Fig.X.2A en B). (2) Het herstel van stromale schade tijdens de 
groei en/of na een tweede beschadiging wordt veroorzaakt door de normale (groei) 
of geinduceerde (tweede beschadiging) proliferatie van stromale cellen (zie Fig.X.lB-
D en Fig.X.2B-D). De door de cytotox:ische stoffen beschadigde stromale cellen 
sterven af nadat ze aan de deling zijn begonnen en worden vervangen door cellen 
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FiguurX2 Een mogelijke verklaring voor de waargenomen stromale defieienties na 
bestraling van jonge, nog groeiende muizen. In A is het nonnale in situ hemopoe-
tisehe stroma in jonge muizen sehematiseh weergegeven evenals de nonnale in 
vitro groei van CFU-F. Fig. B-E geven sehematiseh de effeeten van bestraling 
weer op het stroma van jonge muizen. De door bestraling besehadigde (geareeerde) 
stromale eellen, met een nonnale eapaeiteit om in vivo de hemopoese te stimuleren, 
sterven af tijdens de deling en zijn niet in staat om in vitro kolonies te vonnen 
(B). Tijdens de groei (waarbij ook de stromale eellen van de hemopoetisehe organen 
delen) worden de besehadigde (geareeerde) eellen vervangen door eellen met een 
nonnale proliferatieve capaciteit en een nonnaal vennogen om stam- en progenitor-
cellen te stimuleren (witte eel/en)( C en D). Een jaar na bestraling (E) is er een 
tweede dating ziehtbaar in de in vitro kolonie vonning en in de in vivo stimulatie 
van de hemopoese, mogelijk als gevolg van een beperkte delingseapaeiteit van 
stromale eel/en met als resultaat een langzaam v.erdwijnen van stromale eellen 
(zwarte eel/en). 
met een normaal proliferatief vermogen die de cytotoxische behandeling hebben 
overleefd. Dit resulteert tenslotte in een normaal in vitro kolonievormend vermogen 
van de CFU-F en in een normale hemopoetische activiteit van ectopisch geimplan-
teerde organen. De hemopoetische activiteit in vooraf bestraalde organen, die 
subcutaan worden getransplanteerd, blijft verlaagd, ook de tijdens de groei be-
straalde organen tonen geen herstel terwijl de in vitro kolonievormende capaciteit 
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van de CFU-F wel hersteld. De fibroblastaire voorlopercellen zijn dus niet de 
beperkende factor voor de regeneratie van het stroma van ectopisch geimplanteerde 
hemopoetische organen. Een late (tweede) verlaging in de stromale functie wordt 
gezien na behandeling met cis-platinum, busulfan en bestraling en gaat tevens 
gepaard met een verlaging van het aantal hemopoetische stam- en progenitorcellen 
in situ. Deze late stromale schade kan verklaard worden door te veronderstellen 
dat een percentage van de stromale cellen de limiet van hun proliferatief vermogen 
hebben bereikt door de voortdurende vervanging van beschadigde cellen. De beperkte 
delingscapaciteit van stromale cellen kan een natuurlijk aanwezige limiet zijn maar 
ook geinduceerd zijn door de behandeling met cytoto:xische middelen. Deze limiet 
in de delingscapaciteit zou kunnen leiden tot een verstoorde omvorming en opbouw 
van de hemopoetische micro-omgeving met als gevolg een verminderde capaciteit 
hemopoetische stam- en progenitorcellen te huisvesten en te stimuleren tot proli-
feratie en differentiatie (zie Fig.X.2E). 
Extrapolatie van de dierexperimentele gegevens zoals beschreven in de hoofd-
stukken III-VI naar de mogelijke schadelijke bijwerkingen van het klinische gebruik 
van cytostatica en bestraling is slechts in beperkte mate mogelijk, maar kan wel 
een indruk geven van de schadelijke effecten die na deze behandelingen op kunnen 
treden. De voordelen van het gebruik van zowel cytostatica als bestraling voor de 
behandeling van patienten met kanker wegen zeker op tegen de mogelijke schade-
lijke bijwerkingen. Het op lange termijn volgen van patienten die behandeld zijn 
met deze middelen blijft echter noodzakelijk om de eventuele bijwerkingen vast te 
leggen en om de voor deze bijwerkingen verantwoordelijke stoffen te identificeren. 
Na evaluatie is het dan mogelijk om de therapie aan te passen door gebruik te 
maken van die cytoto:xische middelen die de minste kans op schadelijke effecten 
geven met tegelijkertijd de beste kwaliteit en duur van overleving. 
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